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Abstract 
 
This thesis examines chronic obstructive pulmonary disease (COPD) exacerbation recovery 
in depth. This is an important topic to study since prolonged recovery and recurrence are 
common, severe and poorly understood events. 
 
The methodology involved patient reported outcome (PRO) tools and objective cough 
monitoring to examine symptomatic changes during exacerbations, and also the measurement 
of systemic and airway biomarkers during COPD exacerbations to identify patients at risk of 
non-recovery and recurrence. Finally, this thesis also included a randomised placebo-
controlled trial to investigate if Roflumilast can improve exacerbation recovery. 
 
This thesis showed that PROs provide reliable measurements of exacerbation severity. 
Furthermore, cough frequency increased acutely from baseline levels at exacerbation and fell 
during subsequent recovery. The biomarker work demonstrated that increased systemic 
inflammation at exacerbation onset predicts non-recovery and that faster resolution of 
neutrophilic inflammation is associated with shorter recovery. Roflumilast did not accelerate 
reduction of sputum neutrophils from exacerbation onset to 2 weeks post exacerbation, but 
did improve lung function recovery when given on top of standard therapy.  
 
This thesis demonstrates that PROs can be used in clinical practice to evaluate exacerbation 
recovery, and in trials of acute exacerbation therapies. It also provides evidence that targeting 
inflammation may improve recovery time. Future research should seek to define the use of 
Roflumilast as part of a personalised strategy that treats patients according to exacerbation 
phenotype. 
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1 
INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD), is a common preventable, treatable 
condition characterised by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases (1).  It is a critically important disease that is a leading cause of 
death worldwide (2). The World Health Organisation estimates 80 million people worldwide 
have COPD (3). Approximately 15 million people in the USA (4) and over 3 million people 
in the UK are estimated to have COPD (5).  
 
COPD is associated with episodic periods of symptom deterioration termed exacerbations. 
Exacerbations are amongst the commonest causes of medical admission to hospital (6) and 
the rate at which they occur appears to reflect an independent susceptibility phenotype (7). 
They are also important events in the natural history of COPD that drive lung function 
decline (8, 9), increased risk of cardiovascular events (10) and are responsible for much of 
the morbidity (11) and mortality (12) associated with this highly prevalent condition.  
25 
 
 
Exacerbations can be severe and prolonged events, with recovery incomplete in a significant 
proportion of exacerbations (13). Hospital admissions account for over 1 million bed days per 
year in the UK and 90 day mortality following admission is over 15% (14). Mean length of 
hospital stay is over 8 days with 40% of patients staying more than 1 week and 15% 
remaining inpatients for more than 14 days (14). Furthermore, approximately 25% of 
exacerbations are followed by a second recurrent event within 8 weeks, and approximately 
one third of exacerbations are recurrent exacerbations (15). This places a huge burden upon 
healthcare resources with approximately one third of patients being readmitted within 3 
months of their initial discharge (14). 
 
Despite this, exacerbation recovery and recurrence are poorly understood and novel therapies 
to reduce exacerbation length and recurrence rates are lacking. This thesis will examine 
exacerbation recovery in depth, to elucidate symptomatic changes during exacerbations to 
enable improved monitoring and assessment during recovery. It will also study systemic and 
airway biomarkers during COPD exacerbations to identify patients at risk of non-recovery 
and recurrence. Finally, this thesis will investigate a new approach to acute exacerbation 
treatment to improve these critical clinical outcomes.  
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1.1  Use of Patient Reported Outcomes to Monitor COPD Exacerbation Recovery 
 
An exacerbation of COPD is an acute worsening of respiratory symptoms, accompanied by a 
variable degree of physiological deterioration (13). The critical Anthonisen study defined 
exacerbations symptomatically with a particular focus on the symptoms of increased 
dyspnoea, sputum volume and sputum purulence (16). However, most pharmaceutical studies 
have used a healthcare utilisation (HCU) definition based on sustained worsening of the 
patient‟s condition from the stable state that requires a change in regular medication (17), 
which frequently take the form of unscheduled physician visits, the use of antibiotics or oral 
steroids at exacerbation, and hospital admission. This is reflected in the Global Initiative for 
chronic Obstructive Lung Disease (GOLD) strategy which defines an exacerbation as “an 
acute event characterised by a worsening of the patient's respiratory symptoms that is beyond 
normal day-to-day variations and leads to a change in medication” (1).  
 
An HCU definition of exacerbations has significant limitations. Healthcare use in COPD 
varies depending on access, resulting in a lack of generalisability across different healthcare 
systems. Most importantly, up to two-thirds of COPD exacerbations are not reported to 
health-care professionals and are either self-treated or untreated and may not be captured by 
such definitions. Unreported exacerbations are important events to recognise and quantify. 
Previous studies have shown that up to two-thirds of all exacerbations are not reported to 
health care professionals for evaluation and treatment (11, 18, 19). These events impair 
health-related quality of life (11, 18, 19) and failure to report exacerbations is also associated 
with increased risk of emergency hospitalisation (20). 
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Symptom diary cards are capable of capturing all exacerbation events to yield an accurate 
exacerbation frequency but most are not sensitive enough to assess severity of these events. 
Assessment of exacerbation severity is an important outcome measure and most clinical trials 
of preventative therapy to date have used therapy and hospitalisation rates to gauge this 
parameter: mild if increases in regular inhaled medication are needed, moderate if courses of 
steroids or antibiotics are administered, and severe if the patient requires hospital admission. 
The use of therapy to define exacerbation severity is also compromised by failure to capture 
unreported exacerbations, as well as differential prescribing guidelines and thresholds 
between clinicians and healthcare systems. 
 
Partially in response to these limitations, the Food and Drug Administration (FDA) 
recommended the development of patient reported outcome (PRO) instruments to measure 
treatment benefit in medical product clinical trials, including symptom-based methods for 
standardizing the severity of reported and unreported exacerbations (21). The FDA defines a 
PRO as “any report of the status of a patient‟s health condition that comes directly from the 
patient, without interpretation of the patient‟s response by a clinician or anyone else. The 
outcome can be measured in absolute terms (e.g., severity of a symptom, sign, or state of a 
disease) or as a change from a previous measure”. The standard assessment of an 
exacerbation involves the reporting of symptoms which are known directly by the patient and 
clinical assessments are based on patient description to the clinician. It would be more 
reliable to gather reports directly from patients and thus PROs are ideally suited to the 
assessment of COPD exacerbations. This thesis will explore the use of patient reported 
outcomes to quantify COPD exacerbation symptom severity, specifically examining the 
COPD Assessment Test
TM
 (CAT) and the Exacerbations of Chronic Obstructive Pulmonary 
Disease Tool (EXACT). 
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The COPD Assessment Test
TM
 (CAT) 
The COPD Assessment Test
TM
 (CAT) was developed to enhance communication between 
patients and healthcare professionals by providing a standardised, patient-centred assessment 
tool that quantifies information on daily symptoms, exercise limitation and other COPD 
manifestations. Detailed questionnaires such as the St George‟s Respiratory Questionnaire 
(SGRQ) are well validated but are not practical for use outside of a research setting due to the 
length of the instrument and the complexity of scoring algorithms. Therefore the CAT was 
designed to provide valuable information in the form of a simple, brief PRO that could be 
routinely used in clinical practice (22).  
 
Initially 21 draft items were generated following interviews and focus groups with COPD 
patients, community physicians and respiratory physicians (23). These were systematically 
reduced to 8-items following detailed study (22) to cover the following aspects of COPD:  
CAT items 
1. Cough 
2. Sputum (phlegm) 
3. Chest tightness 
4. Breathlessness 
5. Activity 
6. Confidence 
7. Sleep 
8. Energy 
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Each item is graded 0-5 so that the total tool provides a score out of 40 to indicate disease 
impact, without the need for complex calculation (Figure 3.3). Higher scores indicate more 
severe disease. Initial studies demonstrated that the tool is simple for patients to complete and 
that CAT scores correlate closely with health-related quality of life as measured by the St. 
George‟s Respiratory Questionnaire (SGRQ) when patients are stable (22). It was also shown 
that in the stable state, CAT scores are not affected by low levels of comorbidity (24), but are 
responsive to pulmonary rehabilitation and able to distinguish different levels of response 
(25).  
 
Preliminary studies showed that CAT scores were higher in patients at exacerbation 
compared to scores obtained in the stable state (22, 24). Chapter 4.1 describes the first study 
examining the utility of the CAT to evaluate HCU COPD exacerbation severity and model 
recovery. 
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The Exacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT) 
The Exacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT) is a daily 
symptom diary developed to capture frequency, severity, and duration of exacerbations in 
clinical trials of COPD (26). The initial development of the EXACT involved focus groups 
and interviews with 83 patients with COPD and a recent history of exacerbations, and 2 
expert panel meetings to inform the development of instrument content and structure. Patients 
were asked to describe their exacerbation experiences, including key symptoms, progression, 
and recovery. Additionally, cues for self-diagnosis and triggers to self-manage or seek 
assistance from healthcare professionals were elicited (27). These results were then reviewed 
by physicians and experts in questionnaire development to generate a preliminary framework 
consisting of 23 items (Figure 1.1): 
 
 
 
Figure 1.1. Preliminary Conceptual Framework for the EXACT. Reproduced from (24). 
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Following this a large observational study comprising 410 patients with COPD (188 stable; 
222 at exacerbation) in the US was performed to collect data for item reduction and to assess 
the tool‟s measurement properties (26). The item-reduction process was conducted in the 
stable cohort and resulted in a final tool consisting of 14 questions (Figure 3.5) that address 
the same themes as the CAT but with multiple questions assessing some items: 
1. Cough-two questions 
2. Sputum (phlegm)-two questions 
3. Chest tightness--two questions 
4. Breathlessness--two questions 
5. Activity-three questions 
6. Confidence-one question 
7. Sleep-one question 
8. Energy-one question 
 
EXACT scores are calculated from the responses to these 14 questions (further details 
available in methods 3.2.2).  Scores range from 0 to 100, with higher scores indicating more 
severe symptoms. Validation studies showed that the EXACT is a reliable tool to assess 
symptom severity and found that EXACT scores were significantly elevated at exacerbation 
compared to patients in the stable state (26). As a result, the authors proposed thresholds for 
exacerbation detection and severity based on rises in EXACT score so that the tool might be 
used as an outcome measure in pharmaceutical trials of novel COPD medications (Figure 
1.2). 
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However, no external validation of the ability of the EXACT to detect or assess the severity 
of exacerbations was performed. Chapter 4.2 describes the first study to assess ability of the 
EXACT to accurately assess the severity of both reported and unreported COPD 
exacerbations, defined by the London COPD cohort diary card. 
 
  
Figure 1.2. Proposed Utility of the EXACT. Reproduced from (24). 
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1.2  Monitoring COPD Exacerbation Recovery using Objective Cough Frequency 
Measurements 
 
Cough (either with or without sputum) is one of the principle symptoms of COPD, along with 
dyspnoea, and is one of the key domains assessed in both the CAT and EXACT PROs. 
Cough has a high impact on the lives of COPD patients, being reported in approximately 60% 
of patients, with almost 30% of patients rating their cough as moderately to extremely severe 
(28). Epidemiological studies have found that the reported presence of chronic cough and 
mucus hypersecretion may be linked to accelerated decline in lung function (29), more 
frequent exacerbations (30), and hospitalizations (31) in COPD patients. However, previous 
work has shown that subjective measures of cough and cough reflex sensitivity are only 
moderately correlated to objective measures of cough (32), and have insufficient predictive 
value for understanding the determinants of cough. The inconsistency between subjective and 
objective measures is probably because patients rate cough severity on more than just 
frequency. The length of coughing bouts, forcefulness of the cough, severity of 
accompanying breathlessness and the extent to which daily activities and sleep are disrupted 
are likely to be key determinants of self-reported severity (33).  
 
To overcome these issues, colleagues at the University of South Manchester led by Professor 
Jacklyn Smith have developed a system for making sound recordings over 24 hours in 
ambulatory patients, which allows the objective quantification of coughing (Vitalojak; 
Vitalograph Ltd., Buckingham, UK) (34). In a recent publication, this group showed that in 
the stable state, current healthy smokers and COPD ex-smokers have similar cough 
frequencies, both significantly greater than healthy nonsmokers. Amongst COPD patients, 
current smoking had an additive effect, giving COPD current smokers double the cough 
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frequency of those with either factor alone. Prior studies have shown that chronic 
expectoration is associated with increased neutrophilic inflammation (35) and in this paper, 
the degree of neutrophilic airway inflammation in COPD patients as measured in sputum 
samples in the stable state was positively related to cough frequency, independent of the 
influence of current smoking. In those patients who provided sputum samples, over a third of 
the variation in cough rates was explained by the degree of neutrophilic airway inflammation 
and current smoking (34). 
 
Exacerbations are symptomatic deteriorations in respiratory symptoms and cough plays a 
prominent role in these events. Recovery from exacerbations is often prolonged and cough 
may be a protracted feature of some events (13). Exacerbations are also characterised by 
increased neutrophilic airways inflammation (36, 37) and frequent exacerbators have higher 
neutrophilic inflammation than infrequent exacerbators in the stable state (38). Given the 
relationship between cough and inflammation, objective cough monitoring may be a useful 
tool in the setting of acute exacerbations of COPD. Thus in collaboration with the University 
of South Manchester I have examined the utility of objective cough monitoring to 
differentiate between stable COPD and exacerbation and whether cough frequency can 
distinguish patient exacerbation frequency phenotype in the stable state. We also examined 
the utility of cough monitoring as an objective means of determining the severity of an 
exacerbation, and investigated if different exacerbation phenotypes have different cough 
responses at exacerbation and during recovery. This work is described in Chapter 5. 
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1.3  Systemic and Airway biomarkers to evaluate COPD exacerbation recovery and 
recurrence 
 
The increased cough and sputum seen at exacerbation is associated with increased 
inflammation. In studies of COPD patients presenting to primary-care physicians, increasing 
sputum purulence was associated with increasing sputum neutrophilia, and systemic 
inflammation as measured by serum C-reactive protein was also higher in exacerbations 
associated with purulent rather than mucoid sputum (39). The increased inflammation seen in 
this work appeared to be related to the presence of bacteria. 
 
Exacerbation Aetiology 
In the same study by Stockley and colleagues (39), positive bacterial cultures were obtained 
from 84% of patients if sputum was purulent at presentation but only 38% if the sputum was 
mucoid. Moreover, the median bacterial load for positive purulent culture samples was 
significantly higher than for mucoid samples. When the same patients were re-examined in 
the stable state following antibiotics, sputum colour improved significantly in the group who 
presented with purulent sputum. The presence of green (purulent) sputum was 94.4% 
sensitive and 77.0% specific for a high bacterial load (>10
7
 colony forming units (cfu)/mL) 
(39). Both the prevalence of potentially pathogenic microorganisms (PPM), and airway 
bacterial load in sputum have been shown to increase from stable state to exacerbation, the 
most frequently isolated organisms being Haemophilus influenzae, Moraxella catarrhalis and 
Streptococcus pneumoniae (40). These studies suggest a causative role for increasing bacterial 
load at acute exacerbations. 
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Strain changes may also play an important role in the aetiology of COPD exacerbations. In a 
prospective study, Sethi and colleagues hypothesised that acquisition of a new bacterial strain 
would be associated with an exacerbation of COPD and so collected sputum samples from 81 
outpatients with moderate to severe COPD on a monthly basis and at exacerbation. Molecular 
typing of sputum showed that isolation of a new strain of a pathogen (Haemophilus 
influenzae, Moraxella catarrhalis and Streptococcus pneumoniae) was associated with a 
significant increase in the risk of exacerbation. These findings were proposed as a mechanism 
to explain recurrent bacterial exacerbations of COPD, the authors speculating that following a 
first exacerbation, patients develop a protective immune response that is strain specific. 
Therefore, acquisition of a different strain from the same bacterial species may still lead to a 
second exacerbation (41).  However, not all exacerbations were associated with strain change, 
and not all strain changes were associated with exacerbation. 
 
Rhinovirus 
Respiratory viral infections are detected in up to 60% of exacerbations using polymerase 
chain reaction (PCR) techniques, with rhinovirus being the most common species identified 
(42, 43). Experimental rhinovirus infection models also provide evidence of a direct causal 
relationship between respiratory virus infection and acute exacerbations of COPD (44). When 
COPD patients are infected with rhinovirus they develop increased respiratory symptoms, fall 
in peak expiratory flow (PEF), and increased blood and airway inflammation. A temporal 
relationship is observed between virus detection in the respiratory tract and the onset of 
symptoms and airflow obstruction, and virus clearance is followed by clinical recovery.  
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Furthermore, peak sputum virus load correlates positively with peak serum C-reactive protein 
(CRP) concentration and sputum inflammatory markers (neutrophils, interleukin (IL)-6, IL-8, 
neutrophil elastase (NE) and tumour necrosis factor (TNF)-α). Indeed, naturally occurring 
viral infections appear to be more severe events than non-viral exacerbations since 
exacerbations associated with dyspnoea and cold symptoms (a surrogate for rhinovirus 
infection) at onset are associated with larger falls in peak flow, prolonged recovery times and 
higher levels of airway inflammatory markers (IL-6) (13, 38). 
  
Interaction of Bacteria and Viruses 
Experimental rhinovirus models have also provided evidence of potential synergy between 
bacterial and viral infections (45, 46). COPD patients infected with rhinovirus exhibit 
subsequent secondary bacterial infection as evidenced by increased bacterial load and 
disruption of the respiratory microbiome. A limitation of this experimental rhinovirus model 
is that the patients included had only moderate COPD and the exacerbations induced did not 
require additional systemic therapy. 
  
Recent work in the London COPD cohort examined coinfection in naturally occurring 
exacerbations which all required treatment with additional systemic therapy (47). Patients 
with moderate to severe COPD who had known rhinovirus infection at exacerbation were 
examined closely during their recovery phase. In samples without bacteria detected at 
exacerbation, bacterial load increased by day 14 with 73% of negative samples becoming 
positive for bacteria by day 14. HRV prevalence and load increased at COPD exacerbation, 
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and resolved during recovery. Studies have also shown that exacerbations associated with 
both human rhinovirus and Haemophilus influenzae exhibit a greater bacterial load and 
inflammation than those without both pathogens (48). These data confirm that rhinovirus 
infection at naturally-occurring COPD exacerbations is commonly associated with secondary 
bacterial infection and greater airway inflammation, thus providing another possible 
mechanism for exacerbation recurrence.  
 
Eosinophilic Inflammation at exacerbation 
As described above exacerbations are triggered mainly by respiratory viruses and bacteria, 
which infect the lower airway and increase airway inflammation (49). Typically, the rise in 
inflammation seen at exacerbation has been considered predominantly neutrophilic (36, 37, 
50, 51). However more recently there has been considerable interest in eosinophilic 
inflammation, which had previously been thought more confined to asthmatic patients. 
Bafadhel and colleagues used cluster analysis to propose 4 distinct biological clusters at 
exacerbation: bacterial-, viral-, or eosinophilic-predominant, and a fourth associated with 
limited changes in the inflammatory profile termed "pauciinflammatory" (52). In this work, 
28% of events were associated with sputum eosinophilia which might be identified using a 
peripheral blood eosinophil count of 2%. This threshold had a sensitivity of 90% and 
specificity of 60% for identifying a sputum eosinophilia of greater than 3% at exacerbation. 
Following on from this work, it has been proposed that the use of corticosteroids both in the 
stable state, in the form of inhaled corticosteroid-containing combination therapy (53, 54), 
and in terms of systemic therapy at exacerbation (55), might have the greatest benefit in 
patients with peripheral blood eosinophil levels above this threshold. However, to date 
prospective studies based on blood eosinophil profiling are limited and previous studies have 
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not examined the relationship of blood eosinophil levels to exacerbation recovery and 
recurrence. 
 
Inflammation during exacerbation recovery 
Not all exacerbations recover and patients are susceptible to another or recurrent exacerbation 
after an index event. In the London COPD cohort, in 23% of patients, symptoms did not 
recover to baseline by day 35 and 22% of patients had a recurrent exacerbation within 50 
days of the first (index) exacerbation (56).  
 
Monitoring the temporal profile of inflammatory mediators during recovery from an acute 
exacerbation is challenging. Previous studies of inflammatory markers measured at 
exacerbation and during recovery have shown elevated levels of systemic inflammatory 
markers such as CRP, IL-6 and IL-8, which fall rapidly with treatment (56-59). In 
hospitalised exacerbations, changes in CRP levels (between measurements taken at intensive 
care unit admission and discharge) correlated with the duration of mechanical ventilation and 
severity of dyspnoea on the Medical Research Council (MRC) scale (60). 
 
Persistent inflammation appears to be associated with worse clinical outcomes. Patients with 
prolonged recovery have persistently higher levels of serum CRP during the recovery period 
(56). Previous studies have suggested that the period 14 days after exacerbation onset may be a 
critical time, with those patients with a recurrent exacerbation having a significantly higher 
CRP level 14 days after the index exacerbation, compared to those who did not have a 
recurrence (56).   
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It is unclear why airway and systemic inflammation remain persistently high in some patients 
treated appropriately at an initial exacerbation.  As discussed above, it is possible that there is 
persistence of the initial infective agent, acquisition of a new organism or bacterial type (41), or 
an interaction between pathogens present in the airways in the stable state (61) and also when 
these pathogens act as exacerbation triggers. However, it had previously not been possible to 
accurately identify which COPD patients are likely to have a prolonged recovery or recurrent 
exacerbation based on their biochemical characteristics at exacerbation onset, or which 
features of the index exacerbation predict recurrence (56, 59). 
 
To investigate whether increased inflammatory markers at exacerbation can inform on these key 
clinical outcomes, we have intensively sampled patients in the London COPD cohort at 
exacerbation, during their recovery and also captured subsequent recurrent events. Samples were 
tested for high value biomarkers which were selected based on their biological/mechanistic 
plausibility to inform on exacerbation recovery and recurrence. Past studies examining these 
biomarkers are summarised in Appendix 1. This has enabled me to examine whether elevated 
systemic and airway biomarkers at exacerbation onset predict abnormal exacerbation recovery 
and recurrent exacerbations within 8 weeks after an index event. This work is described in 
Chapter 6. 
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1.4 Treatment with Roflumilast at ExAcerbaTion (TREAT) 
 
Existing exacerbation treatments have limited efficacy to reduce the increased inflammation 
seen at exacerbation, improve recovery and reduce recurrence. Current standard therapy of 
moderate to severe exacerbations include increased bronchodilators, oral corticosteroids and 
if exacerbations are associated with increasing sputum volume and/or purulence, antibiotics 
(49). Bronchodilators relieve dyspnoea and airflow obstruction during exacerbations (62) and 
short-acting inhaled β2 agonists are usually the preferred bronchodilators for the initial 
treatment of COPD exacerbations (1).  
 
Antibiotics 
There is considerable evidence (as described above) to support the role of bacteria in COPD 
exacerbation aetiology and most guidelines highlight that antibiotics are beneficial in selected 
patients (1). Purulent sputum is a reasonable surrogate of bacterial infection (39) and routine 
antibiotic use is normally advised only in the context of exacerbations associated with an 
increase in sputum purulence (1). Much of the evidence for these recommendations stems 
from the seminal study by Anthonisen and colleagues that provided strong evidence that 
antibiotics had a significant effect on PEFR and led to earlier resolution of symptoms (16). 
Type 1 exacerbations (those associated with increased sputum volume, sputum purulence and 
dyspnoea) benefited the most with resolution of symptoms in 63% of the antibiotic treated 
exacerbations and 43% of the placebo group. However, patients with type 3 exacerbations 
(who met just one of the three cardinal symptoms) did not show significant benefit.  
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Studies have also assessed the benefits of stratifying antibiotic use according to exacerbation 
severity, determined by therapy. Antibiotics have been shown to increase clinical cure rate 
and prolong time to next exacerbation in mild to moderate exacerbations (those requiring 
increased bronchodilators, oral antibiotics and/or steroids) (63). A recent Cochrane review 
found that antibiotics had no statistically significant effect on mortality and length of hospital 
stay in inpatients (64). However, in COPD exacerbations requiring mechanical ventilation, 
oral ofloxacin reduced in-hospital mortality, duration of hospital stay, length of mechanical 
ventilation and reduced the need for additional courses of antibiotics (65). Therefore, in 
addition to exacerbations associated with increased sputum purulence, antibiotics are 
recommended in „severe‟ exacerbations requiring mechanical ventilation (1). 
 
The choice of antibiotics remains uncertain, predominantly due to methodological limitations 
hampering comparison of studies examining different antibiotics. At present, most guidelines 
suggest initial empirical treatment should be in the form of an aminopenicillin, a macrolide or 
a tetracycline, taking into account guidance from local microbiologists and in the light of 
local resistance patterns (66). In hospitalized patients, sputum should be sent for culture at 
exacerbation if purulent, and the appropriateness of therapy checked against sensitivities 
when available. In those patients at high risk of Pseudomonas aeruginosa, fluoroquinolones 
should be considered. 
 
Unfortunately, antibiotic resistance is become increasingly prevalent in both hospitals and the 
community and many in the respiratory community question the wisdom of antibiotics for 
acute exacerbations of COPD. Respiratory viruses are detected in more than 50% of 
exacerbations and are a major infectious trigger (42) which will not respond to antibiotics. 
43 
 
Additionally, antibiotic therapy is associated with increased side effects, particularly gastro-
intestinal, such as diarrhoea. To offer a definitive answer verdict on this issue, a large 
randomised double-blind trial is currently underway to demonstrate non-inferiority of placebo 
against adequate antibiotic treatment in addition to standardized treatment, with the 
hypothesis that antibiotics are not needed for COPD exacerbations (67). 
 
Systemic Corticosteroids 
Multiple studies have found significant short-term benefits of corticosteroids in the treatment 
of COPD exacerbations. Corticosteroids lead to improvements in FEV1 in the first three to 
five days of treatment (68-70) and Arterial partial pressure of oxygen (PaO2) in the first 72 
hours in comparison to placebo (70, 71).  Corticosteroids have also been shown to reduce 
hospitalisation length (68, 69), and the likelihood of treatment failure (72). However, 
treatment of exacerbations with corticosteroids has not been shown to improve mortality (72) 
and recent studies have suggested that the benefit of corticosteroid therapy at exacerbation is 
limited to patients with an eosinophilic inflammatory profile, and that in fact use of 
corticosteroids in non-eosinophilic exacerbations may impair recovery (55).  
 
Controversy also exists regarding the optimal dose and duration of treatment for acute 
exacerbations, often owing to the heterogeneity of treatment regimens in different clinical 
trials (73). There is no clear benefit of intravenous therapy over oral preparations and most 
guidelines recommend a dose of 30-40mg oral prednisone per day for a duration of 7-14 days 
(1, 66).  There is no advantage in prolonged courses of therapy (69) and shorter courses of 
therapy reduce the risk of adverse effects, with tapering of dose not required for most patients 
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(74). The commonest reported adverse effect of corticosteroid therapy is hyperglycaemia, 
particularly in patients with pre-existing diabetes mellitus (69). 
 
Self Management 
Rapid recognition of exacerbation symptoms and earlier treatment improves recovery and 
reduces the risk of hospitalisation (20). Self-management plans are designed to enable 
patients to respond appropriately to the first signs of an exacerbation without leading to 
overtreatment of minor symptom variations. Patients at high risk of exacerbations are 
therefore often provided with a course of “rescue” antibiotics and corticosteroids to keep at 
home and instructed to commence oral corticosteroid therapy if their increased dyspnoea 
interferes with activities of daily living, either independently or after seeking advice from a 
health-care professional. Antibiotics may be started in response to increased sputum volume 
and/or purulence and bronchodilator therapy increased to control symptoms (66). Such 
interventions have been shown to reduce admission rates (75, 76), however not all patients 
are suitable for these strategies. COPD patients are frequently elderly and may have cognitive 
difficulties limiting their ability to self manage, particularly when acutely unwell. 
Furthermore, patients suffer from repeated exacerbations (7, 11) and may need repeated 
courses of corticosteroids, exposing patients to significant side effects including cataracts, 
osteoporosis and suppression of the immune system (77). Therefore there is a risk that self-
management of exacerbations may lead to uncontrolled and unnecessary corticosteroid use 
with all its associated complications. Furthermore, corticosteroid resistance is common in 
COPD patients (78). Crucially, 27% of patients fail treatment with combined antibiotic and 
corticosteroid therapy by 30 days, and treatment failure rates rise to 37% by 90 days (69, 79).  
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Thus, new therapies for management of acute exacerbations are urgently needed, in particular 
specifically targeting the increased inflammation seen at exacerbation. 
 
TNFα antagonists 
Unfortunately, to date attempts to use alternative agents to treat exacerbations have been 
unsuccessful. As described above, exacerbations are inflammatory events, associated with 
increased sputum concentrations of Tumour Necrosis Factor-alpha (TNFα) (36). TNFα 
upregulates adhesion molecules and facilitates migration of leucocytes into the bronchial 
mucosa during AECOPD,  stimulates neutrophil degranulation and superoxide production 
(80). 
 
Etanercept binds to soluble TNF and blocks the interaction of TNF with cell surface TNF 
receptors. Therefore, the drug competitively inhibits TNF binding to cell surface TNF II 
receptors, rendering TNF biologically inactive (81). Observational data suggested that use of 
Etanercept in patients with both rheumatoid arthritis and COPD reduced hospitalisation risk 
(82). Subsequently, Aaron and colleagues conducted a randomised placebo controlled trial to 
establish if etanercept improved lung function and decreased treatment failure rates compared 
corticosteroids (83). Both groups received oral antibiotics and bronchodilators as part of 
standard therapy. Unfortunately, Etanercept failed to demonstrate any improved clinical 
efficacy compared to standard treatment with prednisone with respect to change in FEV1 
from baseline. Furthermore, the non-statistically significant differences observed in the trial 
tended to favour the prednisolone treated group, the relative risk of 90-day treatment failure 
being greater (by 25%) in those randomised to Etanercept. 
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CXCR2 antagonists 
As outlined previously, neutrophils are one of the key inflammatory cells in COPD, and a 
recent trial examined whether targeting neutrophilic inflammatory pathways using the CXC 
receptor antagonist MK-7123 could improve lung function in stable COPD patients (84). 
CXC chemokines recruit neutrophils to the lungs. These factors are recognized by receptors 
(CXCR1 and CXCR2) on neutrophils (85, 86). MK-7123 is a CXC receptor antagonist with 
high affinity for CXCR2, the receptor responsible for neutrophil trafficking (87). MK-7123 
had previously been shown to reduce neutrophilia in animal (87, 88) and human (89) models 
of pulmonary inflammation.  
 
Therefore the investigators performed a 6-month, randomized, double-blind, placebo-
controlled trial, comparing three doses of MK-7123 with placebo in patients with moderate to 
severe COPD already receiving standard therapy (84). After 6 months, the highest dose of 
MK-7123, 50 mg daily, increased post-bronchodilator FEV1 significantly relative to placebo. 
The effects of the two lower doses were not significant. Furthermore, compared with placebo, 
treatment with MK-7123 50 mg resulted in a significant reduction of sputum neutrophils at 3 
months and a trend toward reduction at 6 months.  
 
However, use of the higher effective dose resulted in severe serum neutropaenia, and 18% of 
subjects treated with the highest dose had to be withdrawn from the trial. These side effects 
therefore preclude current use of this agent in clinical practice. Nevertheless, this study adds 
further weight to the argument that targeting neutrophilic inflammatory pathways can lead to 
clinical benefit in COPD patients.  
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Roflumilast 
Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor, a non-steroid, anti-inflammatory agent 
designed to target both the systemic and pulmonary inflammation associated with COPD. 
The mechanism of action is the inhibition of PDE4, the major cyclic adenosine 
monophosphate (cAMP)-metabolising enzyme in structural and inflammatory cells important 
in the pathogenesis of COPD. Inhibition of PDE4 increases intracellular cAMP and typically 
leads to an anti-inflammatory effect (90).  
 
In vivo, roflumilast reduces tobacco smoke-induced lung inflammation, mucociliary 
malfunction, lung fibrotic and emphysematous remodelling, oxidative stress, pulmonary 
vascular remodelling and pulmonary hypertension (91). In vitro, roflumilast N-oxide has 
been demonstrated to affect the functions of many cell types, including neutrophils, 
monocytes/macrophages, CD4+ and CD8+ T-cells, endothelial cells, epithelial cells, smooth 
muscle cells and fibroblasts (91). In particular, roflumilast and roflumilast N-oxide potently 
inhibit neutrophil recruitment, chemotaxis and adhesion (91).  
Figure 1.3. Effect of PDE4 
inhibition on inflammatory cell 
activity. Reproduced from (70). 
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COPD exacerbations are associated with an increased neutrophilic inflammation (38) which 
is relatively insensitive to corticosteroids. In contrast to corticosteroids, roflumilast has been 
shown to reduce neutrophilic airway inflammation in COPD patients (92). This suppression 
of inflammation has been shown to improve key clinical outcomes in trials of COPD patients.  
 
In two double-blind, multicentre studies, compared with placebo, roflumilast was found to 
consistently improve lung function when taken daily for 24 weeks in patients treated with 
salmeterol, and in those treated with tiotropium (93). Furthermore, in two placebo-controlled, 
double-blind, multicentre trials including COPD patients with severe airflow limitation, 
bronchitic symptoms, and a history of exacerbations, roflumilast reduced the rate of moderate 
(corticosteroid treated) but not severe (hospitalised) exacerbations. Although in this study 
patients were not on maximal preventative therapy, and were only taking longacting β2 
agonists since those taking inhaled corticosteroids and longacting anticholinergic drugs were 
not allowed during the study (94). More recently, roflumilast has been shown to reduce rates 
of moderate (oral antibiotic and/or corticosteroid treated) exacerbations and hospital 
admissions in patients with severe COPD, chronic bronchitis and a history of frequent 
exacerbations, taking triple preventative therapy consisting of a fixed inhaled corticosteroid 
plus longacting β2 agonist combination, and background tiotropium (95). 
 
Additionally, roflumilast has been shown to reduce endotoxin-induced inflammation in 
healthy volunteers (96). Bronchoalveolar lavage following segmental endotoxin challenge 
after 28 days treatment found that the influx of total cells was 36% lower in the subjects 
receiving roflumilast compared to placebo. The influx of neutrophils and eosinophils of 
roflumilast-treated subjects was also 39% and 74% lower than with placebo, respectively. 
Thus, roflumilast should be beneficial in the acute treatment of COPD exacerbations.  
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Therefore in the final section of this thesis I shall describe the TREAT (Treatment with 
Roflumilast at ExAcerbaTion) study: a novel, proof-of-mechanism trial to investigate if 
roflumilast can reduce exacerbation severity. Specifically in this study I examined whether 
roflumilast can ameliorate neutrophilic airways inflammation during exacerbations. Sputum 
neutrophils increase at exacerbation and are related to exacerbation severity, as measured by 
reduction in lung function, regardless of the presence of bacterial or viral infection (97). 
Furthermore, sputum neutrophil measurements can be safely and successfully obtained from 
COPD patients (98, 99), are reproducible (98) and therefore have been proposed as an 
effective biomarker to assess the effectiveness of novel therapies in early phase COPD trials 
(100), particularly those drugs that target neutrophils in the airways, such as Roflumilast (92). 
 
In addition, during this trial we have examined the potential benefit of roflumilast on the 
recovery period of exacerbations, measuring the length and the severity of exacerbations 
using patient diaries and the CAT and EXACT patient reported outcome tools. The results of 
this study are described in depth in Chapter 7. 
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2 
HYPOTHESIS AND AIMS 
 
The introduction to this thesis has highlighted the current paucity of tools to assess 
exacerbation severity and the lack of treatments to improve clinical outcomes following 
exacerbation. To address these important unmet needs this thesis aimed to address the 
following general hypotheses: 
1) Patient symptoms can be used to accurately monitor exacerbation severity and 
recovery 
2) Inflammation is a key driver and indicator of exacerbation intensity, measurements of 
which can be used to predict important clinical outcomes  
3) Reduction of inflammation at exacerbation by novel pharmacotherapy will decrease 
exacerbation severity.  
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Specifically, we sought to address the following key questions:    
 Can patient reported outcomes, specifically the CAT and EXACT questionnaires, be 
used to monitor COPD exacerbation severity and recovery? (Chapter 4) 
 What is the relationship between exacerbations diagnosed using validated London 
COPD cohort diary cards and physician review, and symptom-defined events 
captured by the EXACT patient reported outcome? (Chapter 4) 
 Is objective cough monitoring an accurate means of determining the severity of an 
exacerbation and can this method identify patients at risk of prolonged recovery and 
recurrence? (Chapter 5) 
 Can airway and systemic inflammatory biomarkers measured at onset or during the 
recovery phase of a COPD exacerbation predict prolonged recovery and recurrence? 
(Chapter 6) 
The final part of this thesis describes a randomised, placebo controlled trial to test the 
hypothesis that Roflumilast reduces neutrophilic inflammation during exacerbations of 
COPD when added to the usual care of these patients. This study serves as a proof-of-
mechanism trial to examine whether roflumilast can improve clinical recovery following 
COPD exacerbations. In addition, the potential benefit of roflumilast to reduce the length and 
severity of exacerbations has been assessed using patient diaries and the CAT and EXACT 
PROs (Chapter 7). 
 
The methodology employed to investigate these questions is the subject of the following 
chapter. 
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3 
METHODOLOGY 
 
3.1  Subject recruitment 
 
Patients enrolled in the MRC (Patient Research Cohorts Initiative) London COPD cohort 
were recruited for this study. The patients form part of a rolling cohort of approximately 200 
patients used to prospectively investigate the mechanisms of COPD exacerbations (11). 
Patient recruitment was performed from both primary and secondary care settings to ensure a 
range of disease severity. Patients were allowed to leave the study at any point following 
recruitment and to ensure confidentiality, each subject was assigned with a unique study 
number. Ethical approval for the study was granted from the Royal Free Hospital research 
ethics committee (Ref. 09/H0720/8) and all patients gave written informed consent. 
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Inclusion criteria 
Patients were included if the post-bronchodilator forced expiratory volume in 1 second 
(FEV1) was ≤100% predicted from age, height, and sex and FEV1/forced vital capacity 
(FVC) ratio was <0.7, in keeping with GOLD grades I-IV (101). 
 
Exclusion criteria 
Patients were excluded if they had a history of asthma, primary bronchiectasis or any other 
significant respiratory diseases. Patients unable to complete the daily symptoms diary cards 
(described below) were also excluded. Specific additional exclusion criteria were also 
specified for the TREAT randomised controlled trial (see methods section 3.5).   
 
Clinical measurements 
Clinical measurements were performed by either by myself, or by the research nurse and 
clinical research fellows who are part of the London COPD research team. 
 
Spirometry 
Spirometry was performed on study participants at all clinic visits. FEV1 and FVC were 
measured in accordance with ATS/ERS guidelines using a Vitalograph Gold Standard 
spirometer (Vitalograph Ltd, Maids Moreton, UK) except for during the TREAT trial when 
patients used a FlowScreen
®
CT (ERT
®
, Philadelphia, PA, USA). Values were taken as the 
best of three reproducible attempts, and are expressed either as absolute volume or as a 
percentage predicted based on sex, weight and height (using Quanjer tables). 
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Health assessment questionnaires 
At annual review, the St George‟s Respiratory Questionnaire (SGRQ) (102), the Medical 
Research Council (MRC) dyspnea score, and the patient reported outcome (PRO) 
questionnaires; the COPD Assessment Test
TM
 (CAT) and the Exacerbations of Chronic 
Obstructive Pulmonary Disease Tool (EXACT) were completed. For specific studies these 
PROs were also completed at all other clinic visits, including 3-monthly stable visits, at 
exacerbation and exacerbation-follow-up. Further details of the use of these patient reported 
outcome is detailed in section 3.2. 
 
Diary cards  
At recruitment, patients were taught how to record on daily symptom diary cards, and 
provided with written instructions for filling these in (Figure 3.1 and Figure 3.2). 
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Figure 3.1. Front of Symptom Diary Card 
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Figure 3.2. Back of Symptom Diary Card including completion instructions. 
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Patients were asked to record their daily morning post-bronchodilator peak expiratory flow 
rate (PEFR), recording the best of three attempts (using a Mini-Wright peak flow meter, 
Clement Clarke International Ltd, Harlow, UK).  In addition, there were asked to record any 
increase in their usual respiratory symptoms using a letter-annotated system (Table 1), and 
hours spent outside the home. Patients were instructed not record any symptoms that they 
normally experience when they are well or stable, but only to document any perceived 
increase in symptoms over their normal, stable condition.  
 
Letter Major or Minor Symptom/Symptom Change 
A Major Increased breathlessness 
B1 Major Increased sputum colour 
B2 Major Increased sputum amount 
C Minor A cold (e.g. runny or blocked nose) 
D Minor Increased wheeze/chest tightness 
E1 Minor Sore throat 
E2 Minor Increased cough 
F Minor Fever 
 
 
Table 3.1. Letter-annotated system to record any increase in patients' usual respiratory 
symptoms, either major or minor, on daily diary cards. 
 
Example: if a patient has symptoms of a cold, „C‟ should be recorded on the diary card. If on 
the subsequent day the patient has both cold and increased breathlessness symptoms, then „C‟ 
and „A‟ should be recorded.  
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Patients were asked to contact the study team, via a dedicated mobile telephone number, if 
they experienced a worsening in any symptoms to arrange a clinic assessment visit, and to do 
this before starting any antibiotic or steroid tablets. 
 
Diary card definition of stable state 
Stable state was defined as those patients without evidence of symptom-defined 
exacerbations in the preceding 4 weeks and the subsequent 2 weeks post-clinic visit.   
 
Diary card definition of exacerbations 
An exacerbation was defined using previously validated symptomatic criteria (11) as an 
increase for two consecutive days in respiratory symptoms, with at least one major symptom 
(dyspnoea, sputum purulence or sputum volume) plus either another major or a minor 
symptom (wheeze, cold, sore throat, and cough), the first of which was defined as the day of 
onset of the exacerbation. Symptom counts were obtained by summating each increased 
respiratory symptom recorded on diary cards per day. 
 
Exacerbation duration was defined as the number of days after onset that worsening 
symptoms persisted. The last day of recorded worsening symptoms before two consecutive 
symptom-free days defined the end of the exacerbation. Exacerbation recovery was not 
determinable if patients failed to record diary card symptoms or continuously recorded 
symptoms for more than 99 days after onset.  
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Exacerbations were classified as „physician reported exacerbations‟ – those seen by the study 
clinical team or the patient‟s general practitioner and „unreported exacerbations‟ – those 
unseen by physicians but recorded on diary cards. 
 
Recording of exacerbation treatment on diary cards 
Patients with any worsening in their daily symptoms were asked to record any changes to 
their usual treatment, using a letter-annotated system, as shown below. 
 
 
Letter Treatment 
H Admitted to hospital 
I Increased use of inhaled corticosteroids 
(red/brown/purple inhalers) 
R Increased reliever medication and no. of puffs 
S Use of steroid tablets and no. taken 
X Use of antibiotic tablets and name 
 
Table 3.2. Letter-annotated system to record any changes to patients' usual treatment 
on daily diary cards. 
 
Clinic visits schedule 
Recruitment and annual review 
At recruitment and annual review, a full medical and smoking history was obtained, and 
clinical examination performed, including measurement of oxygen saturations (PureSAT
®
, 
Nonin Medical Inc, Plymouth, MN, USA). Body mass index (BMI) was calculated from 
60 
 
height and weight. Completion of health assessment questionnaires were requested. 
Comorbid diagnoses were established using clinical history and examination findings, 
supported where appropriate with a review of the available medical records. Medication 
history was reviewed and where necessary, treatment optimised. Patients were taught, or re-
educated, on completing daily symptom diary cards. Spirometry was performed and sputum 
and venous blood samples were collected.  
 
Stable visits 
Following recruitment, patients were regularly seen at 3-monthly intervals when stable. Diary 
cards, medical history and concurrent medication were reviewed to ensure the patient was 
stable before spirometry was performed. Patients were requested to complete health 
questionnaires, and sputum and venous blood samples were collected. 
 
Exacerbation visits 
Patients contacted the study team for review if they experienced any worsening of their 
respiratory symptoms and prior to commencing any additional systemic therapy. Patients 
were only included if they presented within 7 days of exacerbation symptom onset and had 
not yet taken any systemic therapy, such as antibiotics or oral corticosteroids prior to 
assessment. Exacerbations were treated according to the prevailing guidelines and clinical 
judgment with increased inhaled therapy, antibiotics and/or oral steroids. When patients 
attended for an exacerbation, medical assessment was performed by one of the clinical 
research team. Spirometry was performed and patients were requested to complete the 
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relevant questionnaires. Sputum and venous blood samples were taken prior to commencing 
exacerbation treatment.  
 
Exacerbation follow-up visits 
Patients were reviewed in clinic at day 3, one week, two weeks and five weeks following 
presentation for exacerbation. Clinical assessment was performed, and diary cards were 
reviewed to determine exacerbation end date, and if ongoing symptoms were present, 
together with clinical history, to determine whether re-treatment was clinically recommended. 
Spirometry was performed, patients were requested to complete the relevant health 
questionnaires, and sputum and venous blood samples were taken. 
 
Calculation of exacerbation frequency 
Exacerbation frequency was calculated for each patient using diary card data obtained 
between recruitment and onset of the sub-study. For recently recruited patients with less than 
one year diary data, exacerbation frequency was based on the number of exacerbations the 
patient recalled for the year prior to recruitment. Previous work has shown a good correlation 
between the number of exacerbations recorded on diary cards and the number of 
exacerbations remembered by the patient over the same 1 year period (103) and has shown 
that exacerbation frequency represents a stable patient phenotype (7). 
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3.2  Patient Reported Outcomes 
 
3.2.1 COPD Assessment Test (CAT) 
 
The COPD Assessment Test
TM
 (CAT) is a validated 8-item questionnaire. Each item is 
graded on a six-point scale from zero (“no symptoms”) to five (“very severe symptoms”). It 
is short and simple for patients to complete, providing a score out of 40 to indicate disease 
impact, without the need for complex calculation (Figure 3.3). Permission to use the CAT 
questionnaire was obtained from GlaxoSmithKline (GlaxoSmithKline plc, Middlesex, UK). 
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Figure 3.3. The COPD Assessment Test (CAT) 
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CAT administration 
For the study described in Chapter 4.1, patients completed the CAT at least once under 
supervision in clinic and then at home, based on their symptoms experienced on the day of 
completion. Patients completed at least one CAT questionnaire in the stable, baseline state. 
Baseline occurred more than 35 days post- and 21 days pre- exacerbation onset. If 
unavailable pre-index exacerbation, CAT scores during periods of stability post-exacerbation 
were used to provide a baseline. No differences were seen between baseline scores obtained 
pre-index exacerbation and baseline scores post-exacerbation. Repeat scores were averaged 
to give a baseline CAT score. CAT questionnaires were also administered during 
exacerbation between April 2010 and June 2011. The exacerbation CAT score took place 
within 7 days of the symptomatic onset of the exacerbation as judged by diary cards, was 
completed prior to starting therapy and was recorded on the day treatment commenced. These 
were mandatory study criteria.  
 
A subgroup of patients also completed CAT scores on a daily basis during their recovery. For 
the recovery subgroup, the first exacerbation was selected for analysis provided the patient 
had fully completed the questionnaire on at least 21 of 35 days post onset. CAT Recovery 
was the time taken from exacerbation onset for the CAT score to return to baseline value 
(Figure 3.4). 
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Figure 3.4. Schematic timeline of CAT scores (x) recorded during exacerbation. 
Exacerbation CAT score ( ) was the CAT score recorded on the day treatment 
commenced. CAT Recovery  was the time taken from exacerbation onset for the 
CAT score to return to baseline value. This figure is for illustrative purposes only and 
does not indicate real data.  
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3.2.2 Exacerbations of Chronic Pulmonary Disease Tool (EXACT) 
 
The EXACT consists of 14-items (Figure 3.5). To calculate the EXACT score, responses for 
each of the 14 questions are summed to yield a “raw summed score”. Each “raw summed 
score” is converted to a 0 to 100 score using a simple conversion table, with higher scores 
indicating more severe symptoms. Permission to use the EXACT questionnaire was obtained 
from United BioSource Company (UBC, Bethesda, MD, USA).  
67 
 
 
  
Figure 3.5. The Exacerbations of Chronic Pulmonary Disease Tool (EXACT) 
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EXACT administration 
For the study described in Chapter 4.2, patients completed a paper version of the EXACT at 
least once under supervision in clinic and were instructed to complete the EXACT diary each 
evening before bedtime, based on their symptoms experienced that day.  Patients 
prospectively completed the EXACT on a daily-basis when stable and continued long-term to 
enable capture of the exacerbation prodrome, the onset of the event, its nadir and recovery. 
Patients in the analysis completed at least one EXACT at both the symptomatic onset of an 
exacerbation and during a baseline period -14 to -8 days before onset. The median number of 
EXACT questionnaires completed per person was 196 (IQR 106-311).  
 
EXACT Scoring Definitions  
Each patient‟s baseline value was represented by the mean value recorded during the stable 
state (median 7 days (IQR 7-7) of data recorded during baseline period). As specified in the 
User Manual, EXACT events were defined as an increase of 12 points above the patient‟s 
mean baseline for 2 consecutive days OR an increase of 9 points above patient mean baseline 
for 3 consecutive days. The presence of either constitutes onset of an event. For the purposes 
of this study, EXACT recovery was defined as the time taken from exacerbation onset for the 
EXACT score to return to baseline value.  
 
Exacerbation Severity  
Total net EXACT recovery score of an exacerbation was created to give a novel measure of 
exacerbation severity which reflects the overall symptomatic intensity of an exacerbation. 
Total net EXACT recovery score of an exacerbation was calculated as the sum of daily mean 
change from baseline EXACT scores from exacerbation onset to symptomatic resolution as 
judged by London COPD cohort diary cards (Figure 3.6). 
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Figure 3.6. Illustration of calculation of Total Net EXACT Recovery Score. Daily mean 
changes from baseline EXACT scores are represented by dashed arrows and Total Net 
Recovery Score is represented by the grey shaded area. 
 
70 
 
3.3  Monitoring COPD Exacerbation Recovery using Objective Cough Frequency 
Measurements  
 
Cough monitoring 
Ambulatory cough sound monitoring was performed using the VitaloJAK model 7100 cough 
monitor (Figure 3.7, Vitalograph, UK). This a custom-built device attached to a lapel 
microphone and a chest wall sensor positioned over the sternum (Figure 3.8). Devices were 
supplied by the University of South Manchester under the supervision of Dr Jaclyn Smith. I 
was trained in the use of this device and its accompanying software by staff at the University 
of Manchester. 
  
Figure 3.7: VitaloJAK Cough Monitor Figure 3.8: Placement of cough sensor 
Cough monitors were placed on patients at clinic visits and worn for the immediate 24 hours 
after each visit. Recordings stored on data cards within the device were transferred securely 
via Filezilla data transfer systems to a separate computer system. Subsequently, recordings 
were processed by validated software that removes silences and background noise but retains 
the coughs present (104). The resulting compressed version of the recording was listened to 
by staff at the University of South Manchester, who were specifically trained to identify and 
count coughs, and tags placed on each explosive cough sound. University of South 
71 
 
Manchester in house software extracts the tags to generate all the coughs from the original 24 
hour recording then creates a standard hourly report. To ensure consistency, the same counter 
tagged all recordings for one patient. Furthermore, 10% of each cough counters work is 
quality control checked by a senior member of staff, using pre-defined acceptable limits of 
agreement based on 95% confidence intervals from a collection of previous data. 
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3.4  Systemic and Airway biomarkers to evaluate COPD exacerbation recovery and 
recurrence 
 
Classification of Exacerbations 
Exacerbations are categorized into three types: „„isolated,‟‟ „„initial,‟‟ and „„recurrent‟‟. An 
isolated exacerbation was not followed within 8 weeks by any other exacerbation. An initial 
exacerbation was an exacerbation that was followed within 8 weeks of onset by the onset of a 
second exacerbation. A recurrent exacerbation was an exacerbation that had an onset within 8 
weeks of a preceding exacerbation. All exacerbations were separated by at least 5 days on 
which no symptoms were recorded (Figure 3.9)(15).  
 
 
Recovery Visits 
Patients were asked to attend recovery monitoring visits at Days 3 (±1), 7 (±2), 14 (±2), 35 
(±3) after the initial exacerbation visit. Recurrent exacerbations occurring within 56 days 
after exacerbation onset were assessed and sampled in the same manner as for an index 
exacerbation, as described above.  
 
  
Figure 3.9. Classifications of 
Exacerbations. Exacerbation X is a 
„„recurrent‟‟ exacerbation if onset is 
within 8 weeks of onset of the index 
exacerbation (B ≤ 56 days). 
Recovery is defined as ≥5 symptom-
free days (A). 
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Sputum sampling and processing 
Patients were asked to spontaneously expectorate sputum samples into a sterile pot, after 
rinsing their mouth. Sputum samples were kept at 4
°
C for no longer than 2 hours prior to 
further processing to prevent RNA degradation. Sputum plugs were separated from any saliva 
macroscopically. Sputum plugs were homogenised with Dulbecco‟s phosphate buffered 
saline (D-PBS), as previously published (48, 105). Selected sputum plugs were transferred 
into an empty, pre-weighed polypropylene centrifuge tube. The weight of the sputum was 
calculated (weight of tube and sputum – weight of the empty centrifuge tube). Eight volumes 
x sputum weight (in grams) of D-PBS was added, and the sputum dispersed by repeated 
gentle aspiration into a plastic pipette.  
 
Approximately 0.5ml of glass beads (Glass Balls 2.5-3.5mm. VWR International Ltd Cat No. 
33212 4G) was added and the tube was vortexed for 15 seconds (Whirlimixer IKA-Vibrax-
VXR, Scientific & Chemical Supplies Ltd.) and then subsequently for 15 minutes on a bench 
rocker (Voltex Mixer, Bench rocker (variable speed) Scientific & Chemical Supplies Ltd.). 
The centrifuge tube was re-vortexed for further 15 seconds. A 500μl aliquot of the 
homogenized sputum samples was stored in 1.5ml Eppendorf tubes and frozen at -80°C for 
later batch analysis for qPCR. 
 
The remaining homogenized sputum was filtered through a nylon filter mesh (Plastok (Mesh 
and Filtration) Ltd, Merseyside, UK), and centrifuged at 790g for 10 minutes with the brakes 
off (Benchtop refrigerated centrifuge. Hettich Universal 380 R. Wolf Laboratories Ltd.). 
500μl aliquots of the sputum supernatant were stored in 1.5ml Eppendorf tubes, taking care 
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not to disturb the cell pellet. The aliquots were frozen at -80°C for later batch analysis for 
sputum biomarkers. 
 
Quantitative PCR for typical bacteria and Human Rhinovirus 
Multiplex bacterial polymerase chain reaction (PCR) was performed for the most prevalent 
bacterial pathogens in exacerbated COPD: Haemophilus influenzae, Streptococcus 
pneumoniae, and Moraxella catarrhalis (40) by the Centre for Clinical Microbiology, 
University College London. The lower limit of detection for this technique was 1x10
4
 colony-
forming units per millilitre. Reverse transcriptase PCR for human rhinovirus, the most 
prevalent virus at COPD exacerbation, was also performed (47). The sensitivity of this 
technique was also high with a lower limit of detection of 10.23 plaque-forming units per 
millilitre. 
 
Blood sampling and processing 
Full Blood Count 
3ml of whole blood was collected from study participants by venepuncture in Vacutainer
® 
EDTA tubes for total white blood cell count and differential neutrophil and eosinophil counts.  
Serum for CRP 
3.5ml of whole blood was collected from study participants by venepuncture in Vacutainer
® 
SST tubes, containing spray-coated silica and a polymer gel for serum separation. Serum C-
reactive protein (CRP) was measured using Modular Analytics E 170 Module (Roche, 
Burgess Hill, UK). The lower limit of detection was 1mg/l. 
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Plasma for fibrinogen 
2.7ml of whole blood was collected by venepuncture in Vacutainer
® 
Citrate tubes containing 
3.2% buffered sodium citrate solution. Plasma fibrinogen was measured using the Clauss 
method (IL ACL Top Coagulation Analyzer, Lexington, MA, USA).  
 
Serum for Cytokines 
Venous blood was collected into a sterile vacutainer, centrifuged, and the serum stored at -
80°C until batch analysis. 
 
Cytokine Measurement 
Levels of cytokines in serum (excluding those listed above) and sputum were measured using 
the Aushon multiplex immunoassay platform (Aushon BioSystems, Billerica, MA). The 
Aushon platform is a quantitative multiplexed sandwich ELISA containing up to 12 different 
capture antibodies spotted on the bottom of a 96-well polystyrene microtiter plate.  Each 
antibody captures a specific protein present in the standards and samples added to the plate.  
The bound proteins are then detected with a biotinylated detection antibody, followed by the 
addition of streptavidin-horseradish peroxidase (HRP) and lastly, a chemiluminescent 
substrate.  The luminescent signal produced from the HRP-catalyzed oxidation of the 
substrate is measured by imaging the plate using the Aushon Cirascan Imaging System, 
which is a cooled charge-coupled device (CCD) camera.  The amount of luminescent signal 
produced is proportional to the amount of each protein present in the sample. Concentrations 
are interpolated from a standard curve.  Aushon Bio systems were funded by Novartis 
Pharmaceuticals UK Ltd for this project. 
  
76 
 
Cytokine Selection 
The following biomarkers were measured using the Aushon multiplex immunoassay 
platform: 
Serum Biomarkers: IL-6, IL-8, IP-10, PLGF, TNFα, MMP-1, MMP-8, MMP-9, sRAGE, 
PARC, α2-macroglobulin, CC16, SAA 
Sputum Biomarkers: IFNγ, IL-18, IL-1β, IL-5, IL-6, TNFα, IL-8, MMP-1, MMP-8, MMP-
9, MPO, TIMP-1, α2-macroglobulin 
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3.5  Treatment with Roflumilast at ExAcerbaTion (TREAT) 
 
The Treatment with Roflumilast at ExAcerbaTion (TREAT) study was a novel, proof-of-
mechanism trial to investigate if roflumilast can reduce exacerbation severity. It was 
conducted as a randomised, double-blind, parallel-group, single centre, phase II trial.  
 
Inclusion Criteria 
All patients were recruited from the London COPD patient cohort at exacerbation (see 
methods section 3.1 for exacerbation definition).  Patients were eligible for trial inclusion if 
presenting with an exacerbation with predominantly bronchitic symptoms, characterised by 
increased sputum volume or a change in sputum colour. This selection criterion was used 
because Roflumilast has been shown to be most effective in bronchitic patients during 
maintenance therapy trials. Patients were randomised 1:1 to either roflumilast 500 μg 
(standard maintenance therapy dose) or placebo, once daily for 4 weeks. As discussed in the 
introduction, 8 weeks post an initial exacerbation is a high risk period for exacerbation 
recurrence (15), and excess inflammation 14 days post exacerbation is associated with both 
non-recovery and recurrence (56). Therefore a 4 week period post exacerbation onset was 
chosen to both reduce exacerbation non-recovery and recurrence, whilst minimising exposure 
to adverse effects.  
 
To measure the efficacy of Roflumilast in separate exacerbations within the same patient, 
repeated exacerbations from the same patient were included if the second event occurred at 
least 3 months after end of the initial 8 week exacerbation follow-up period. Therefore 2 
groups were available for analysis: 
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1. Initial Approach-including just one exacerbation per patient 
2. Extended Approach-repeat exacerbations within the same patient were also included 
 
All patients continued their standard maintenance COPD therapy (except theophyllines, see 
below) and additionally received standard treatment for COPD exacerbations (oral 
corticosteroids for 10 days and antibiotics for 7 days), therefore the placebo treatment did not 
bear any additional risk and was thus ethically justified. All COPD severity stages were 
included, except for patients who developed type 2 respiratory failure during the 
exacerbation.  
 
Exclusion Criteria 
 Diagnosis of asthma and/or other relevant lung disease 
 Recurrent exacerbations (within 8 weeks of a preceding exacerbation) 
 Treatment of current exacerbation with oral corticosteroids and/or antibiotics already 
started at enrolment 
 Treatment with PDE4 inhibitors within 3 months prior to Visit V0 
 Contraindications to sputum collection or inability to obtain valid sputum sample for 
analysis 
 Respiratory failure or hospitalisation required when presenting at Visit V0 
 Severe psychiatric or neurological disorders 
 History of depression associated with suicidal ideation or behaviour 
 Congestive heart failure (NHYA Grade IV), haemodynamically significant cardiac 
arrhythmias or heart valve deformations 
 Immunological diseases or known HIV infection 
 Liver impairment Child-Pugh B &C and/or active viral hepatitis 
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 Severe infectious diseases 
 Any diagnosis of a malignant disease (other than basal or cutaneous squamous cell 
carcinoma) within 5 years before trial start  
 Alcohol or drug abuse within the past year 
 Suspected hypersensitivity to the IMP or its ingredients  
 Female patients of childbearing potential, not using and not willing to continue using 
a medically reliable method of contraception for the entire trial duration, such as oral, 
injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless 
they are surgically sterilised/hysterectomised or post-menopausal >1 year  
 Pregnancy, breast feeding, planned oocyte donation or oocyte implantation  
 Planned donation of germ cells, blood, organs or bone marrow during the course of 
the trial  
 Participation in another trial (use of investigational product) within 30 days of Visit 
V0 
 Suspected inability or unwillingness to comply with trial procedures  
 Suffering from any concomitant disease that might interfere with trial procedures or 
evaluations  
 Employee at the trial site, relative or spouse of the investigator  
 Use of disallowed concomitant medication: 
o Maintenance therapy with oral and parenteral corticosteroids Oral or 
transdermal β2-agonists  
o Theophylline containing products  
o Lipoxygenase inhibitors  
o Leukotriene antagonists  
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o Use of immunosuppressive medications within 4 weeks prior to enrolment 
(e.g. cyclosporine, methotrexate, tumour necrosis factor alpha receptor 
inhibitors or antibodies, gold, azathioprine)  
o PDE4 inhibitors (with the exception of the IMP provided by the sponsor)  
 
Clinical Trial Overview 
Clinic visits were performed at Days 1 (=V0, inclusion and randomisation), 7 (Visit V1), 14 
(Visit V2), 28 (Visit V3) and 56 (Follow-up Visit VFU) (Figure 3.10). During the entire trial 
period patients completed daily London COPD cohort symptom diary cards on which they 
recorded their morning post-medication peak expiratory flow (PEF) and any increase in their 
daily respiratory symptoms. At clinic visits pulmonary function tests were performed, and 
sputum and blood collected to assess airway and systemic inflammatory biomarkers.  
 Figure 3.10. Clinical trial overview. 
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Blinding  
During the double-blind treatment period and until database hard lock, all parties involved in 
the trial (patients, investigators, site personnel, monitors, sponsor) were blinded. Roflumilast 
and placebo tablets were of identical appearance, shape and colour (both yellow, triangular 
tablets embossed with a 'D') and had identical labelling and packaging.  
 
Sputum induction and processing 
Sputum induction was performed by inhalation of 5ml 3% (v/v) saline aerosol performed 
using an ultrasonic nebuliser (output approximately 2ml/min), in three, five-minute cycles 
(106). After the initial 5 minutes, FEV1, and if clinically indicated, oxygen saturations were 
re-measured. If FEV1 fell by <10%, the nebulisation was continued with 3% (v/v) saline. If 
FEV1 fell by >20%, or if the participant experienced any distressing symptoms, the process 
was discontinued. Study participants were allowed to expectorate sputum at any point during 
the induction process. Prior to expectoration, patients were requested to blow their nose and 
rinse their mouth out with water before attempting sputum expectoration. 
 
Samples were examined within 2 hours of collection. Sputum plugs were separated from 
contaminating saliva by macroscopic examination and selected portions of the sputum 
processed with dithiothreitol (DTT) for measurements of cell counts. For measurements of 
inflammatory markers and bacterial and viral quantitative polymerase chain reaction (PCR), 
sputum samples were processed without DTT (as per methods section 3.4). 
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Total and differential cell counts 
Total cell count (absolute number of nonsquamous cells per gram of the original sputum 
sample) and cell viability was determined with a Neubauer haemocytometer and the trypan 
blue exclusion method. For differential cell counts, aliquots of a cell suspension prepared 
from the sputum sample were used to prepare cytospin slides. Cytospin slides were stained 
with Diff-Quik to obtain differential cell counts by counting 400 nonsquamous cells per slide 
(107). Absolute cell numbers were calculated as (% cell x total cell count)/sputum weight. 
 
Measurement of biomarkers in sputum 
Interleukin (IL)-6, IL-8, neutrophil elastase (NE) and myeloperoxidase (MPO) were 
quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA) (R&D 
Systems, Abingdon, UK; BioVendor, Heidelberg, Germany). 
 
Blood sampling for and determination of biomarkers 
Peripheral venous blood (up to 25 mL) was collected, serum separated and stored in 
appropriate aliquots at -80C until batch analysis (as per methods section 3.4) (56). Serum IL-
6 and IL-1β was quantified using commercial sandwich ELISAs (R&D Systems, Abingdon, 
UK). Serum CRP was measured using Modular Analytics E 170 Module (Roche, Burgess 
Hill, UK). The Clauss method was used to process plasma fibrinogen. 
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ELISAs 
Serum and sputum supernatants were thawed and processed according to the manufacturer‟s 
instructions to measure biomarker levels using high sensitivity ELISA kits (R&D Systems, 
Abingdon, UK; BioVendor, Heidelberg, Germany). 
 
Supernatants were diluted in as necessary (IL-6: no dilution, IL-8: 1:100, IL-1β: no dilution, 
MPO: 1:100, NE: 1:100). Assay diluents then samples or standards were added to the 
appropriate microplate wells, covered and left at room temperature for 2 hours (the MPO 
plate was placed onto a horizontal microplate shaker set at 500±50 rpm; NE was incubated 
for only 1 hour whilst shaking at 350rpm), before being washed three times (for IL-1β), or 
four times (for IL-6, IL-8, MPO and NE) in wash buffer.  
 
The appropriate detection antibody was added to all wells, (200μl for IL-1β, IL-6 and MPO 
conjugate; 100μl for IL-8 conjugate; 150μl for NE conjugate), and the plates were re-covered 
and incubated for a further 1 hour (for IL-8; IL-1β; NE-on shaker) or 2 hours (IL-6, MPO-on 
shaker). Plates were washed three or four times as above, and 200μl of the substrate solution 
was added to each well (equal volumes of Colour reagent A (H2O2) and Colour Reagent B 
(Tetramethylbenzidine) mixed directly before addition to the plates). The plates were covered 
and incubated in the dark for 20 minutes (IL-6, IL-β, NE) or 30 minutes (IL-8 and MPO), 
following which, the reaction was stopped by the addition of 50μl/well Stop solution (1M 
H2SO4).  
 
84 
 
The OD of each well was determined using a spectrophotometer (BioTek Gen5 v2.0 All-In-
One Microplate Reader Software), read at 450nm with wavelength correction set at 570nm to 
correct for any optical imperfections in the plate. Concentrations of cytokines were derived 
from extrapolation from standard curve graphs generated from the spectrophotometer (Figure 
3.11). The lower limit of detection for the ELISA assays were 0.7 pg/ml, 3.5 pg/ml, <1.0 
pg/ml, 0.014 ng/ml and 0.2ng/ml for IL-6, IL-8, IL-1β, MPO and NE respectively. 
 
 
 
 
 
  
Figure 3.11. Example of standard curve generated using spectrophotometer 
programme, used to determine unknown concentrations of IL-1β in cell supernatants. 
The absorbance was read at λ450nm. Similar standard curve graphs were generated for 
IL-6, IL-8, neutrophil elastase and MPO. 
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Spirometry 
Spirometry for pulmonary function testing was performed according to the recommendations 
of the American Thoracic Society - European Respiratory Society consensus guidelines on 
pulmonary function testing (108) using a FlowScreen
®
CT (ERT
®
, Philadelphia, PA, USA). 
Spirometry was performed after patients have taken their standard COPD medications. FEV1 
and FVC was chosen as the largest value from different efforts. These values could come 
from different test curves. FEV1/FVC was calculated from the largest FEV1 and largest 
FVC. 
 
Patient-reported outcome measures 
Patients completed London COPD cohort diary cards, the CAT (©GSK) as well as the 
EXACT-PRO (©UBC) questionnaires on a daily basis throughout the 2 month trial period. 
 
Study Endpoints 
The primary endpoint was change in sputum neutrophil counts from Visit V0 to V2, 14 days 
after randomisation. The time to normalisation of neutrophil counts after an acute 
exacerbation is unknown. However, it was assumed that it will parallel symptom recovery 
after an acute exacerbation, which was reported to be 5 days (median) with an interquartile 
range (IQR) of 2 to 10 days (15). Based on this recovery time a 14-day period was considered 
adequate. As data was also being collected 1 week prior to Day 14 and 2 weeks after Day 14, 
the double-blind treatment period covered 4 weeks from the start of the exacerbation.  
 
Secondary endpoints included the assessment of change from visit V0 to each post 
randomisation visit for sputum markers (total and differential cell counts (absolute and 
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percentage): neutrophils, macrophages, eosinophils, lymphocytes; IL-6, IL-8, MPO, 
neutrophil elastase) and blood biomarkers (change from Visit V0 to each post-randomisation 
visit for the blood concentration of: CRP, fibrinogen, IL-6, and IL-1β).  
 
Additional secondary endpoints included spirometric assessments (change from Visit V0 to 
each post-randomisation visit for the following: FEV1, FVC, FEV1/FVC percentage), and 
exacerbation length as judged by daily symptom diary cards. Patient reported outcomes 
assessments were also important secondary endpoints, including changes on a weekly basis 
for the CAT and EXACT-PRO questionnaires, and total symptom burden, measured by Area 
under Curve of changes from V0 (exacerbation presentation, Day1) to V3 (4 weeks) and 
VFU (8 weeks) in daily CAT and EXACT scores . 
 
Safety 
In addition to the above endpoints safety was assessed by comparing rates of adverse events, 
in particular changes in body weight, between both treatment groups. 
 
Registration and Funding 
This study is registered with ClinicalTrials.gov, number NCT01473758 and was funded by 
Takeda.   
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3.6  Statistical Analysis 
The statistical techniques used are detailed in the methods section of each individual chapter. 
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4 
USE OF PATIENT REPORTED 
OUTCOMES TO MONITOR 
COPD EXACERBATION 
RECOVERY 
 
This chapter assesses the utility of the COPD Assessment Test
TM
 (CAT) and the 
Exacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT) to monitor COPD 
exacerbation recovery. The data presented has been published in the American Journal of 
Respiratory and Critical Care Medicine and the European Respiratory Journal respectively, 
and was presented at the American Thoracic Society. 
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4.1 Utility of the COPD Assessment Test
TM
 (CAT) to evaluate severity of 
COPD exacerbations in Clinical Practice 
 
4.1.1 Introduction 
COPD exacerbations are characterized by a worsening of respiratory symptoms from the 
usual stable state, especially dyspneoa, increased sputum volume and purulence. Changes in 
exacerbation symptoms relate to exacerbation recovery time (13), which is an index of 
exacerbation severity. In addition to exacerbation length, exacerbation severity influences 
acute treatment (13), drives hospital admission and also mortality (12).  
 
Patient diary cards are direct measures of exacerbation symptoms that provide accurate 
information regarding the commencement and resolution of exacerbations (13). They can 
detect exacerbations that are both reported and unreported to health care professionals thus 
allowing accurate determination of exacerbation frequency (11). However, currently there is 
no standardised, objective method for assessing symptom severity at exacerbation that has 
been universally accepted and available for use in both routine clinical practice and clinical 
trials. 
 
The COPD Assessment Test
TM
 (CAT) is a validated 8-item questionnaire It has excellent 
measurement properties (22) and is short and simple for patients to complete, providing a 
score out of 40 to indicate disease impact, without the need for complex calculation (Figure 
3.3). Initial studies have shown that the CAT correlates closely with health-related quality of 
life as measured by the St. George‟s Respiratory Questionnaire (SGRQ) when patients are 
stable (22), and is responsive to pulmonary rehabilitation (25). 
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4.1.2 Aim  
We hypothesised that elevated CAT scores at COPD exacerbation relate to exacerbation 
severity as measured by exacerbation length, lung function impairment and systemic 
inflammation. Furthermore, we hypothesised that CAT scores can be used to model recovery. 
Therefore, well characterized patients were prospectively assessed using the CAT in the 
baseline stable state, at exacerbation presentation and thereafter for five weeks during the 
recovery period. 
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4.1.3 Methods 
Full methodology for this chapter is described in methods section 3.2.1. This study involved 
161 COPD patients enrolled in the London COPD cohort between 1st January 2009 and 1st 
June 2011. Exacerbation frequency was calculated for each patient using diary card data 
obtained between January 2009 and June 2011. Patients completed at least one CAT 
questionnaire in the stable, baseline state. CAT questionnaires were also administered during 
exacerbation between April 2010 and June 2011. The exacerbation CAT score took place 
within 7 days of exacerbation onset as judged by diary cards. A subgroup of patients also 
completed CAT scores on a daily basis during their recovery (Figure 3.4). 
 
Exacerbations were treated according to guidelines. CAT scores played no role in treatment 
decisions. At exacerbation, blood samples were taken (for serum CRP and Fibrinogen) and 
spirometry performed prior to commencing exacerbation treatment. 
 
Statistical analysis 
Data were analysed with STATA 8.2 (Stata Corporation, Texas, USA). Normally distributed 
data were expressed as mean and standard deviation (SD) and skewed data as median and 
interquartile range (IQR). Comparisons were made by paired Student t-test or Wilcoxon 
signed-rank test. The relationship between exacerbation frequency and baseline CAT scores 
was examined with a negative binomial regression model, whilst Poisson regression was used 
to model exacerbation recovery and CAT scores. Cross-sectional regression models were 
used to analyze the relationship between inflammatory markers during exacerbation and CAT 
score as allowance could be made for repeated measures on the same patient. 
92 
 
4.1.4 Results 
Patient Characteristics 
161 COPD patients completed at least one CAT questionnaire when stable (exacerbation 
free). Their baseline characteristics are reported in Table 4.1 alongside 75 patients who were 
assessed using the CAT at exacerbation and the 52 of these who completed the CAT 
questionnaire daily during exacerbation recovery. The patients had moderate to severe 
disease with a mean FEV1 % predicted of 50.3% (range 14.0-79.7%). Patients in whom CAT 
was assessed at exacerbation had significantly higher exacerbation frequencies (p<0.001) but 
differed in no other respect.  
 
Patients completed the CAT successfully when stable and when acutely unwell during an 
exacerbation. In total, 6404 out of 6514 questionnaires (98.3%) were completed fully. There 
was no significant difference in the percentages fully completed at baseline, 3496 of 3561 
(98.2%) compared to those at exacerbation onset and during recovery, 2908 of 2953 (98.5%; 
p=0.35).  
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Table 4.1.Clinical characteristics of patients in the baseline, exacerbation and recovery analyses 
‡ Comparison between 75 patients with exacerbation CAT scores at exacerbation and 86 patients in whom an exacerbation 
was not examined. 
† 
Comparison between 52 patients with exacerbation CAT scores during recovery and 109 patients in whom a recovery 
time course was not examined. 
 
  
 Baseline 
n=161 
Exacerbation 
n=75 
p-value‡ Recovery Subgroup 
n=52 
p-value† 
 Mean±SD Mean±SD  Mean±SD  
Age (years) 71.3±9.4 71.3±8.4 0.99 71.3±7.9 0.96 
FEV1 (L) 1.22±0.47 1.14±0.41 0.10 1.14±0.4 0.12 
FEV1 (% predicted) 50.3±16.9 47.9±16.3 0.10 47.1±16.6 0.10 
FVC (L) 2.59±0.78 2.51±0.79 0.09 2.52±0.9 0.45 
FEV1 / FVC ratio (%) 47.4±12.6 46.5±13.0 0.38 46.2±13.1 0.40 
Smoking pack years 53.5±38.9 52.2±39.9 0.62 50.6±37.3 0.53 
SpO2 (%) 94.7±2.0 94.6±2.1 0.52 94.4±2.1 0.10 
BMI (kg/m2) 26.4±5.6 26.6±5.4 0.56 27.0±5.1 0.31 
      
 Median (IQR) Median (IQR)  Median (IQR)  
Exacerbation frequency 1.95 (0.90-3.00)  2.73 (1.70-4.10) <0.01 3.00 (2.20-4.40) <0.01 
      
 N (%) N (%)  N (%)  
Male gender 97 (60) 43 (57) 0.48 31 (60) 0.91 
Current Smokers 49 (31) 20 (27) 0.36 11 (22) 0.08 
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Use of CAT at Baseline 
Baseline CAT and exacerbation frequency 
The 161 patients had a mean baseline CAT score of 18.1 (SD 7.45). Patients with more 
frequent exacerbations had higher CAT scores (negative binomial regression coefficient = 
0.018 exacerbations per year per CAT unit increment, 95% CI 0.001-0.036; p=0.048). 
Frequent exacerbators (≥2 exacerbations per year, n=80) had a mean CAT score of 19.5 (SD 
6.6) compared to infrequent exacerbators (<2 exacerbations per year, n=81) whose mean 
CAT score was 16.8 (SD 8.0; p=0.025, Figure 4.1). Thus, there was an average 2.7 point 
difference in CAT score between the frequent and infrequent exacerbators.  
 
 
Figure 4.1. Mean baseline CAT 
scores between frequent and 
infrequent exacerbators (161 
patients). Vertical lines represent 
standard errors. 
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Relationship between CAT score and systemic inflammatory markers in the baseline state 
At baseline, serum CRP was measured on the same day as a CAT was completed in 318 
blood samples obtained from 150 separate patients and plasma fibrinogen in 282 blood 
samples from 144 patients. There was a significant relationship between systemic 
inflammation, as measured by log10 fibrinogen, and CAT score on the day of baseline 
sampling, regression coefficient= 0.0014 (95% CI 0.0001-0.0027; p=0.035, Figure 4.2), 
R
2
=0.024 using random-effects GLS regression. However, there was no statistically 
significant relationship between log10 CRP and CAT scores, regression coefficient = 0.0059 
(95% CI -0.0016-0.0133; p=0.122).  
 
No difference in baseline CAT scores was seen between patients with or without potentially 
confounding comorbidities (congestive heart failure, renal failure, obesity or sleep disordered 
breathing, Table 4.2), confirming previous work that CAT scores appear unaffected by low 
levels of comorbidity (18). 
Figure 4.2. Relationship 
between log10 fibrinogen and 
CAT score at baseline (282 
samples from 144 patients). 
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Table 4.2. Effect of Comorbidities on Baseline CAT Score 
 CAT Score 
Comorbidity Absent 
CAT Score 
Comorbidity Present 
p-value 
(unpaired t-test) 
 
 
Mean  ± SD Mean  ± SD  
Congestive heart failure 18.2 ± 7.6 
(n=143) 
 
18.1 ± 6.8 
(n=16) 
0.968 
Ischemic heart disease 17.9 ± 7.6 
(n=130) 
 
19.4 ± 7.2 
(n=29) 
0.328 
Any cardiovascular disease  
(excluding hypertension) 
17.8 ± 8.0 
(n=102) 
 
18.9 ± 6.6 
(n=57) 
0.396 
Hypertension 17.7 ± 8.4 
(n=73) 
 
18.6 ± 6.7 
(n=86) 
0.469 
Obstructive sleep apnoea 18.0 ± 7.5 
(n=153) 
 
22.9 ± 5.4 
(n=6) 
0.119 
Obesity  
(body mass index >30kg/m2) 
18.0 ± 7.7 
(n=122) 
 
18.7 ± 6.4 
(n=36) 
0.655 
Chronic kidney disease 
(estimated glomerular filtration 
rate <60ml/min) 
18.5 ± 7.6 
(n=126) 
16.5 ± 6.2 
(n=29) 
0.205 
Severe chronic kidney disease  
(estimated glomerular filtration 
rate <30ml/min) 
18.1 ± 7.4 
(n=152) 
21.0 ± 4.5 
(n=3) 
0.500 
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Use of CAT at exacerbation 
The CAT was completed at 152 treated exacerbations by 75 patients. The median interval 
from diary card exacerbation onset to the day of treatment was 2 days (IQR 1-4). Figure 4.3 
shows that the CAT score rose from an average baseline value of 19.4 (SD 6.8) to 24.1 (SD 
7.3; p<0.001) at exacerbation. 
 
The magnitude in rise of CAT score from baseline to exacerbation was not affected by patient 
baseline characteristics. Patients whose change in CAT score at exacerbation was on average 
greater or equal to 2 units displayed no significant difference in age (73.2 vs 70.3 years; 
p=0.13), FEV1% predicted (47.6 vs 47.3 %; p=0.94) or exacerbation frequency (2.73 vs 2.48; 
p=0.586) from those with smaller changes in CAT score.  
 
Results were also unaffected by the timing of the baseline. In 98 exacerbations where a 
baseline CAT score was available prior to the index exacerbation, the CAT score rose from 
an average baseline value of 19.0 to 24.3 (p<0.001) at exacerbation. In the main analysis, in 
152 exacerbations using baselines obtained during stable periods that occurred prior to or 
following exacerbations, the CAT score rose from an average baseline value of 19.4 to 24.1 
(p<0.001) at exacerbation. 
Figure 4.3. Mean CAT scores at 
baseline and exacerbation for 152 
exacerbations (75 patients). 
Vertical lines represent standard 
errors. 
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Exacerbation characteristics 
The symptomatic characteristics of exacerbations did not affect the magnitude of CAT rise at 
exacerbation, except those few exacerbations characterized by the presence of the 3 
symptoms of dyspnea, cold and sore throat only, which had significantly increased rises in 
CAT scores at exacerbation compared to those without (n=8, mean 11.5, SD 8.2 vs n=144, 
mean 4.4, SD 6.3, p=0.003). Exacerbations associated with symptoms of both increased 
sputum volume and purulence did not display a significantly increased change in CAT score 
compared to those without (n=61, mean 5.3, SD 6.7 vs n=91, mean 4.4, SD 6.5, p=0.392). 
This may be a due to the absence of a specific question assessing sputum purulence in the 
CAT. 
 
Peak CAT scores 
CAT scores rose further following exacerbation onset to reach a maximum, peak CAT score. 
CAT scores in the recovery subgroup increased from a mean baseline score of 18.3 (SD 7.5) 
to a mean peak score of 26.5 (SD 7.1; p<0.001, Figure 4.4).  
 
  
Figure 4.4. Change in CAT 
scores from baseline to peak 
exacerbation value for 52 
exacerbations (52 patients). 
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Effect of Exacerbation Treatment 
Whilst patients within the London COPD cohort complete daily symptom diary cards which 
allows detection of exacerbations that are unreported to healthcare professionals and 
untreated with extra medication (7), all 152 exacerbations included in the analyses were 
treated. The vast majority of exacerbations were treated with systemic treatment following 
clinical review by a member of the research team; 103 exacerbations were treated with 
antibiotics and oral corticosteroids, 22 with antibiotics alone, and 7 with oral steroids alone. 
Just 20 patients increased inhaled therapy (bronchodilators and/or inhaled corticosteroids) 
alone without systemic treatment. Increases of more than 2 units in CAT score were 
associated with a greater likelihood of treatment with antibiotics (88.7% vs 70.4%; p=0.004) 
but not oral steroids (75.5% vs 66.7%; p=0.243).  
 
The main analysis was repeated using a strict health care utilisation (HCU) definition of an 
exacerbation, based on physician review and increased systemic treatment. 132 exacerbations 
fitted this criterion. The mean change in CAT score from baseline to HCU exacerbation was 
5.2 units (SD 6.7, n=132). Mean change in CAT score from baseline to exacerbation for 
patients who received increased inhaled therapy alone was 2.0 (4.9), although this was based 
on just 20 exacerbations. Further work is required to further explore the relationships between 
changes in CAT at exacerbation and choice of exacerbation treatment. 
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Effect of exacerbation frequency phenotype on CAT change at exacerbation 
It does not appear that the exacerbation data from 75 patients who experienced 152 
exacerbations was affected by a few patients with frequent exacerbations. In analyses which 
examined the average change from baseline to exacerbation for each of the 75 patients, the 
mean change was 4.98 units, compared to 4.70 in the main results for 152 exacerbations. 
 
Repeatability during exacerbations 
Of the 75 patients included in the main exacerbation analysis, 38 underwent at least one 
further subsequent exacerbation. No difference was seen in the magnitude of change from 
baseline to exacerbation between their first and second exacerbation (mean 5.2 vs 5.3, 
p=0.924). 19 of the 52 recovery subgroup patients recorded CAT scores during a second 
exacerbation. There was no difference in peak CAT score between first and second 
exacerbation (mean 27.0 (SD 7.86) versus 26.4 (8.5); p=0.687, Figure 4.5) or in the change 
from baseline to peak score (6.7 (SD 4.9) versus 6.1 (5.1); p=0.687). 
 
 
  
Figure 4.5. Repeatability of 
CAT changes at separate 
exacerbations (19 patients). 
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Relationship between CAT score and systemic inflammatory markers at exacerbation  
CAT scores at exacerbation were significantly related to concurrent levels of systemic 
inflammatory markers. At exacerbation, serum CRP was measured on the same day as a CAT 
was completed in 114 exacerbations and plasma fibrinogen in 111 exacerbations. After log10 
transformation, both inflammatory markers were significantly related to the CAT score 
recorded at exacerbation, and with allowance for repeated measures in the same patient, 
log10CRP increased by 0.028 (95% CI 0.013-0.043; p<0.001) and log10fibrinogen by 0.003 
(95% CI 0.001-0.005; p=0.015), per unit increase in CAT score. Change in CAT score from 
baseline to exacerbation onset was significantly related to change in CRP (rho=0.26; 
p=0.008) but not to change in fibrinogen (rho=0.09, p=0.351) from baseline to exacerbation. 
 
Lung function changes and CAT scores at exacerbation  
CAT scores were significantly related to contemporaneous spirometry, as measured by FEV1. 
At exacerbation, spirometry was performed on the same day as a CAT was completed in 112 
exacerbations. Mean paired FEV1 measured at baseline was 1.12 L (SD 0.44) and 1.01 L at 
exacerbation (SD 0.44) (p<0.001). Rises in the CAT score recorded at exacerbation were 
significantly associated with falls in FEV1 at exacerbation (rho=-0.20, p=0.032).  
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Time Course of CAT scores during exacerbation recovery 
52 different patients completed the CAT questionnaire on at least 21 of 35 days during the 
recovery phase following an exacerbation. All of these 52 exacerbations were treated; 41 with 
antibiotics and oral steroids, 5 with antibiotics alone, 3 with oral steroids alone, and 3 were 
treated with increased inhaled therapy alone. Figure 4.6 shows the time course of the CAT 
scores, PEFR and diary card symptom counts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Time course of CAT 
scores, PEFR and diary card 
symptom counts during 
exacerbation recovery (52 
patients). Vertical bars represent 
standard errors. Horizontal lines 
indicate mean baseline scores. 
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Symptom counts were obtained by summating each increased respiratory symptom recorded 
on the London cohort diary cards per day. The mean baseline symptom count (denoted by a 
horizontal line) lies at greater than zero because patients may record sporadic increases in 1 
or more symptoms but not reach the definition of an exacerbation (increase for two 
consecutive days in respiratory symptoms, with at least one major symptom (dyspnea, 
sputum purulence or sputum volume) plus either another major or a minor symptom (wheeze, 
cold, sore throat, and cough)). This phenomenon of patients experiencing sporadic increases 
in respiratory symptoms following the end of an exacerbation is also the reason for the slight 
elevation of symptom counts above baseline at 12 days (recovery time). The last day of 
recorded worsening symptoms before two consecutive symptom-free days defined the end of 
the exacerbation. 
 
Relationship between CAT score and symptom recovery 
CAT scores reflected symptomatic recovery following exacerbations. Amongst the 52 
episodes, the median recovery time as judged by symptom diary cards was 12 days (IQR 9-
23, n=47) and this was significantly related (rho=0.42; p=0.012) to the time taken for the 
CAT score to return to baseline (median 11 days, IQR 4.5-17, n=40).  
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4.1.5 Discussion 
This novel study prospectively assessed the utility of the CAT to evaluate exacerbation 
severity in COPD patients. At exacerbation, CAT scores were significantly elevated from 
paired baseline values and this work uniquely demonstrated that CAT scores reflect 
exacerbation severity as measured by exacerbation length and reduction in lung function. A 
weak relationship was also found between systemic inflammatory markers and CAT scores at 
exacerbation. Furthermore, this work demonstrated that baseline CAT scores are significantly 
elevated in stable COPD patients with a history of frequent exacerbations. 
 
The CAT is a validated health status questionnaire that is free to use and can be administered 
without prior permission for research purposes and by individual practitioners 
(http://www.catestonline.org). Previous studies have shown that the instrument can be 
successfully administered in both primary (109) and secondary care settings (110), and is 
responsive to a course of pulmonary rehabilitation and able to distinguish different levels of 
response (110). Additionally, CAT scores exhibit little variability across countries; they are 
not influenced by age or sex but reflect disease severity in the stable state as determined by 
Global Initiative for chronic Obstructive Lung Disease (GOLD) spirometric staging, MRC 
dyspnoea score, SGRQ and clinician-judged severity (22, 109).  
 
This study complements this existing work by demonstrating that the CAT can be used as a 
score of the multi-dimensional nature of COPD exacerbation severity. At present the 
assessment of symptom severity at exacerbation and during recovery is subjective in nature, 
with no established scoring system in clinical practice. Exacerbation therapy is currently 
determined by a subjective physician assessment of exacerbation severity and so an objective 
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tool to determine exacerbation severity will fulfill an important unmet need. This has 
particular relevance as patients are increasingly seen by healthcare professionals in the 
community, often within their own homes, without the benefit of objective measures of 
exacerbation severity such as accurate spirometry or systemic inflammatory markers. PEFR 
is a cheap, reliable and easy way for patients to assess lung function on a daily basis. 
Previous studies have shown that PEFR decreases to a small extent but significantly at 
exacerbation onset and can be a useful tool to indicate exacerbation recovery in population 
studies. However the changes are not large enough to use PEFR at an individual level for 
exacerbation detection and monitoring (13). 
 
The CAT provides an objective quantification of the impact of symptoms that is acceptable to 
patients and can be easily completed at exacerbation and during recovery. Systemic 
inflammation, as measured by plasma fibrinogen and serum CRP increases at exacerbation 
(37, 111, 112), and this study has demonstrated a weak relationship between CAT scores at 
exacerbation and systemic inflammatory markers. Inflammatory changes at COPD 
exacerbations are also related to clinical non-recovery and recurrent exacerbations within 50 
days (56). Recovery time is an index of exacerbation severity (13) and for the first time this 
study has evaluated use of the CAT during exacerbation recovery. CAT scores reflect 
recovery following exacerbations; the time taken for scores to return to baseline being 
significantly related to recovery time as judged by symptom diary cards. Additionally, at 
exacerbation, CAT scores are significantly but modestly related to contemporaneous lung 
function impairment, as measured by FEV1, consistent with previous data examining the 
relationship between baseline CAT scores and FEV1 (109). Thus CAT scores provide an 
easily quantifiable, overall score of exacerbation severity and may be useful in studies 
evaluating interventions for the management of acute exacerbations.  
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When measured in the stable state CAT scores are highly correlated to concurrent SGRQ 
measurements (22). However, this study has shown a divergence between the behavior of the 
CAT and SGRQ during exacerbation recovery.  Following a study of exacerbations of 
chronic bronchitis, whilst an early improvement is seen in SGRQ scores when measured 4 
weeks after an index event, improvements can also slowly continue for several months (113). 
In this study CAT scores have returned to baseline levels more rapidly. This may be a result 
of the daily use of the instrument in this study and the response system in the CAT, which is 
based on categories of difference between two extreme statements about the same COPD 
impact. In contrast, the SGRQ has predominantly dichotomous yes/no responses and is 
administered at intervals. Thus, although the CAT can reliably assess exacerbation severity, 
daily CAT readings may over-estimate the speed of recovery of health status post-
exacerbation. 
 
This study has also added to previous data examining the use of the CAT in the baseline 
stable state by examining the relationship between baseline CAT scores and exacerbation 
frequency. Patients with a history of frequent exacerbations have worse quality of life (11), 
increased risk of hospitalisation (114) and greater mortality (12). Frequent exacerbators also 
exhibit faster decline in lung function (8) and may have worse functional status, as measured 
by time outdoors (115). In this study baseline CAT scores relate to exacerbation frequency. 
When used in the stable state, scores were significantly elevated in frequent exacerbators, 
defined by two or more exacerbations per year, compared to infrequent exacerbators. Also, 
baseline CAT scores were weakly but significantly related to concurrent fibrinogen levels. 
Plasma fibrinogen levels are elevated in stable patients with COPD (112) and that increased 
systemic inflammation, as measured by fibrinogen, in stable COPD patients over time is 
directly linked to disease progression, as defined by lung function decline (27). Further work 
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is required to explore whether CAT scores may potentially be a useful marker of disease 
progression over time in COPD.  
 
The CAT is a potentially useful, widely applicable tool which can aid assessment of 
exacerbation severity. The instrument can be easily and rapidly completed in many healthcare 
settings and could potentially be integrated into care bundles of COPD patients without 
additional cost.  Patient recognition of exacerbation symptoms and prompt treatment 
improves exacerbation recovery and reduces the risk of hospitalisation in COPD patients 
(20). Further evaluation is now required of the CAT within exacerbation management 
strategies to assess utility of the tool within clinical practice.  
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4.1.6 Conclusion 
In conclusion, the CAT provides a reliable score of exacerbation severity. CAT scores 
increase at exacerbation and reflect exacerbation severity as determined by lung function and 
exacerbation length. A weak relationship was also found between systemic inflammatory 
markers and CAT scores at exacerbation. Thus, the CAT is a valuable instrument to enhance 
and standardise COPD exacerbation assessment. Incorporating this questionnaire into 
assessment strategies may aid health care professionals to determine the severity of 
exacerbations, particularly in situations where access to other objective measures of severity 
is limited.  
 
This work formed the basis an original publication published in the American Journal of 
Respiratory Critical Care Medicine:  
 
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate 
severity of COPD exacerbations. 
Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. 
American Journal of Respiratory and Critical Care Medicine. 2012 June 1;185(11):1218-24. 
doi: 10.1164/rccm.201110-1843OC. 
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4.2 Performance of the Exacerbations of Chronic Pulmonary Disease Tool 
(EXACT) in detection and severity grading of COPD exacerbations 
 
4.2.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is associated with episodes of symptomatic 
deterioration termed exacerbations (49). COPD exacerbations are amongst the commonest 
causes of medical admission to hospital (6). Patients with frequent exacerbations (7) have 
accelerated lung function decline (8, 9), worse quality of life (11), are at increased risk of 
cardiovascular events (10) and have greater mortality (12).  
 
Assessment of exacerbation severity is an important outcome measure in COPD and most 
clinical trials of preventive therapy to date have used a dichotomous approach to assigning 
severity levels, with outpatient drug therapy (antibiotics and/or steroids) categorized as 
“moderate” and hospitalisations labelled “severe”. These outcome measures are limited by 
inaccurate reporting, lack of generalisability across different healthcare systems and their 
failure to capture unreported exacerbations. Unreported exacerbations are common (11, 18, 
19) and important events, associated with worsening quality of life (11, 18) and increased risk 
of subsequent hospitalisation (20).  
 
Exacerbation symptoms systematically recorded on daily diary cards accurately detect both 
reported and unreported exacerbations (11, 13), but most symptom diary cards are not 
sensitive enough to assess severity of these events. The FDA‟s patient-reported outcome 
(PRO) guidance document (21) offers recommendations for developing PRO instruments for 
use in medical product development, including symptom-based methods for standardising the 
severity of reported and unreported exacerbations.  
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The Exacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT) is a PRO daily 
symptom diary developed to capture frequency, severity, and duration of exacerbations in 
clinical trials of COPD (26). Scores range from 0 to 100, with higher scores indicating more 
severe symptoms. To date, no published data have examined the relationship between 
EXACT scores and pulmonary function or markers of inflammation during exacerbations. 
Furthermore, the EXACT was designed to quantify the evaluation of exacerbations of COPD. 
Specifically, the intent was to capture unreported events, using a threshold-based definition of 
sustained symptomatic worsening, and provide a standardised metric for evaluating the 
severity of unreported and reported, healthcare utilisation (HCU) events. However, in 
published papers thus far, no data has been reported examining the relationship between 
symptom-defined events captured by the EXACT, exacerbations detected by London COPD 
cohort symptom diary cards, and HCU events. 
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4.2.2 Aim  
We hypothesised that the EXACT can accurately assess the severity of both reported and 
unreported COPD exacerbations, defined by the London COPD cohort diary card, as 
measured by exacerbation length, lung function impairment and systemic inflammation. 
Furthermore, we sought to examine the relationship between exacerbations diagnosed using 
validated London COPD cohort diary cards (8, 11, 13) and physician review, and symptom-
defined events captured by the EXACT. Therefore, patients in the London COPD cohort 
prospectively completed the EXACT at baseline and during exacerbation.  
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4.2.3 Methods  
Full methodology for this chapter is described in methods section 3.2.2. This study involved 
58 COPD patients enrolled in the London COPD cohort between January 2010 and April 
2012. Exacerbation frequency was calculated for each patient using diary card data obtained 
between 1/4/2010 and 1/4/2012.  
 
Patients completed a paper version of the EXACT at least once under supervision in clinic 
and were instructed to complete the EXACT diary each evening before bedtime, based on 
their symptoms experienced that day.  Patients prospectively completed the EXACT on a 
daily-basis when stable and continued long-term to enable capture of the exacerbation 
prodrome, the onset of the event, its nadir and recovery (Figure 4.7). Exacerbations were 
treated according to guidelines. EXACT scores played no role in treatment decisions. At 
exacerbation, blood samples were taken (for serum CRP and Fibrinogen) and spirometry 
performed prior to commencing exacerbation treatment. 
 
Statistical analysis 
Data were analysed with STATA 8.2 (Stata Corporation, Texas, USA). Normally distributed 
data were expressed as mean and standard deviation (SD) and skewed data as median and 
interquartile range (IQR). Comparisons were made by paired Student t-test or Wilcoxon 
signed-rank test. The relationship between exacerbation frequency, determined using London 
COPD cohort diary cards, and baseline EXACT scores was examined with a negative 
binomial regression model, whilst Poisson regression was used to model exacerbation 
recovery and EXACT scores. Cross-sectional regression models were used to analyse the 
relationship between CRP levels during exacerbation and EXACT score as allowance could 
be made for repeated measures on the same patient.  
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4.2.4 Results 
Patient Characteristics 
Full baseline clinical characteristics of the 58 patients included in this analysis are reported in 
Table 4.3. Patients had moderate to severe COPD with a mean FEV1 % predicted of 48.6%.  
 Mean±SD 
Age (years) 70.2±8.2 
FEV1 (l) 1.22±0.56 
FEV1 (% predicted) 48.6±18.1 
FEV1/ FVC (%) 46.6±14.2 
Smoking pack years 54.0±42.1 
SpO2 (%) 94.6±2.0 
BMI (kg/m2) 26.8±5.7 
 Median (IQR) 
Diary card Exacerbation Frequency (per patient per year) 2.88 (1.92-4.43) 
 n= 
Male, n (%) 36 (62.1) 
Current Smokers, n (%) 11 (19.0) 
Comorbidity present, n (%) 47 (81.0) 
Congestive heart failure, n (%) 6 (10.3) 
Ischemic heart disease, n (%) 13 (22.4) 
Hypertension, n (%) 32 (55.2) 
Diabetes Mellitus, n (%) 4 (6.9) 
Patients receiving maintenance inhaled corticosteroids, n (%) 52 (89.6) 
  
Table 4.3. Clinical characteristics of the 58 patients at time of recruitment to the cohort. 
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Baseline Studies 
Baseline EXACT scores were significantly related to disease severity.  These baseline 
EXACT scores in 58 patients were significantly correlated with London COPD cohort diary 
card exacerbation frequency (rho=0.38, p=0.003), FEV1 (rho=-0.32, p=0.015) and FEV1% 
predicted (rho=-0.30, p=0.020).  
 
Stability of baseline EXACT scores over time 
53 patients had two 7-day baseline periods distinct from the pre-exacerbation baseline, on 
average 278 days apart (Figure 4.7).  
 
 
Overall EXACT scores were stable over time, with no significant difference found between 
EXACT scores recorded between the first 7-day baseline and the last 7-day baseline (mean 
39.2 (SD 9.5) vs. 39.8 (10.3), p=0.117). However, in a small but important proportion of 
Figure 4.7. Schematic timeline of EXACT scores (x) recorded when stable and during 
exacerbation. This figure is for illustrative purposes and does not indicate real data. 
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patients, baseline scores did vary over time. EXACT scores rose between the 1
st
 and 2
nd
 
baseline periods by more than 12 points in 3 patients and by more than 9 points in 5 patients. 
EXACT scores fell between baseline periods by more than 12 points in 3 patients and by 9 
points in 3 patients (Figure 4.8).  
 
 
Exacerbation Studies 
58 patients completed the EXACT during 128 London COPD cohort diary card 
exacerbations. 85 of 128 (66.4%) were treated with systemic therapy; 82 (64.1%) with 
antibiotics and 64 (50.0%) with oral corticosteroids. There were no hospitalised 
exacerbations.  
 
The baseline mean EXACT score averaged over 7 days (-14 to -8 days before exacerbation 
onset) was 42.6 (SD 8.6). This increased to 48.0 (8.6) at London COPD cohort diary card 
exacerbation onset, 5.4 (7.1) above baseline (p<0.001), representing a 13% rise. EXACT 
scores increased further to a maximum score of 54.1 (8.9) or 11.4 (7.6) above baseline 
(p<0.001), during the 2 weeks following exacerbation onset (Figure 4.9). The median time 
Figure 4.8. Variability in mean 
EXACT scores between two 
separate seven day baseline 
periods (53 patients). 
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from exacerbation onset to peak EXACT score was 3 days (IQR 1-5.5).  No difference was 
seen in the maximum increase from onset in EXACT score between type 1 Anthonisen 
exacerbations (events associated with increased sputum volume, purulence and dyspnoea) 
and other types (n=27, 6.6 (6.3) vs. n=101, 5.9 (5.4), p=0.541). 
 
 
 
Relationship between EXACT score and systemic inflammation 
EXACT score changes at exacerbation presentation were significantly related to concurrent 
levels of systemic inflammation. At exacerbation, log10CRP was related to the change in 
EXACT score from baseline to exacerbation (rho=0.30; p=0.041, Figure 4.10). The median 
exacerbation CRP score was 9 (IQR 4.3-16.8). 
 
 
Figure 4.9. Mean EXACT scores 
at baseline ( ), exacerbation onset 
( ), and the maximum ( ) 
EXACT scores during the 2 weeks 
following exacerbation onset. 
Vertical lines represent standard 
errors. 
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Evolution of EXACT scores during exacerbation recovery  
EXACT scores accurately reflected exacerbation recovery. The time taken for EXACT scores 
to return to baseline (median 7 days, IQR 0-12; n=93) was significantly related (rho=0.44; 
p<0.001) to symptom recovery time as judged by London COPD cohort diary cards (median 
8 days, IQR 4-12; n=114). Recovery in EXACT was also significantly correlated with lung 
function recovery as measured by PEFR (rho=0.32; p=0.003). Time course plots of recovery 
of EXACT score, London COPD cohort diary card symptom counts and peak expiratory flow 
rate (PEFR) generated using daily mean values of all 128 exacerbations are presented in 
Figure 4.11(a), (b) and (c) respectively. 
Figure 4.10. Relationship 
between log10CRP and change in 
EXACT scores at exacerbation 
(rho=0.30; p=0.041). 
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Relationship between EXACT scores and exacerbation treatment 
No difference was observed in exacerbation onset EXACT scores between treated (systemic 
therapy) and untreated (no systemic therapy) events (n=85, mean 48.2 (8.5) vs. n=43, 47.7 
(9.0), p=0.762). However, maximum EXACT scores were significantly higher in treated than 
untreated events (n=85, mean 55.2 (9.1) vs. n=43, 51.8 (8.1), p=0.040, Figure 4.12a). 
 
Figure 4.11. Time course plots of 
recovery of EXACT score, 
London COPD cohort diary card 
symptom counts and peak 
expiratory flow rate (PEFR) 
generated using daily mean 
values of all 128 exacerbations 
are presented in Figure 4.11(a), 
(b) and (c) respectively. Vertical 
bars represent standard errors. 
Horizontal lines indicate mean 
baseline scores. 
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Time course of EXACT scores during treated and untreated exacerbations 
Median time from exacerbation onset to initiation of systemic therapy for the 85 treated 
exacerbations was 2 days (1-4). Despite the higher maximum EXACT score following 
exacerbation onset, no significant difference was seen between treated and untreated 
exacerbations in EXACT recovery time (n=61, median 7 days (0-12) vs. n=32, 5.5 (2-12), 
p=0.656, Figure 4.12b) or total net EXACT recovery score (n=61, median 24.2 EXACT.day 
(0-75.3) vs. n=32, 13.1 (1.5-65.9), p=0.455).  
 
 
 
  
Figure 4.12. (a) Maximum EXACT scores in COPD patients treated with ( ) and without ( ) 
increased systemic therapy at exacerbation. Vertical lines represent standard errors. (b) Time 
course of EXACT scores during treated ( ) and untreated ( ) exacerbations. Vertical lines 
represent standard errors. 
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EXACT Concordance 
Relationship between EXACT scores and London COPD cohort diary card-defined 
exacerbations 
58 patients had 128 London COPD cohort diary card defined exacerbations, 27 of which 
(21.1%) attained a 12 point increase in EXACT score above baseline for 2 consecutive days. 
34 of 128 (26.6%) of exacerbations attained a 9 point increase for 3 consecutive days. 57 
(44.5%) of 128 exacerbations attained a 12 point increase in EXACT score above baseline at 
least once during the 14 day period following exacerbation onset. On average this threshold 
score of 12 was breached 4.4 days after symptomatic onset.  59 of 128 exacerbations (46.1%) 
had a 9 point increase in EXACT score above baseline at least once during the 14 day period 
following exacerbation onset, on average 3.7 days after symptomatic onset.  
 
Relationship between EXACT scores and healthcare utilisation (HCU) exacerbations 
85 (66.4%) of 128 London COPD cohort diary card defined exacerbations were treated with 
additional systemic therapy (oral antibiotics and/or corticosteroids) by the study team, 
consistent with a moderate severity HCU exacerbation. 22 of 85 (25.9%) HCU exacerbations 
attained a 12 point increase in EXACT score above baseline for 2 consecutive days. 29 of 85 
(34.1%) attained a 9 point increase for 3 consecutive days. The 12 point threshold was 
breached at least once during the 14 day period following exacerbation onset in 43/85 
(50.6%) of these HCU exacerbations and the 9 point threshold in 44/85 (51.8%).  
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Relationship between symptom-defined events using the EXACT and London COPD 
cohort diary card and HCU exacerbations 
The scoring algorithm for a symptom-defined event using the EXACT is an increase of 12 
points above the patient‟s mean baseline for 2 consecutive days or an increase of 9 points 
above the patient‟s mean baseline for 3 consecutive days. Previous analyses for the EXACT 
have examined the day of presentation of an HCU exacerbation ± 7 days for the presence of 
an EXACT event (Leidy & Murray, personal communication, 2013). In this study we 
analysed the period of exacerbation onset ± 7 days, as defined by London COPD cohort diary 
cards. 86 diary card defined exacerbations had a complete dataset of daily EXACT scores 
during this period. 24 (27.9%) of these exacerbations met the EXACT threshold for a 
symptom-defined event. Of these 86 exacerbations with a complete dataset, 52 were HCU 
exacerbations, 18 (34.6%) of which met the criteria for an EXACT event.  
 
Alternative thresholds for concordance 
A number of alternative thresholds were examined in an attempt to find a level that provides 
improved concordance compared to the 9 and 12 point thresholds. The highest sensitivity and 
specificity was attained using a threshold of 7.5 points for 2 consecutive days under which 43 
of 85 HCU exacerbations would be consistent with this definition. This provided a sensitivity 
of 62.35% and specificity of 58.14% giving an area under the receiver operating 
characteristic curve of 0.55. 
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Relationship between exacerbation EXACT scores and baseline disease severity  
Patients exhibited smaller rises in EXACT score at exacerbation as baseline disease severity 
(judged by baseline EXACT score) increased. Figure 4.13 shows that change between 
maximum exacerbation and baseline EXACT score seen at London COPD cohort diary card 
exacerbation was significantly related to baseline EXACT score (rho =-0.61, p<0.001) 
allowing for repeated measures.  
 
 
 
 
 
 
 
Figure 4.13. Relationship between baseline EXACT score and maximum rise in EXACT 
score at exacerbation. Black filled dots ( ) represent HCU exacerbations. White unfilled 
dots ( ) represent London COPD cohort diary card defined exacerbations which were not 
treated with additional systemic therapy.   
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4.2.5 Discussion 
This novel study is the first to independently validate the EXACT as an effective tool to 
assess exacerbation severity. EXACT scores increase at COPD exacerbation, the magnitude 
of which reflects the severity of the event in terms of treatment, systemic inflammation, 
airflow limitation and symptom recovery time. For the first time this work studied the 
EXACT against the validated London COPD cohort daily symptom diary card (8, 11, 13) and 
thus uniquely examined the complex relationship between symptom-defined events using the 
EXACT and both healthcare utilisation (HCU) exacerbations and London Cohort diary-card 
identified, untreated exacerbations. Approximately 50% of both diary card-defined and HCU 
exacerbations crossed the EXACT event threshold but only approximately one third fulfilled 
the criteria for an EXACT event. Thus this study has highlighted important potential 
limitations of the EXACT in its ability to independently identify events which were captured 
by physician review (HCU) or London COPD cohort diary cards. Baseline disease severity 
appears to play an important role in symptom reporting and physician prescribing thresholds 
at exacerbation. 
 
In this study, EXACT scores at exacerbation were significantly related to systemic 
inflammation, as measured by concurrent levels of serum CRP. This is an important asset for 
a successful outcome measure of exacerbation severity since elevated systemic inflammation 
during exacerbations relates to both clinical non-recovery and exacerbation recurrence (56). 
Furthermore, the time taken for EXACT scores to return to baseline was significantly related 
to recovery time as judged by London COPD cohort symptom diary cards and was also 
modestly correlated with lung function recovery as measured by PEFR. Thus these data 
supports the use of the EXACT as an effective tool to measure exacerbation severity and 
assess recovery, particularly suited to trials of interventions to treat acute exacerbations. In 
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this setting, the relative proportion of patients whose EXACT scores have returned to 
baseline (or fallen by a predetermined magnitude) by 7 days (the median recovery time in a 
study evaluating recovery in over 500 exacerbations (13)) could be a valuable outcome 
measure. 
  
In this work, patients completed both London COPD cohort diary cards and EXACT 
questionnaires prospectively to allow us to examine EXACT changes during unreported 
exacerbations which were not treated with increased systemic therapy. EXACT scores 
recorded on the day of exacerbation onset were the same for both reported and unreported 
events. However, while no significant difference was seen in total symptomatic burden or 
exacerbation length as judged by EXACT scores between either type of exacerbation, the 
pattern of recovery observed was different, and maximum EXACT scores recorded during 
the exacerbation were significantly higher in treated compared to untreated, unreported 
events. Furthermore, the lack of statistical significance in the total net EXACT recovery score 
may be due to insufficient sample size. These results demonstrate for the first time that the 
EXACT is responsive to both reported, HCU exacerbations, and unreported exacerbations 
where patients do not report symptomatic deterioration to primary care physicians or 
members of a research team. Identification of unreported exacerbations may be a particular 
advantage in pharmaceutical interventional trials which historically have experienced 
unexpectedly low rates of HCU exacerbations (116, 117). 
 
The assessment of exacerbation frequency during clinical trials was an initial aim in the 
development of the EXACT (26, 27). To facilitate the identification of unreported 
exacerbations, the instrument pre-specifies a threshold for these symptom-defined events 
based on a persistent increase in EXACT score over 2-3 days.   In this study, the relationship 
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between exacerbations identified using the HCU definition, the London Cohort diary card, 
and the EXACT was investigated.  The strength of the relationship was modest. It should be 
noted that patients in the London COPD cohort are instructed to report increased respiratory 
symptoms as recorded in their diary to ensure prompt assessment and therapy as required, 
and were not instructed to report based upon EXACT responses. Some studies have 
attempted to use EXACT scores to enhance reporting of exacerbations by remotely 
monitoring EXACT scores in real-time and using worsening scores to generate an alert 
regarding a possible exacerbation (118), however this was not the case in our study. 
 
Both the London COPD cohort diary cards and the EXACT are responsive to a worsening of 
respiratory symptoms. However the EXACT requires the increase in symptoms to meet a 
strict numerical threshold to fulfil criteria for symptom-defined events using the EXACT, 
thus potentially increasing the likelihood of undercounting relative to London COPD cohort 
diary card defined exacerbations. Furthermore, the seminal event for the calculation of 
concordance of EXACT symptom-defined events is more typically the HCU exacerbation, 
with the date of treatment administration as the day of onset, unlike in this paper where 
cohort diary cards were used to define the onset of events and then examined the 
corresponding EXACT scores of both HCU and London COPD cohort diary card defined 
exacerbations. 
 
Patients in the London COPD Cohort are specifically trained to rapidly recognise and report 
the increased respiratory symptoms that characterise COPD exacerbations. This may also 
have impacted on the relationship between symptom-defined events using the EXACT and 
HCU exacerbations seen in the clinic. Since our patients present early in the course of their 
exacerbation and receive prompt systemic treatment, this may alter the evolution of 
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symptoms for HCU exacerbations compared to when presentation is markedly delayed. In 
such circumstances, if patients do not commence therapy until late in their exacerbation, their 
symptoms may be of a higher intensity, and thus be more likely to cross the threshold for 
symptom-defined events using the EXACT. Nonetheless, despite these caveats it remains a 
concern that only approximately one third of HCU exacerbations within this study fulfilled 
the criteria for an EXACT event. The strength of the relationship between EXACT events 
and HCU exacerbations in our study is consistent with preliminary data from the FORWARD 
trial, which used the traditional physician diagnosis of exacerbations as a co-primary 
outcome, and the EXACT to enhance exacerbation detection, and also found marked 
inconsistencies between EXACT events and HCU exacerbations (118, 119).  
 
The relationship between EXACT scores and HCU exacerbations was examined further by 
exploring the role of baseline COPD disease severity. At baseline, EXACT scores accurately 
reflected disease severity as judged by lung function impairment and London COPD cohort 
diary card exacerbation frequency. At exacerbation, patients exhibited smaller rises in 
EXACT score as baseline disease severity increased, suggesting that patients with more 
severe stable disease are more likely to report and receive additional systemic therapy at 
exacerbations associated with smaller increases in symptom intensity than patients with 
milder baseline disease. This result confirms that people seek care and are treated for 
exacerbations for a variety of reasons, including varied tolerance to symptomatic change. 
More severe patients may be more sensitive to change in symptoms, more frightened by 
smaller changes, or be better trained and therefore report their changes earlier. The London 
cohort is carefully trained to detect change and seek treatment early, and these results support 
the success of this program.  These results also suggest that the EXACT thresholds for 
symptom-defined events are conservative, and are not overestimating the frequency of 
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symptom-defined events that are unreported. It remains important to count HCU events as 
HCU events, particularly since they remain prominent in major guidelines for the diagnosis 
of an exacerbation (1). However, all unreported and untreated symptom-defined events also 
need to be accurately detected with a diary since these events are both common (11, 18, 19) 
and important, contributing to impaired health status (11, 18).   
 
The EXACT has previously been used in conjunction with a personal digital assistant (PDA) 
(26, 120) or smartphone (121). A potential limitation of this study is that the EXACT was 
administered in paper rather than electronic format. However, PROs can be reliably 
completed at exacerbation and during recovery in paper format (122). Furthermore, since the 
content of the EXACT is identical in both formats, this is unlikely to significantly alter the 
results obtained. Indeed, recent work in the Patient Reported Outcomes Measurement 
Information System (PROMIS®) initiative has confirmed that method of administration, 
including comparisons of PDA versus paper questionnaire, does not lead to statistically or 
clinically significant differences in score levels or psychometric properties of patient reported 
outcome tools (123). The use of a paper version of the tool also ensures that the results of the 
study are applicable to the widest range of COPD patients, since patients were not excluded 
because they were not technically capable of using an electronic instrument. 
 
This work demonstrated that the EXACT is an effective tool to evaluate exacerbation severity 
in outpatient settings when the event was captured by physician review (HCU) or by London 
COPD cohort diary cards. Future studies should also assess the efficacy of the instrument in 
hospitalised patients and can use the EXACT to assess both the maximum symptomatic 
intensity of exacerbations and the total symptomatic burden of events.  
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4.2.6 Conclusion 
In conclusion, the EXACT is an effective method of evaluating exacerbation severity. 
EXACT scores reflect severity as determined by lung function, exacerbation length and 
systemic inflammation. The tool is responsive to both treated and untreated exacerbations and 
can be effectively used in conjunction with daily symptom diary cards to provide novel 
outcome measures in clinical trials of acute exacerbation therapies. However, uncertainty 
remains regarding the effectiveness of the instrument to independently and accurately detect 
the onset and frequency of exacerbations, a particular concern in the study of preventative 
therapies for COPD exacerbations.  
 
This work formed the basis of an original publication published in the European Respiratory 
Journal:  
Detection and Severity Grading of COPD Exacerbations Using The Exacerbations of 
Chronic Obstructive Pulmonary Disease Tool (EXACT). 
Mackay AJ, Donaldson GC, Patel AR, Singh R, Kowlessar B, Wedzicha JA.  
European Respiratory Journal. 2014 March;43(3):735-44. doi: 10.1183/09031936.00110913. 
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5 
MONITORING COPD 
EXACERBATION RECOVERY 
USING OBJECTIVE COUGH 
FREQUENCY MEASUREMENTS  
 
The previous chapter has demonstrated that patient reported outcomes can provide important 
information in the assessment of exacerbation severity. Following this we wished to explore 
the ability of objective physiological tools to enhance exacerbation evaluation using 
ambulatory cough monitors. 
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5.1 Introduction  
Cough (either with or without associated sputum expectoration) is one of the principle 
symptoms of COPD, along with dyspnoea. Epidemiological studies have found that the 
reported presence of chronic cough and mucus hypersecretion may be linked to accelerated 
decline in lung function (29), more frequent exacerbations (30), and hospitalisations (31) in 
COPD patients. However, previous work has shown that subjective measures of cough and 
cough reflex sensitivity are only moderately correlated to objective measures of cough (32), 
and have insufficient predictive value for understanding the determinants of cough. 
 
Colleagues at the University of South Manchester have developed a system for recording 
sounds over 24 hours in ambulatory patients, which allows the objective quantification of 
coughing (Vitalojak; Vitalograph Ltd., Buckingham, UK) (34). In a recent publication, this 
group showed that in the stable state, current healthy smokers and COPD ex-smokers have 
similar cough frequencies, both significantly greater than healthy non-smokers. The degree of 
neutrophilic airway inflammation measured in sputum samples from COPD patients in the 
stable state was positively related to cough frequency, independent of the influence of current 
smoking. In those patients who provided sputum samples, over a third of the variation in 
cough rates was explained by the degree of neutrophilic airway inflammation and current 
smoking (34). 
 
Exacerbations are symptomatic deteriorations in respiratory symptoms and cough plays a 
prominent role in these events. Recovery from exacerbations is often prolonged and cough 
may be a protracted feature of some events (13). Exacerbations are also characterised by 
increased neutrophilic airways inflammation (36, 37) and frequent exacerbators have higher 
neutrophilic inflammation than infrequent exacerbators in the stable state (38). A subset of 
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COPD patients are also associated with increased eosinophilic inflammation when stable and 
at exacerbation (52) and eosinophilic inflammation is known cause of chronic cough (124). 
Therefore objective cough monitoring may be a useful tool both in the stable state and during 
acute exacerbations of COPD to assess exacerbation severity and recovery.  
 
Thus in collaboration with the University of South Manchester I examined the utility of 
objective cough monitoring to differentiate between stable COPD and exacerbation and 
whether cough frequency can distinguish patient exacerbation frequency and inflammatory 
phenotype in the stable state.  
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5.2 Aim 
We hypothesised that frequent exacerbators would exhibit a higher cough frequency than 
infrequent exacerbators when stable. We also hypothesised that cough monitoring could serve 
as an objective means of determining the severity of an exacerbation, with those 
exacerbations with higher cough frequency at exacerbation experiencing prolonged 
exacerbation length and increased inflammation. Furthermore, this work examined whether 
cough monitoring could be a useful objective tool to assess exacerbation recovery and would 
identify those exacerbations at high risk of recurrence. Therefore, in this study patients were 
prospectively examined with an objective cough monitor in the baseline stable state, at 
exacerbation presentation and thereafter for five weeks during the recovery period. 
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5.3 Methods 
Full methodology for this chapter is described in methods section 3.3. This study involved 64 
COPD patients enrolled in the London COPD cohort between 1st March 2013 and 1st April 
2014. Cough monitors were used to measure 24 hour cough frequency at baseline, 
exacerbation and during recovery. Cough monitors were placed on patients at the end of 
clinic visits, following completion of sputum sampling, blood sampling and spirometry. 
Equipment was worn for the immediate 24 hours after each visit and then returned for data 
download the following day. 
 
Exacerbations were treated according to the prevailing guidelines and clinical judgment with 
increased inhaled therapy, antibiotics and/or oral steroids. When patients attended for an 
exacerbation, venous blood samples for full blood count, CRP and Fibrinogen were taken and 
spirometry performed prior to commencing exacerbation treatment.  
 
Statistical Analysis 
Data were analysed using IBM SPSS Statistics for Windows, Version 22.0 (Armonk, NY: 
IBM Corp) and GraphPad Prism 6 (La Jolla, CA, USA).Normally distributed data were 
expressed as mean and standard deviation (SD) and skewed data as median and interquartile 
range (IQR). For normally distributed data, unpaired t tests were used to assess differences 
between independent groups, for non-parametric data the Mann-Whitney U test was used. 
Paired non-parametric data was analysed using Wilcoxon matched-pairs signed rank test. 
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5.4 Results 
Patient Characteristics 
Full baseline clinical characteristics of the 64 patients included in this analysis are reported in 
Table 5.1. Patients had moderate to severe COPD with a mean FEV1 % predicted of 54.4%.   
 Mean±SD 
Age (years) 74.1±7.1 
FEV1 (l) 1.35±0.53 
FEV1 (% predicted) 54.5±19.6 
FEV1/ FVC (%) 47.9±13.6 
Smoking pack years 52.0±32.3 
SpO2 (%) 95.1±2.2 
BMI (kg/m2) 25.4±5.3 
 Median (IQR) 
HealthCare Utilisation Exacerbations in year prior to assessment 2.00 (1.00-3.00) 
 n= 
Male, n (%) 41 (64.1) 
Current Smokers, n (%) 17 (26.6) 
Comorbidity present, n (%) 50 (78.1) 
Congestive heart failure, n (%) 4 (6.3) 
Ischemic heart disease, n (%) 14 (21.9) 
Hypertension, n (%) 32 (50.0) 
Patients receiving ACE inhibitors, n (%) 7 (10.9) 
Diabetes Mellitus, n (%) 3 (4.7) 
Patients receiving maintenance inhaled corticosteroids, n (%) 51 (79.7) 
Bronchitic Phenotype, n (%) 33 (51.6) 
Table 5.1. Stable state clinical characteristics of the 64 patients included in the baseline analysis.  
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Relationship between baseline cough frequency and exacerbation status 
There was no significant difference seen in 24 hour total cough frequency (coughs/hour, c/h) 
between frequent exacerbators (patients with 2 or more exacerbations in the year prior to 
assessment) and infrequent exacerbators (patients with less than 2 exacerbations in the year 
prior to assessment (n=38, median 5.6 (IQR 2.8-8.6) coughs/hour vs. n=26, 6.6 (2.2-15.7), 
p=0.702). Furthermore, there was no significant relationship between 24 hour total cough 
frequency and total number of exacerbations (treated and untreated events) experienced in the 
year prior to assessment (regression coefficient = -0.039; p=0.758). Also, no relationship was 
seen between exacerbation frequency and 24 hour total cough frequency when just treated, 
health care utilization events, were analysed (regression coefficient = -0.024; p=0.851). 
 
There was also no difference in diurnal cough variation between frequent and infrequent 
exacerbators. Total cough frequency per hour whilst awake for frequent exacerbators was not 
significantly different than infrequent exacerbators (n=38, median 7.5 (3.1-12.3) vs. n=26, 
9.3 (2.5-19.8), p=0.637). Total cough frequency per hour whilst asleep for frequent 
exacerbators was not significantly different than infrequent exacerbators (n=38, median 0.9 
(0.2-4.8) vs. n=26, 1.6 (0.1-3.4), p=0.794). 
 
Higher cough frequency was significantly related to worsening health-related quality of life, 
as measured by concurrent CAT score and SGRQ. Baseline CAT scores recorded on the day 
of cough recording were significantly related to log10 transformed 24 hour cough frequency 
(n=49, r=0.299, p=0.037) and SGRQ scores were also significantly related to log10 
transformed 24 hour cough frequency (n=59, r= 0.3912, p= 0.002; Figure 5.1). 
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Bronchitic patients had significantly higher waking cough rates than non-bronchitic patients 
(n=33, mean 0.9 (SD 0.4) vs. n=31, 0.64 (0.7) log10cough/h, p=0.046). There was also a trend 
for bronchitic patients to have higher 24hour cough frequency than non-bronchitic patients 
(n=33, mean 0.8 (0.4) vs. n=31, 0.5 (0.7) log10cough/h, p=0.078). However, no significant 
difference was seen in sleep cough rates between bronchitic and non-bronchitic patients 
(n=33, mean -0.4 (1.6) vs. n=31, -0.9 (2.1) log10cough/h, p=0.310). 
 
The baseline inflammatory phenotype of patients did not affect cough frequency. No 
significant difference was seen in 24 hour total cough frequency between eosinophilic 
patients (baseline blood eosinophilic percentage ≥ 2%) and non-eosinophilic patients 
(baseline blood eosinophilic percentage < 2%) (n=18, median 7.4 (IQR 3.0-10.9) coughs/hour 
vs. n=34, 4.8 (2.6-9.3), p=0.403).    
 
The presence or absence of comorbidities, including self-reported gastro-oesophageal reflux, 
did not affect baseline cough frequency. Median 24 hour cough frequency in patients with 1 
or more comorbidities was not significantly greater than in patients without comorbidities (n= 
50, median 6.1 coughs/hour (IQR 2.7-11.6) vs. n=14, 5.9 (2.4-6.9), p=0.808). Furthermore, 
Figure 5.1. Relationship 
between log10Coughs per 
hour (24 hr) and SGRQ 
score at baseline (59 
patients). 
 
137 
 
median 24 hour cough frequency in patients with self-reported gastro-oesophageal reflux was 
not significantly greater than in patients without reflux symptoms (n=14, 6.7 (2.2-8.2) vs. 5.8 
(2.7-12.3), p=0.691).      
 
 
Exacerbation studies 
Exacerbation Characteristics 
17 patients performed cough recording at exacerbation presentation. All exacerbations were 
health-care utilisation (HCU) exacerbations, receiving additional systemic therapy (all 
patients received oral antibiotics and 13 of 17 (76%) patients also received oral 
prednisolone).  
 
Unpaired Exacerbation Data 
24-hour cough rate rose from a median baseline value of 6.0 (n=64, IQR 2.7-9.7) to 25.9 
(n=17, 9.0-31.7; p<0.001, Figure 5.2) coughs/h at exacerbation. 
 
  
Figure 5.2. Median 
24 hour cough 
frequency in patients 
at baseline (n=64) 
and exacerbation 
(n=17). Bars 
represent 
Interquartile Range. 
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Paired Exacerbation Data 
13 patients had paired cough recordings performed at baseline and also at exacerbation onset. 
Exacerbation 24-hour cough rate was significantly higher than paired baseline levels: median 
exacerbation 24-hr cough rate 30.2 (16.2-38.0) vs. 6.5 (3.1-18.0) coughs/h, p=0.008 (Figure 
5.3). 
 
Both day and night cough rates were significantly higher at exacerbation than at baseline, 
with a larger relative increase in nocturnal cough rates than daytime. Day exacerbation cough 
rate 35.6 (17.5-45.3) vs. 9.6 (4.5-23.7) coughs/h, p= 0.011 (Figure 5.4). 
  
Figure 5.3. Change 
in 24hr cough 
frequency seen in 
13 paired patients 
from baseline to 
exacerbation. 
Figure 5.4. Change 
in day cough 
frequency seen in 13 
paired patients from 
baseline to 
exacerbation. 
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Night exacerbation cough rate 13.2 (8.8-23.1) vs. 0.7 (0-4.2) coughs/h, p= 0.005 (Figure 
5.5). 
 
Exacerbation Phenotype 
Eosinophilic exacerbations (blood eosinophilic percentage ≥ 2%) did not have higher cough 
frequency than non-eosinophilic events (n=6, median exacerbation 24-hr cough rate 25.2 
(7.6- 34.3) vs. n=9, 30.7 (12.4- 38.0) coughs/h, p= 0.578). 
 
Exacerbation Severity 
No significant correlation was seen between 24-hour cough rate at exacerbation and serum 
inflammatory markers measured concurrently (see Table 5.2).  
Serum Inflammatory Marker Spearman r value P value 
CRP -0.373 0.157 
Fibrinogen -0.207 0.489 
Total white cell count -0.214 0.436 
Absolute Eosinophil Count 0.043 0.882 
Percentage Eosinophils 0.014 0.964 
 
Figure 5.5. Change 
in nocturnal cough 
frequency seen in 13 
paired patients from 
baseline to 
exacerbation. 
Table 5.2. Relationship between 24-hour cough rate at exacerbation and serum 
inflammatory markers measured concurrently. 
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Furthermore, cough frequency was not significantly related to contemporaneous spirometry, 
as measured by FEV1. No significant correlation was seen between the rise in 24 hour cough 
rate and the fall in FEV1 from baseline to exacerbation (Spearman r = 0.132, p = 0.665). 
 
Exacerbation Length 
It was possible to calculate exacerbation length in 15 of 17 exacerbations. 2 patients did not 
accurately complete symptom diary cards and so an accurate exacerbation length could not be 
calculated. Median exacerbation length was 13 days (7-24). 
 
Cough frequency at exacerbation was not related to exacerbation length: no significant 
correlation was seen between 24 hour cough rate and exacerbation length (Spearman r = -
0.057, p = 0.832). Furthermore, no significant correlation was seen between the rise in 24 
hour cough rate from baseline to exacerbation and exacerbation length (Spearman r = -0.169, 
p = 0.442). 
 
Exacerbation Recurrence 
Cough monitoring at exacerbation was not useful to predict exacerbation recurrence. Those 
index exacerbations which were followed by a second recurrent exacerbation with 56 days 
did not have a significantly higher exacerbation cough rate than those not followed by a 
recurrent exacerbation (n=6, median cough rate 23.3 (13.5-47.0) vs. n=10, 27.8 (6.0-31.2) 
coughs/h, p= 0.366, Figure 5.6).  
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10 patients experienced a further exacerbation within 99 days of the index event at which 
monitoring was performed. In those 10 patients where time to next exacerbation could be 
calculated, no significant correlation was seen between the 24 hour cough rate at index 
exacerbation presentation and time to next exacerbation (Spearman r = -0.176, p = 0.613). 
Furthermore, no significant correlation was seen between the rise in 24-hour cough rate and 
time to next exacerbation (Spearman r = 0.342, p = 0.459). 
 
Timecourse of cough frequency during exacerbation recovery 
6 patients completed paired recordings at exacerbation presentation and during exacerbation 
recovery 2 weeks after their index visit. Cough frequency at exacerbation presentation was 
significantly higher than at 2 weeks (n=6, median cough rate 31.7 (26.7-44.7) vs. 16.5 (8.4-
24.8) coughs/h, p= 0.031). Exacerbation cough frequency fell further from 2 weeks to 5 
weeks post exacerbation presentation, although due to limited numbers this was not 
statistically significant (n=3, median cough rate 13.7 (1.5-19.3) coughs/h vs. 3.0 (1.3-10.4) 
coughs/h, p= 0.250).  
Figure 5.6. Median 24 
hour cough frequency in 
index exacerbations 
which were followed by 
a recurrent exacerbation 
(n=6) and those without 
exacerbation recurrence 
(n=10). Bars represent 
Interquartile Range. 
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11 of 17 patients performed cough monitoring at least once during the 5 weeks following 
exacerbation recovery. One patient also performed cough monitoring at a recurrent 
exacerbation occurring 14 days after presentation for the index exacerbation. In this event the 
patient experienced an acute rise in cough frequency following symptomatic recovery, which 
had been achieved one week after exacerbation presentation (Figure 5.7).  
  
Figure 5.7. Timecourse of cough frequency during exacerbation recovery. 
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5.5 Discussion 
This novel study is the first to measure objective cough frequency in COPD patients at 
baseline and at exacerbation onset prior to the initiation of systemic treatment. In the stable 
state, increasing cough frequency was associated with worsening health related quality of life. 
Cough frequency increases acutely from baseline levels at exacerbation and falls during 
subsequent recovery. However, the rise in cough frequency at exacerbation onset did not 
predict exacerbation severity, as reflected by decline in lung function and systemic 
inflammatory levels. Furthermore, cough frequency at exacerbation onset did not predict 
recovery time or the likelihood of recurrence. 
 
Cough is one of the primary symptoms of COPD (1). Chronic cough and mucous 
hypersecretion has been associated with lung function decline (29) and more frequent COPD 
exacerbations (30) and is an important area of unmet need in COPD. Previous work has 
validated objective ambulatory cough recording in COPD and shown that smoking and 
neutrophilic airway inflammation are key determinants of cough frequency in COPD patients 
(34).  
 
This study complements this work by reinforcing the importance of cough in COPD patients. 
In the stable state patients with increasing cough frequency had worse health related quality 
of life as measured by both the SGRQ and the CAT. Bronchitic patients had higher baseline 
cough rates than non-bronchitic patients and this is consistent with previous data that reported 
sputum production is an important determinant of cough frequency (34). The presence of 
chronic bronchitis is an important phenotype amongst COPD patients (125) and targeting this 
phenotype using specific therapies improves outcomes in COPD patients (94). Prophylactic 
azithromycin has recently been shown to improve cough-specific health status in COPD-
144 
 
patients with chronic productive cough to a clinically relevant degree (126) and our study 
reaffirms that further specific treatments are also needed to target COPD patients with 
increased cough frequency to improve health related quality of life. 
 
The presence of chronic bronchitis amongst COPD patients is associated with increased 
exacerbation frequency compared to non-bronchitic patients (127). Patients with a history of 
frequent exacerbations have worse quality of life (11), increased risk of hospitalisation (114) 
and greater mortality (12). Frequent exacerbators also exhibit faster decline in lung function 
(8) and may have worse functional status, as measured by time outdoors (115). We 
hypothesised that frequent exacerbators would experience increased cough frequency in the 
stable state than infrequent exacerbators. However, frequent exacerbators did not have higher 
baseline cough frequency than infrequent exacerbators and we found no relationship between 
cough rates and exacerbation frequency in the year prior to assessment. No relationship was 
seen when all exacerbations (both treated and diary card defined, untreated events) or just 
treated, health care utilisation exacerbations were included in this analysis. 
 
It is possible that our sample size may be underpowered to detect such a difference, although 
significant differences in cough frequency have been seen between COPD smokers and non-
smokers in groups of similar size (34), reducing this possibility. More likely, it may be 
unrealistic to expect a single baseline cough recording to identify patients who are more 
susceptible to exacerbations. Exacerbations are heterogenous and complex events that occur 
when a susceptible individual is exposed to a sufficient trigger, which is usually an infective 
pathogen (128). The relationship between bronchitis and increased exacerbation frequency is 
well established (125, 127) and a significant contributor to this relationship is the presence of 
bacterial colonisation (129). This study assessed the relationship between baseline cough 
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rates and exacerbation frequency rather than examining the effects of cough and sputum .The 
presence of sputum purulence is a robust indicator of increasing bacterial load (39) and 
therefore appears to be a superior indicator of frequent exacerbations than cough frequency 
alone.  
 
Comorbidities are common and extremely important in COPD, often contributing to 
symptoms, exacerbations, hospital admissions and mortality (130). In particular, gastro-
oesophageal reflux symptoms occur in up to 60% of COPD patients and a history of 
heartburn or reflux is associated with increased exacerbation frequency (7). However, in this 
study, the presence of self-reported comorbidities, including gastro-oesophageal reflux, did 
not affect baseline cough frequency. 
 
In addition to reinforcing the significance of cough in the baseline state, this study has also 
highlighted the importance of cough as a feature of acute exacerbations in COPD patients. 
Cough frequency increased significantly from baseline stable levels at exacerbation. In paired 
recordings, exacerbation cough frequency increased almost 5 fold from recordings conducted 
in the stable state. However, cough frequency at exacerbation onset did not relate to the 
intensity of the event as measured by fall in FEV1 and by concurrent systemic inflammatory 
markers. Furthermore, cough frequency at exacerbation did not relate to the length of the 
exacerbation and there was no difference in cough rates between exacerbations followed by a 
recurrent exacerbation and those without. Thus, objective cough monitoring at exacerbation 
was not an effective tool to measure exacerbation severity, predict recovery time or the 
likelihood of recurrence. 
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We collected limited data on the use of objective cough monitoring during the recovery phase 
of exacerbations. These preliminary results suggested that cough frequency reduced during 
exacerbation recovery and therefore cough monitoring may potentially be a useful objective 
measure of symptomatic (cough) recovery post-exacerbation. However, few patients 
performed cough monitoring during exacerbation recovery and further studies are required to 
assess the utility of cough monitoring during the recovery phase. 
 
In addition to the low numbers of recordings obtained during the recovery phase, a significant 
limitation of this study is the generalisability of cough monitoring in a clinical context. At 
present cough monitoring equipment is relatively bulky and expensive and the data generated 
requires sophisticated analysis at specialist centres. Therefore, this technique is not currently 
suitable for use in clinical practice. However, objective cough monitoring may be a useful 
tool in trials of new therapies to reduce cough frequency both in the stable state and at 
exacerbation, to measure the efficacy of such interventions. 
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5.6 Conclusion 
In conclusion, increasing cough frequency was associated with worsening health related 
quality of life. Cough frequency increases acutely from baseline levels at exacerbation and 
falls during subsequent recovery. Objective cough monitoring may be a useful tool to 
measure the efficacy of novel interventions to reduce cough frequency both in the stable state 
and at exacerbation. However, the rise in cough frequency at exacerbation onset did not 
predict exacerbation severity, and further study is required to assess the usefulness of cough 
monitoring during exacerbation recovery.  
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6 
SYSTEMIC AND AIRWAY 
BIOMARKERS TO EVALUATE 
COPD EXACERBATION 
RECOVERY AND RECURRENCE 
 
The previous chapter has demonstrated that cough is a critical symptom at COPD 
exacerbation but that objective cough monitoring was not a useful method of predicting 
exacerbation length. As discussed in the previous chapter, cough and sputum is associated 
with increased airway inflammation and the following chapter evaluates whether direct 
measurement of systemic and airway inflammatory biomarkers can predict exacerbation non-
recovery and recurrence. 
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6.1 Introduction 
Exacerbations are frequently triggered by infective agents and associated with increased 
airway and systemic inflammation. Not all exacerbations recover and patients are susceptible 
to another or recurrent exacerbation after an index event. Previous work has demonstrated 
that in almost 25% of cases, symptoms do not fully resolve 35days after the onset of an 
exacerbation (56). Furthermore, in the same study 22% of patients had a recurrent 
exacerbation within 50 days of the first (index) exacerbation.  
 
Patients who failed to recover within 5 weeks of exacerbation onset had persistently higher 
levels of serum CRP during the recovery period than patients who made a full symptomatic 
recovery during that time (56). The inflammatory burden 14 days after exacerbation onset may 
be a critical time, with those patients with a recurrent exacerbation having a significantly 
higher CRP level 14 days after the index exacerbation, compared to those who did not have a 
recurrence (56).   
 
It is unclear why airway and systemic inflammation remain persistently high in some patients 
treated appropriately at an initial exacerbation.  It is possible that there is persistence of the initial 
infective agent, acquisition of a new organism or bacterial type (41), or an interaction between 
pathogens present in the airways in the stable state (61) and also when these pathogens act as 
exacerbation triggers. However it has not previously been possible to identify which COPD 
patients are likely to have a prolonged recovery period based on their biochemical 
characteristics at exacerbation onset, or which features of the index exacerbation predict 
recurrence (56). Identification of patients at risk of abnormal recovery or recurrence at their 
initial exacerbation presentation would enable those individuals to be closely followed up and 
enable early intervention to attempt to enhance recovery and prevent recurrence. 
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6.2 Aim 
We hypothesised that elevated systemic and airway biomarkers at exacerbation onset predict 
abnormal exacerbation recovery and recurrent exacerbations within 8 weeks after an index 
event. Therefore, patients in the London COPD cohort were intensively sampled at 
exacerbation, during their recovery and also subsequent recurrent events were captured. Samples 
were analysed for systemic and airway biomarkers specifically chosen to inform on exacerbation 
severity and aetiology. 
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6.3 Methods 
Full methodology for this chapter is described in methods section 3.4. This study involved 67 
COPD patients enrolled in the London COPD cohort between 1
st
 May 2010 and 1
st
 July 2013. 
Patients attended at exacerbation, within 7 days of symptom onset, prior to the onset of 
systemic therapy and thereafter at recovery monitoring visits at Days 3 (±1), 7 (±2), 14 (±2), 
35 (±3) after the initial exacerbation visit. The median interval from diary card exacerbation 
onset to the day of assessment was 4 days (IQR 3-5). Recurrent exacerbations occurring 
within 56 days after exacerbation onset were assessed and sampled in the same manner as for 
an index exacerbation. Exacerbations were treated according to the prevailing guidelines and 
clinical judgment with increased inhaled therapy, antibiotics and/or oral steroids. 
 
At each visit, patients were assessed, had diary cards reviewed, and sputum and blood was 
collected for analysis. The following biomarkers were selected based upon their 
biological/mechanistic plausibility to inform on exacerbation recovery and recurrence. For full 
details regarding rationale of biomarker selection see Table 9.1 in Appendix 1. 
 
Blood biomarkers: Total white cell count, eosinophils (absolute and percentage), 
neutrophils, Fibrinogen, CRP, IL-6, IL-8, IP-10, PLGF, TNFα, MMP-1, MMP-8, MMP-9, 
sRAGE, PARC, α2-macroglobulin, CC16, SAA 
Sputum Biomarkers: IFNγ, IL-18, IL-1β, IL-5, IL-6, TNFα, IL-8, MMP-1, MMP-8, MMP-
9, MPO, TIMP-1, α2-macroglobulin 
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Sputum was also collected at exacerbation presentation for PCR detection of Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Human Rhinovirus (HRV). 
 
Statistical Analysis  
Data were analysed using GraphPad PRISM version 6.0 (GraphPad Software Inc., San Diego, 
CA, USA) and PASW Statistics version 21 (SPSS Inc., Chicago, IL, USA). Normally 
distributed data were expressed as mean and standard deviation (SD) and non-parametric data 
as median and interquartile range (IQR). Exacerbations from the same patient were 
considered as separate events because their trigger (viral or bacterial), inflammatory response 
and recovery time could differ within the same individual. Differences between groups were 
analysed by paired t-test, Mann-Whitney U Test, Wilcoxon-matched pairs, or Kruskal-Wallis 
analysis, depending on the sample population being investigated. Survival analyses were 
performed using Log-rank (Mantel-Cox) test. A probability of p < 0.05 was considered to be 
statistically significant. 
 
  
153 
 
6.4 Results 
Patient Characteristics 
Full baseline clinical characteristics of the 67 patients included in this chapter are reported in 
Table 6.1. The patients had moderate-severe disease with a mean FEV1 % predicted of 49%.  
 
  
 Baseline Values 
n=67 
 Mean±SD 
Age (years) 71.1±17.0 
FEV1 (L) 1.2±0.4 
FEV1 (% predicted) 49.1±18.0 
FVC (L) 2.6±0.8 
FEV1 / FVC ratio (%) 47.5±13.0 
Smoking pack years 54.5±42.3 
SpO2 (%) 94.3±2.3 
BMI (kg/m
2
) 26.4±5.5 
  
 Median (IQR) 
Total Exacerbation frequency               
(treated and untreated events) 
2.3 (1.3-3.3) 
HCU exacerbations  in year prior to 
assessment 
2.0 (1.0-3.0) 
  
 N (%) 
Male gender 41 (61.2) 
Current Smokers 20 (29.9) 
Table 6.1. Stable state clinical characteristics of the 67 patients included in the biomarker analysis. 
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Isolated Exacerbation Analysis  
58 patients were sampled at 75 separate isolated exacerbations. All events were physician 
confirmed and treated with systemic therapy.  62 exacerbations received antibiotics and oral 
corticosteroids, 11 antibiotics alone, and 2 oral steroids alone. Mean paired FEV1 was 1.2 
(SD 0.4) L at baseline and 1.1 (0.4) L at exacerbation presentation (p< 0.001).  
 
Changes in Blood Biomarkers between Baseline and Exacerbation 
Concentrations of the blood biomarkers, at baseline and exacerbation presentation, are 
reported in Table 6.2 (2 exacerbations did not have a paired baseline). Serum TNFα levels 
were below the detectable threshold of the assay and are therefore not reported. Significant 
differences were observed between baseline and exacerbation for 10 blood biomarkers: CRP, 
Fibrinogen, IL-6, IL-8, IP-10, PLGF, MMP-1, sRAGE, α2-macroglobulin, SAA (Figure 6.1). 
 
Blood Biomarker Units Baseline Median (IQR) Exacerbation Median (IQR) p-value 
(Wilcoxon) 
CRP mg/L 3.0 (1.0-7.25) 9.0 (3.5-33.5) < 0.001
 
Fibrinogen g/L 3.6 (3.3-4.1) 4.2 (3.5-5.1) < 0.001 
Total wcc 10
9
/L 7.3 (6.4-8.8) 7.8 (6.2-10.1) 0.248 
Neutrophils 10
9
/L 4.6 (3.9-6.1) 5.0 (3.8-6.7) 0.096 
Eosinophils 10
9
/L 0.20 (0.11-0.35) 0.15 (0.10-0.29) 0.107 
IL-6 pg/ml 8.2 (5.25-12.6) 11.6 (7.3-29.0) < 0.001 
IL-8 pg/ml 0.3 (0.0-1.9) 1.4 (0.5-2.6) 0.010 
IP-10 pg/ml 337.8 (261.0-490.6) 266.6 (157.1-404.4) < 0.001 
PLGF pg/ml 2.3 (0.1-4.5) 4.5 (3.4-7.1) < 0.001 
MMP-1 pg/ml 3601 (1662-6866) 10157 (6488-13449) < 0.001 
MMP-8 pg/ml 2028.0 (1004.0-4614.0) 869.8 (131.6-4850.0) 0.188 
MMP-9 pg/ml 1.0 (0.7-1.3) x10
6
 1.0 (0.7-1.8) x10
6
 0.192 
sRAGE pg/ml 127.5 (57.2-218.5) 155.0 (102.3-271.2) < 0.001 
PARC pg/ml 137615 (108035-184632) 151714 (110145-199870) 0.070 
α2-macroglobulin pg/ml 1.8 (1.2-3.1) x10
10
 1.0 (0.6-1.5) x10
10
 < 0.001 
CC16 pg/ml 7400 (4363-14306) 6654 (4266-11882) 0.540 
SAA pg/ml 0.3 (0.2-0.9) x10
8
 1.0 (0.3-3.6) x10
8
 < 0.001 
Table 6.2. Differences in Blood Biomarkers between baseline and exacerbation (73 pairs) 
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Figure 6.1. Blood biomarkers present at significantly different concentrations between baseline and exacerbation. N=73. Box plots represent 
median and interquartile range, and whiskers represent 5-95% range with outliers plotted separately. 
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Use of Blood Biomarkers in the prediction of Exacerbation Recovery 
 
Median isolated recovery time was 21.5 days (n=70, IQR 12.0-40.25; 5 exacerbations had 
exacerbation length >99days).  Data was analysed to determine the ability of individual 
biomarkers at exacerbation onset to predict non-recovery (failure of an exacerbation to 
symptomatically recover) at 35 days after exacerbation onset. This time-point was chosen 
because previous pivotal studies have analysed non-recovery at 35 days (56). In addition, 
significant financial penalties can apply to healthcare organizations if patients are readmitted 
to hospital within 30 days of discharge following an exacerbation of COPD, the median 
length of stay in hospital prior to discharge being 5 days (131). 
 
Survival analyses were performed on all blood biomarkers which were significantly increased 
between baseline and exacerbation to determine if elevated biomarkers at exacerbation onset 
predicted non-recovery at 35 days after exacerbation onset. For the purpose of analysis, 
elevated biomarkers were defined as those above the median value.  
 
IP-10 and α2macroglobulin fell at exacerbation. For these biomarkers log rank testing 
examined whether levels below the median value predicted non-recovery, no significant 
relationship was found. 
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Median serum IL-6 value at exacerbation presentation in 74 events was 11.75 (7.3-29.0) 
pg/mL. Log-rank (Mantel-Cox) testing showed that elevated serum IL-6 at exacerbation 
presentation significantly predicted non-recovery at 35 days (p=0.039, Figure 6.2). 
 
 
No other blood biomarker showed significant ability to predict exacerbation non-recovery 
(Table 6.3): 
 
 
 
 
 
 
 
 
 
 
 
  
Blood 
Biomarker 
p value 
(Log-rank test) 
CRP 0.593 
Fibrinogen 0.292 
IL-8 0.227 
IP-10 0.216 
PLGF 0.279 
MMP-1 0.525 
sRAGE 0.805 
α2-macroglobulin 0.600 
SAA 0.253 
Figure 6.2. Kaplan-Meier plot 
of symptom resolution by high 
and low serum IL-6 at 
exacerbation onset. Serum IL-6 
≥ median is represented by 
black line and IL-6 < median is 
represented by red line. 
 
Table 6.3. Results of Log-
rank (Mantel-Cox) testing of 
blood biomarkers at 
exacerbation onset to predict 
non-recovery. 
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Data was also analysed to determine if the change in biomarker levels from baseline to 
exacerbation onset predicted non-recovery at 35 days after exacerbation onset. Again change 
in serum IL-6 levels showed predictive ability but there was no such predictive ability in any 
of the other blood biomarkers (p>0.05 for all), although change in serum IL-8 from baseline 
to exacerbation approached statistical significance, p=0.065 (Figure 6.3). Median change in 
serum IL-8 value at from baseline to exacerbation presentation in 73 pairs was 0.5 (-0.1-1.8) 
pg/mL.  
 
 
 
 
 
 
Median change in serum IL-6 value at from baseline to exacerbation presentation in 73 pairs 
was 4.4 (-0.7-20.5) pg/mL. Log-rank testing showed that elevated change in serum IL-6 from 
baseline to exacerbation predicted non-recovery at 35 days (p= 0.042, Figure 6.4). 
  
 
 
 
Persistence of inflammation during recovery 
Figure 6.4. Kaplan-Meier plot 
of symptom resolution by high 
and low change in serum IL-6 
(ΔIL-6) from baseline to 
exacerbation onset (73 pairs). 
Change in serum IL-6 ≥ median 
is represented by black line and 
change in serum IL-6 < median 
is represented by red line. 
 
Figure 6.3. Kaplan-Meier plot 
of symptom resolution by high 
and low change in serum IL-8 
(ΔIL-8) from baseline to 
exacerbation onset (73 pairs). 
Change in serum IL-8 ≥ 
median is represented by black 
line and change in serum IL-8 
< median is represented by red 
line. 
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Those exacerbations whose inflammation had returned to baseline values by 2 weeks had 
faster recovery than exacerbations whose serum inflammatory levels were still elevated. This 
was reflected in levels of total white cell count, neutrophil count and serum IL-6. Log-rank 
testing showed that exacerbations with persistently elevated levels of total white cell count 
and neutrophil count (above paired baseline levels) at 14 days post exacerbation presentation 
were significantly associated with non-recovery at 35 days compared to exacerbations where 
inflammatory levels had returned to baseline at 14 days (Figure 6.5a: p=0.016, Figure 6.5b: 
p=0.031 respectively). Elevated serum IL-6 at 14 days post exacerbation presentation also 
approached statistical significance (Figure 6.5c: p=0.138). 
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Figure 6.5. Kaplan-Meier plot of symptom resolution determined by biomarker levels at 14 days (71 exacerbations). Black lines represent 
exacerbations where biomarker levels remained above paired baseline levels at 14 days. Exacerbations where biomarker levels have returned to 
baseline at 14 days are represented by red line. a) Total white cell count (wcc), b) Absolute neutrophil counts, c) Serum IL-6. 
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Changes in Sputum Biomarkers between Baseline and Exacerbation 
Concentrations of the sputum biomarkers, at baseline and exacerbation presentation, are 
reported in Table 6.4. Not all patients produced a viable sputum sample at baseline and 
exacerbation so results were available for 69 pairs. The majority of sputum IFNγ and IL-5 
levels were below detectable threshold of assay and are therefore not reported.  
 
Sputum Biomarker Units Baseline Median (IQR) Exacerbation Median (IQR) p-value 
(Wilcoxon) 
IL-18 pg/ml 474.9 (218.2-1077.0) 762.0 (439.6-1770.0) 0.043 
IL-1β pg/ml 377.8 (112.6-2553.0) 2038.0 (502.8-16790.0) < 0.001 
IL-6 pg/ml 2783.0 (1434.0-6168.0) 6165.0 (1360.0-13438.0) 0.002 
TNFα pg/ml 56.1 (0.0-186.8) 195.3 (19.4-1617.0) < 0.001 
IL-8 pg/ml 75732.0 (34469.0-178487.0) 182732.0 (66883.0-473399.0) < 0.001 
MMP-1 pg/ml 9599.0 (4979.0-24088.0) 48328.0 (24396.0-73377.0) < 0.001 
MMP-8 pg/ml 2.4 (1.2-10.0) x10
6
 12.2 (2.2-47.6) x10
6
 < 0.001 
MMP-9 pg/ml 0.8 (0.6-3.7) x10
7
 5.3 (0.8-21.1) x10
7
 < 0.001 
MPO pg/ml 1.8 (1.1-5.1) x10
6
 4.3 (1.7-8.6) x10
6
 0.001 
TIMP-1 pg/ml 1.2 (0.6-2.3) x10
6
 3.9 (2.6-5.3) x10
6
 < 0.001 
α2-macroglobulin pg/ml 4.3 (2.2-16.4) x10
7
 6.4 (2.4-26.8) x10
7
 0.149 
Table 6.4. Concentrations of the sputum biomarkers, at baseline and exacerbation presentation 
(69 pairs) 
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Significant differences were observed between baseline and exacerbation for 11 sputum biomarkers: TIMP-1, IL-18, IL-1β, IL-6, TNFα, IL-8, 
MMP-1, MMP-8, MMP-9, MPO and are illustrated in Figure 6.6. 
 
Figure 6.6. Sputum biomarkers present at significantly different 
concentrations between baseline and exacerbation, n=69. Box 
plots represent median and interquartile range, and whiskers 
represent 5-95% range with outliers plotted separately. 
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Use of Sputum Biomarkers in the prediction of Exacerbation Recovery 
Survival analyses were performed on all sputum biomarkers which were significantly 
different between baseline and exacerbation to determine if elevated sputum biomarkers 
(defined as above the median value) at exacerbation onset predicted non-recovery at 35 days 
after exacerbation onset. No sputum biomarker showed significant ability to predict 
exacerbation non-recovery (all p>0.05, Table 6.5), although sputum IL-18 approached 
statistical significance. Median sputum IL-18 value at exacerbation presentation in 73 events 
was 806.0 (450.0-1855.0) pg/mL. Log-rank (Mantel-Cox) p=0.066, Figure 6.7). 
 
 
  
Sputum 
Biomarker 
p value 
(Log-rank test) 
IL-1β 0.892 
IL-6 0.676 
TNFα 0.473 
IL-8 0.653 
MMP-1 0.626 
MMP-8 0.604 
MMP-9 0.911 
MPO 0.429 
TIMP-1 0.201 
Table 6.5. Results of Log-
rank (Mantel-Cox) testing of 
elevated sputum biomarkers 
at exacerbation onset to 
predict non-recovery. 
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Sputum data was also analysed to determine if the change in biomarker levels from baseline 
to exacerbation onset predicted non-recovery at 35 days after exacerbation onset. Again no 
biomarker showed significant predictive ability, although change in sputum IL-18 from 
baseline to exacerbation was the closest to statistical significance, p=0.111 (Figure 6.8). 
Median change in sputum IL-18 value at from baseline to exacerbation presentation in 69 
pairs was 285.8 (-242.8-680.0) pg/mL.  
 
  
Figure 6.7. Kaplan-Meier plot of symptom resolution 
by high and low sputum IL-18 at exacerbation onset. 
Sputum IL-18 ≥ median is represented by black line 
and IL-18 < median is represented by red line. 
 
Figure 6.8. Kaplan-Meier plot 
of symptom resolution by high 
and low change in sputum IL-
18 (ΔIL-18) from baseline to 
exacerbation onset (69 pairs). 
Change in sputum IL-18 ≥ 
median is represented by black 
line and change in serum IL-18 
< median is represented by red 
line. 
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Effect of exacerbation aetiology on recovery 
 
 
The aetiology of exacerbations did not significantly affect the recovery time of isolated 
exacerbations. 4 exacerbations did not have sufficient sputum for both bacterial and HRV 
PCR testing. 5 exacerbations had exacerbation length >99days. For the remaining 66 
exacerbations, there was no significant difference in exacerbation length between 
exacerbations depending on infection status at exacerbation presentation (Kruskal-Wallis test, 
p=0.2045, Figure 6.9, Table 6.6). 
 
Aetiology Bacterial 
Positive 
Alone 
HRV Positive 
Alone 
Coinfection No organism 
detected 
N 19 9 28 10 
     
Median 
Exacerbation 
Length (IQR) 
23.0 
(15.0-37.0) 
23.0 
(12.5-46.0) 
14.0 
(8.3-33.5) 
48.5 
(9.5-60.8) 
 
Table 6.6. Exacerbation Length depending upon aetiology at exacerbation onset 
Figure 6.9. Aetiology of 
66 isolated exacerbations. 
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Furthermore, there was no significant difference in median exacerbation length between 
bacterial positive and bacterial negative exacerbations (n=47, 18.0 (11.0-37.0) days vs n=19, 
23.0 (12.0-50.0) days, p=0.091) and no significant difference in exacerbation length between 
viral positive and viral negative exacerbations (n=37, 16.0 (10.5-36.0) vs n=29, 23.0 (14.0-
41.0) days, p=0.185). Additionally, for bacterial positive exacerbations, there was no 
significant relationship between exacerbation length and bacterial load at exacerbation onset 
(r= -0.137, p= 0.271) and for HRV positive exacerbations, no significant relationship was 
seen between exacerbation length and viral load at exacerbation onset (r= -0.099, p= 0.431). 
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Index and Recurrent Exacerbation Characteristics 
15 patients were included in this substudy who experienced 17 index exacerbations each 
followed by a recurrent exacerbation occurring within 8 weeks of the onset of the index 
exacerbation. Data was examined to determine if the inflammatory profile of index 
exacerbations which were followed by a recurrent exacerbation were different from isolated 
exacerbations not followed by recurrent events.  
 
Exacerbations with an eosinophilic profile at exacerbation onset appeared more likely to be 
followed by a recurrent event than non-eosinophilic exacerbations. Median percentage blood 
eosinophils was significantly higher at exacerbation onset in index exacerbations which were 
followed by recurrent events, than in isolated exacerbations (n=17, 3.86 (1.67- 7.18) vs. 
n=75, 2.24 (1.24-3.73), p= 0.031, Figure 6.10). Median absolute blood eosinophil count in 
index exacerbations was also greater than in isolated exacerbations, although this did not 
quite reach the threshold for statistical significance (n=17, 0.25 (0.15-0.41) x10
9
 vs. n= 75, 
0.15 (0.10-0.29) x10
9
, p=0.053).  
 
  
Figure 6.10. Percentage 
eosinophils present at significantly 
higher level at index (those 
followed by recurrent event) 
compared to isolated exacerbations 
(no-recurrence). Box plots 
represent median and interquartile 
range, and whiskers represent 5-
95% range with outliers plotted 
separately. 
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Furthermore, index exacerbations displayed significantly higher sputum IL-18 and sputum 
MMP-1 levels than isolated exacerbations. Median sputum IL-18 in index exacerbations was 
significantly higher than at exacerbation onset of isolated exacerbations (n=16, 2196.0 
(759.0-3934.0) vs. n=73, 806.0 (450.0-1855.0), p=0.019, Figure 6.11). Median sputum 
MMP-1 at exacerbation onset in index exacerbations was also significantly higher than at 
exacerbation onset of isolated exacerbations (n=16, 80264.0 (50503.0-111057.0) vs. n=73, 
51094.0 (28464.0-73377.0), p=0.016, Figure 6.12). 
 
 
Median concentrations of all other blood and sputum biomarker levels, at isolated and index 
exacerbation presentation, are reported in Table 6.7.  
Figure 6.11. Sputum IL-18 present 
at significantly higher level at 
index (those followed by recurrent 
event) compared to isolated 
exacerbations (no-recurrence). Box 
plots represent median and 
interquartile range, and whiskers 
represent 5-95% range with outliers 
plotted separately. 
Figure 6.12. Sputum MMP-1 
present at significantly higher level 
at index (those followed by 
recurrent event) compared to 
isolated exacerbations (no-
recurrence). Box plots represent 
median and interquartile range, and 
whiskers represent 5-95% range 
with outliers plotted separately. 
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Blood Biomarker Units Isolated Exacerbation Median (IQR) 
N=74 
Index Exacerbation Median (IQR)  
N=17 
p-value 
CRP mg/L 9.0 (3.5-33.5) 10.0 (1.3-26.8) 0.279 
Fibrinogen g/L 4.2 (3.5-5.1) 4.3 (3.2-4.9) 0.675 
Total wcc 10
9
/L 7.8 (6.2-10.1) 6.1 (5.1-9.8) 0.199 
Neutrophils 10
9
/L 5.0 (3.8-6.7) 4.0 (3.2-6.7) 0.219 
IL-6 pg/ml 11.8 (7.3-29.0) 9.9 (6.5-48.0) 0.886 
IL-8 pg/ml  1.4 (0.5-2.7) 1.7 (1.0-3.9) 0.298 
IP-10 pg/ml 265.5 (153.6-401.4) 299.6 (200.1-632.1) 0.476 
PLGF pg/ml 4.5 (3.4-7.1) 5.7 (4.2-6.6) 0.139 
MMP-1 pg/ml 10184 (6511-13428) 10694 (7554-18501) 0.351 
MMP-8 pg/ml 875.5 (133.4-4800.0) 291.2 (44.0-1044.0) 0.112 
MMP-9 pg/ml 1.0 (0.7-1.8) x10
6 
0.8 (0.5-2.0) x10
6 
0.619 
sRAGE pg/ml 150.5 (101.8-268.7) 116.2 (45.8-218.9) 0.161 
PARC pg/ml  150878.0 (109323.0-199851.0) 194932.0 (131060.0-247725.0) 0.067 
α2-macroglobulin pg/ml 9.2 (5.8-14.6) x10
9
 7.0 (5.9-9.9) x10
9
 0.201 
CC16 pg/ml 6559.0 (4159.0-11582.0) 5185.0 (4257.0-10267.0) 0.472 
SAA pg/ml 9.5 (2.2-36.0) x10
7
 5.9 (1.2-13.0) x10
7
 0.115 
Sputum Biomarker Units Isolated Exacerbation Median (IQR) 
N=73 
Index Exacerbation Median (IQR)  
N=16 
p-value 
IL-1β pg/ml 2038.0 (553.8-16790.0) 3588.0 (871.2-7198.0) 0.938 
IL-6 pg/ml 6310.0 (1444.0-13855.0) 12029.0 (5099.0-16299.0) 0.075 
TNFα pg/ml 195.3 (21.2-1680.0) 466.7 (66.0-1210.0) 0.777 
IL-8 pg/ml 190586.0 (71923.0-498167.0) 163001.0 (112521.0-411692.0) 0.878 
MMP-8 pg/ml 1.2 (0.2-4.8) x10
7 
1.1 (0.3-4.9) x10
7 
0.989 
MMP-9 pg/ml 5.3 (0.8-21.1) x10
7
 4.6 (1.5-16.8) x10
7
 0.803 
MPO pg/ml 4.3 (1.8-8.6) x10
6
 5.5 (2.4-9.9) x10
6
 0.310 
TIMP-1 pg/ml 4.0 (2.6-5.7) x10
6
 4.7 (3.5-6.8) x10
6
 0.232 
α2-macroglobulin pg/ml 6.4 (2.4-26.8) x10
7
 16.2 (4.3-32.8) x10
7
 0.113 
Table 6.7. Differences in Biomarker levels between isolated and index exacerbations  
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Timecourse of inflammation during exacerbation recovery 
The timecourse of airway and systemic inflammatory biomarkers during isolated exacerbations is shown in Table 6.8 and Table 6.9 respectively 
(p value <0.05 are marked with asterix*).  
 
Sputum 
Biomarker 
Baseline Exacerbation 
Presentation 
p-value 
Baseline
-onset 
Day 3 p-value 
Baseline 
-day 3 
Day 7 p-value 
Baseline
-day 7 
Day 14 p-value 
Baseline 
-day 14 
Day 35 p-value 
Baseline 
-day 35 
IL-18 
( pg/mL) 
474.9  
(218.2-1077.0) 
762.0  
(439.6-1770.0) 
0.043* 537.0  
(204.3-957.1) 
0.958 422.0  
(251.8-796.0) 
0.643 459.6  
(245.3-1301.0) 
0.603 523.0  
(264.6-847.0) 
0.797 
IL-1β 
( pg/mL) 
377.8  
(112.6-2553.0) 
2038.0  
(502.8-16790.0) 
< 0.001* 570.1  
(214.0-3142.0) 
0.219 678.4  
(237.5-2461.0) 
0.141 789.5  
(305.3-6844.0) 
0.032* 746.0  
(241.5-2545.0) 
0.184 
IL-6 
( pg/mL) 
2783.0  
(1434.0-6168.0) 
6165.0  
(1360.0-13438.0) 
0.002* 4286.0  
(1726.0-11911.0) 
0.268 4785.0  
(2089.0-8756.0) 
0.102 5463.0  
(900.0-13620.0) 
0.042* 5531.0  
(1318.0-11291.0) 
0.179 
TNFα 
( pg/mL) 
56.1  
(0.0-186.8) 
195.3  
(19.4-1617.0) 
< 0.001* 40.0  
(10.8-173.2) 
0.561 58.5  
(11.9-338.0) 
0.270 67.5  
(14.0-599.8) 
0.063 85.5  
(14.5-277.5) 
0.059 
IL-8 
( pg/mL) 
75732.0  
(34469.0-178487.0) 
182732.0  
(66883.0-473399.0) 
< 0.001* 128065.0  
(54374.0-240769.0) 
0.130 113128.0  
(77880.0-225181.0) 
0.019* 185632.0  
(66917.0-371185.0) 
0.002* 95165.0  
(49752.0-232452.0) 
0.134 
MMP-1 
( pg/mL) 
9599.0  
(4979.0-24088.0) 
48328.0  
(24396.0-73377.0) 
< 0.001* 45212.0  
(13674.0-74801.0) 
< 0.001* 42151.0  
(23699.0-64718.0) 
< 0.001* 36771.0  
(20820.0-81747.0) 
< 0.001* 36360.0  
(20411.0-73033.0) 
< 0.001* 
MMP-8 
( pg/mL) 
2.4 x10
6 
(1.2-10.0) 
12.2 x10
6 
(2.2-47.6) 
< 0.001* 5.5 x10
6
 
(1.5-21.3)   
0.051 3.4 x10
6
  
(1.9-15.5)   
0.078 5.2 (1.8-28.8)  x10
6
 0.013* 2.2 x10
6
  
(1.0-8.4)  
0.900 
MMP-9 
( pg/mL) 
0.8 x10
7 
(0.6-3.7) 
5.3 x10
7 
(0.8-21.1) 
< 0.001* 2.1 x10
7
  
(0.6-9.7)   
0.031* 2.2 x10
7
  
(0.8-6.7)   
0.005* 2.9 (1.0-13.1)  x10
7
 0.002* 1.0 x10
7
  
(0.5-3.6)   
0.668 
MPO 
( pg/mL) 
1.8 x10
6 
(1.1-5.1) 
4.3 x10
6 
(1.7-8.6) 
0.001* 3.2 x10
6
  
(1.3-5.2)   
0.273 2.8 x10
6
  
(1.8-4.7)   
0.093 2.7 (1.4-4.7)  x10
6
 0.193 2.2 x10
6
  
(1.2-3.7)   
0.948 
TIMP-1 
( pg/mL) 
1.2 x10
6 
(0.6-2.3) 
3.9 x10
6 
(2.6-5.3) 
< 0.001* 5.1 x10
6
  
(2.7-7.4)   
< 0.001* 5.0 x10
6
  
(3.6-6.6)   
< 0.001* 4.7 (2.9-7.2)  x10
6
 < 0.001* 4.5 x10
6
  
(2.8-6.9)  
< 0.001* 
α2-
macroglobulin 
( pg/mL) 
4.3 x10
7 
(2.2-16.4) 
6.4 x10
7 
(2.4-26.8) 
0.149 2.9 x10
7
  
(1.1-8.8)   
0.025* 2.5 x10
7
  
(0.9-6.7)   
< 0.001* 4.5 (1.3-8.5)  x10
7
 0.057 3.1 x10
7
  
(1.4-7.4)   
0.043* 
Table 6.8. Time course of airway inflammatory markers during isolated COPD exacerbations 
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Table 6.9. Time course of serum inflammatory markers during isolated COPD exacerbations 
Serum Biomarker Baseline Exacerbation 
Presentation 
p-value 
Baseline
-onset 
Day 3 p-value 
Baseline 
-day 3 
Day 7 p-value 
Baseline
-day 7 
Day 14 p-value 
Baseline 
-day 14 
Day 35 p-value 
Baseline 
-day 35 
CRP  
(mg/L) 
3.0 
(1.0-7.25) 
9.0 
(3.5-33.5) 
< 0.001*
 
4.0 
(2.0-10.0) 
0.153 
 
3.0 
(1.0-7.0) 
0.555 6.0 
(3.0-15.0) 
<0.001* 3.0 
(2.0-7.0) 
0.937 
 
Fibrinogen (g/L) 3.6 
(3.3-4.1) 
4.2 
(3.5-5.1) 
< 0.001* 3.5 
(3.0-4.2) 
0.501 3.1 
(2.8-3.5) 
<0.001* 4.2 
(3.5-4.8) 
<0.001* 3.7 
(3.4-4.2) 
0.366 
Total wcc 
(10
9
/L) 
7.3 
(6.4-8.8) 
7.8 
(6.2-10.1) 
0.248 10.2 
(8.4-11.7) 
< 0.001* 10.9 
(8.3-13.6) 
< 0.001* 8.9 
(7.0-11.5) 
<0.001* 7.8 
(6.5-9.7) 
0.501 
Neutrophils 
(10
9
/L) 
4.6 
(3.9-6.1) 
5.0 
(3.8-6.7) 
0.096 8.0 
(6.2-9.0) 
< 0.001* 7.1 
(5.4-9.0) 
< 0.001* 6.1 
(4.8-8.5) 
<0.001* 5.0 
(3.8-6.3) 
0.379 
Eosinophils 
(10
9
/L) 
0.20 
(0.11-0.35) 
0.15 
(0.10-0.29) 
0.107 0.05 
(0.01-0.10) 
< 0.001* 0.13 
(0.05-0.27) 
< 0.001* 0.17 
(0.11-0.27) 
0.316 0.17 
(0.11-0.33) 
0.570 
IL-6 
(pg/mL) 
8.2 
(5.25-12.6) 
11.6 
(7.3-29.0) 
< 0.001* 5.4 
(3.5-10.8) 
< 0.001* 8.3 
(5.1-13.8) 
0.753 11.4 
(6.2-17.5) 
0.084 9.0 
(5.4-11.6) 
0.528 
IL-8 
(pg/mL) 
0.3 
(0.0-1.9) 
1.4 
(0.5-2.6) 
0.010* 1.3 
(0.5-1.9) 
0.014* 1.4 
(0.7-2.4) 
< 0.001* 1.0 
(0.4-2.1) 
< 0.001* 1.0 
(0.4-2.5) 
0.006* 
IP-10 
(pg/mL) 
337.8 
(261.0-490.6) 
266.6 
(157.1-404.4) 
< 0.001* 168.4 
(96.5-277.3) 
< 0.001* 144.7 
(91.7-248.6) 
< 0.001* 246.0 
(139.4-398.5) 
< 0.001* 237.4 
(140.5-335.2) 
< 0.001* 
PLGF 
(pg/mL) 
2.3 
(0.1-4.5) 
4.5 
(3.4-7.1) 
< 0.001* 4.6 
(3.4-7.7) 
< 0.001* 5.7 
(3.8-7.6) 
< 0.001* 4.8 
(3.5-6.7) 
< 0.001* 4.5 
(3.5-6.2) 
< 0.001* 
MMP-1 
(pg/mL) 
3601 
(1662-6866) 
10157 
(6488-13449) 
< 0.001* 10349 
(6924-16330) 
< 0.001* 11114 
(6869-15711) 
< 0.001* 9074 
(6037-12794) 
< 0.001* 9910 
(5904-13480) 
< 0.001* 
MMP-8 
(pg/mL) 
2028.0 
(1004.0-4614.0) 
869.8 
(131.6-4850.0) 
0.188 1418.0 
(357.2-5456.0) 
0.943 1334.0 
(347.3-4495.0) 
0.390 873.5 
(203.3-3540.0) 
0.170 458.4 
(134.6-2622) 
0.002* 
MMP-9 
(pg/mL) 
1.0 x10
6
 
(0.7-1.3) 
1.0 x10
6
 
(0.7-1.8) 
0.192 1.3 x10
6 
(0.8-2.0) 
0.014* 1.5 x10
6 
(0.9-1.9) 
< 0.001* 1.2 x10
6 
(0.8-1.8) 
0.094 0.9 x10
6 
(0.6-1.4) 
0.471 
sRAGE 
(pg/mL) 
127.5 
(57.2-218.5) 
155.0 
(102.3-271.2) 
< 0.001* 109.7 
(69.5-194.6) 
0.702 125.3 
(71.9-203.6) 
0.438 152.1 
(97.7-281.1) 
0.023* 155.3 
(94.2-308.4) 
0.008* 
PARC 
(pg/mL) 
137615 
(108035-184632) 
151714 
(110145-199870) 
0.070 129866 
(88540-176886) 
0.207 109305 
(80643-153359 
0.003* 143002 
(96664-186609) 
0.957 127572 
(101181-186100) 
0.528 
α2-macroglobulin 
(pg/mL) 
1.8 x10
10
 
(1.2-3.1) 
1.0 x10
10
 
(0.6-1.5) 
< 0.001* 0.9 x10
10
 
(0.5-1.6) 
< 0.001* 0.8 x10
10
 
(0.5-1.5) 
< 0.001* 0.8 x10
10
 
(0.5-1.4) 
< 0.001* 0.9 x10
10
 
(0.6-1.4) 
< 0.001* 
CC16 
(pg/mL) 
7400 
(4363-14306) 
6654 
(4266-11882) 
0.540 6811 
(3615-10252) 
0.249 5493 
(3563-10504) 
0.153 5677 
(3817-10354) 
0.226 5760 
(3759-10945) 
0.187 
SAA 
(pg/mL) 
0.3 x10
8
 
(0.2-0.9) 
1.0 x10
8
 
(0.3-3.6) 
< 0.001* 0.9 x10
8 
(0.4-2.0) 
< 0.001* 0.6 x10
8 
(0.3-1.1) 
< 0.001* 0.5 x10
8 
(0.2-1.2) 
0.017* 0.3 x10
8
 
(0.1-0.6) 
0.779 
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Timecourse of inflammation during exacerbation recovery 
Systemic and airway biomarkers followed distinct patterns during exacerbation recovery and 
can be categorised as follows: 
1) Acute rise and rapid fall 
2) Acute rise and slow fall 
3) Delayed rise and slow fall 
4) Persistent rise 
5) Fall  
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Figure 6.13. Acute Rise and Rapid Fall of 
Biomarkers during Exacerbation Recovery.  
(a) Timecourse of serum CRP, arrow demonstrates 
rapid rise at exacerbation onset.  (b) Time course of 
plasma Fibrinogen, arrow demonstrates fall in 
biomarker levels below baseline. (c) Timecourse of 
serum PARC, arrow demonstrates rise in biomarker 
level at 2 weeks post exacerbation onset. Points 
represent median and interquartile range. 
 
1) Acute rise and rapid fall: 
Serum Biomarkers: 
CRP, Fibrinogen, Serum IL-6, 
PARC, sRAGE. 
Sputum Biomarkers: 
Sputum IL-1β, Sputum IL-6,  
Sputum IL-8, Sputum IL-18,  
Sputum a2M,  Sputum MMP-8, 
Sputum TNFα,  Sputum MPO(3),   
 
The above biomarkers displayed a 
rapid rise at exacerbation onset 
followed by a rapid fall (by day 7) 
to return to baseline levels (Figure 
6.13a) often at 3 days post 
exacerbation presentation. Within 
this group inflammation often fell 
below baseline levels at 1 week 
post presentation (Figure 6.13b), 
probably reflecting the effect of 
exacerbation treatment.  
Biomarkers within this group also 
displayed a rebound rise at 2 weeks post exacerbation onset (Figure 6.13c). 
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Figure 6.14. Acute Rise and Slow Fall of 
Biomarkers during Exacerbation Recovery.  
Time course is shown for (a) SAA, (b) 
Sputum MMP-1 and (c) Serum IL-8. Points 
represent median and interquartile range. 
 
2) Acute rise and slow fall: 
Serum Biomarkers:  
SAA, Serum IL-8.  
Sputum Biomarkers:  
Sputum MMP-1. Sputum MMP-9 
 
The above biomarkers displayed an 
acute rise at exacerbation onset 
followed by a slow descent back 
towards baseline levels. SAA and 
sputum MMP-9 levels had returned 
to baseline levels 5 weeks post 
exacerbation onset (Figure 6.14a), 
whilst serum IL-8 and sputum 
MMP-1 levels remained persistently 
higher than baseline levels at day 35 
after exacerbation onset (Figure 
6.14b and Figure 6.14c).  
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Figure 6.15. Slow Rise and Slow Fall of 
Biomarkers during Exacerbation Recovery.  
The timecourse is shown for (a) Blood total 
white cell counts, (b) Blood neutrophils and 
(c) Serum MMP-9. Points represent median 
and interquartile range. 
 
3) Delayed rise and slow fall: 
Biomarkers:  
Total white blood cells, neutrophils, 
Serum MMP-9. 
 
There was a delayed rise in total 
white cell counts (Figure 6.15a). No 
significant difference was seen 
between total white cell counts (wcc) 
at baseline and exacerbation 
presentation, however at day 3 post 
exacerbation presentation wcc levels 
were significantly greater than 
baseline. This rise persisted for 2 
weeks post exacerbation 
presentation, although levels did 
start to fall from week 1 to week 2. 
Furthermore neutrophil counts 
followed a similar pattern (Figure 
6.15b), along with serum MMP-9 
(Figure 6.15c) which displayed a 
slow rise following exacerbation onset, reaching a peak level at 1 week post exacerbation 
onset before falling to baseline levels at 14 days. 
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Figure 6.16. Persistent Rise of Biomarkers 
during Exacerbation Recovery. Timecourse is 
shown for (a) Serum MMP-1, (b) Serum 
PLGF and (c) Sputum TIMP-1. Points 
represent median and interquartile range. 
 
4) Persistent Rise: 
Serum Biomarkers:  
Serum MMP-1, PLGF. 
Sputum Biomarkers:  
Sputum TIMP-1. 
 
The above biomarkers rose acutely at 
exacerbation onset and remained 
persistently elevated throughout the 
recovery period. Biomarker levels at day 
35 remained significantly higher than 
baseline levels. 
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Figure 6.17. Fall of Biomarkers during 
Exacerbation Recovery. Timecourse is 
shown for (a) Serum α2Macroglobulin, 
(b) Serum IP-10, (c) Serum MMP-8 and 
(d) Blood Eosinophils. Points represent 
median and interquartile range. 
 
5) Fall: 
Biomarkers:  
Serum α2Macroglobulin, Serum MMP-8, 
Serum IP-10, Blood Eosinophils. 
Serum α2Macroglobulin (Figure 6.17a) 
and Serum IP-10 levels (Figure 6.17b) 
fell acutely at exacerbation and remained 
significantly below baseline levels 
throughout recovery. Serum MMP-8 
(Figure 6.17c) levels were also reduced 
following exacerbation but levels were 
only significantly below baseline at day 
35 post exacerbation onset.  
 
Eosinophil levels fell significantly 
following exacerbation presentation, 
being significantly reduced compared to 
baseline at day 3 and 1 week before 
returning to baseline at 2 weeks (Figure 
6.17d). These changes may be the result 
of treatment with oral corticosteroids 
which were administered at exacerbation 
presentation in the majority of 
exacerbations (64 (85%) of 75 events).  
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6.5 Discussion 
This study examined the detailed inflammatory profile of exacerbations of COPD in a well 
characterised cohort and for the first time demonstrated that increased systemic inflammation, 
as measured by absolute levels and change in IL-6, at exacerbation onset predicts clinical 
non-recovery at 35 days. Airway inflammation also increased at exacerbation, although no 
sputum biomarker showed significant ability to predict exacerbation non-recovery. Systemic 
and airway biomarkers followed distinct patterns during exacerbation recovery and slower 
resolution of systemic markers of neutrophilic inflammation was associated with prolonged 
clinical recovery. Uniquely, this study also investigated the inflammatory profile of 
exacerbations which were followed by recurrent events. Exacerbations with an eosinophilic 
profile at exacerbation onset appeared more likely to be followed by a recurrent event than 
non-eosinophilic exacerbations.  
 
Exacerbation non-recovery and recurrence are critical clinical adverse outcomes and are a 
major cause of morbidity, mortality and financial burden to health care systems. Exacerbation 
non-recovery in this study was defined as failure of an exacerbation to symptomatically 
recover 35 days after exacerbation onset. 35 days is a key time-point, since significant 
financial penalties can apply to healthcare organizations if patients are readmitted to hospital 
within 30 days of discharge following an exacerbation of COPD, the median length of stay in 
hospital prior to discharge being 5 days (131). Furthermore, previous pivotal studies have 
analysed non-recovery at 35 days (56).  
 
In almost 25% of cases symptoms do not fully resolve 35 days after the onset of an 
exacerbation (56). Previous biomarker analysis has revealed that serum, plasma and sputum 
IL-6 levels increase from stable values at exacerbation (37, 38, 52, 56, 111) and serum IL-6 
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levels fall during recovery (56, 112). Prior research has also shown that patients who have not 
symptomatically recovered at day 35 after exacerbation onset have a persistently higher 
serum CRP concentration during recovery (56). However, preceding work has failed to 
identify any single biomarker that can be measured at exacerbation onset which enables 
identification of patients at risk of prolonged recovery.  
 
In this study, significant increases were observed between baseline and exacerbation for the 
following blood biomarkers: CRP, Fibrinogen, IL-6, IL-8, PLGF, MMP-1, sRAGE, and 
SAA. This is consistent with previous studies which have shown elevated systemic 
biomarkers at exacerbation (52, 56, 111, 112, 132, 133). However, this work advances the 
field because survival analyses showed that elevated serum IL-6 at exacerbation presentation 
predicted non-recovery at 35 days. This finding has important clinical implications since it 
may now be possible to stratify patients at high risk of non-recovery based on a single blood 
biomarker taken at exacerbation presentation.  
 
In addition to early identification of exacerbations at risk of non-recovery, this study confirms 
that serum biomarkers such as serum IL-6 may be used to monitor the trajectory of recovery. 
Biomarkers showed distinct patterns during exacerbation recovery and serum IL-6 was 
amongst those biomarkers characterised by an acute rise and rapid fall during the 
exacerbation recovery timecourse. In addition to serum IL-6, this group of biomarkers 
contained serum CRP, Fibrinogen, serum PARC, sRAGE, sputum IL-1beta, sputum IL-6, 
sputum IL-8, sputum IL-18, sputum a2M, sputum MMP-8, sputum TNFα, and sputum MPO. 
A number of these biomarkers including IL-8, IL-18 (134) and TNFα are important 
neutrophil chemoattractants, and  MPO is a strong oxidant stored in primary granules of 
neutrophils with potent antibacterial (135). Furthermore, IL-6 itself is a key regulator of 
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neutrophil trafficking during the inflammatory response and acts by orchestrating chemokine 
production and leukocyte apoptosis (136). 
 
This study further reinforces the importance of neutrophilic inflammation at COPD 
exacerbations by demonstrating that exacerbations with persistently elevated total white cell 
(leukocyte) counts, neutrophil counts and serum IL-6 levels above paired baseline at 14 days 
were more likely to have failed to symptomatically recover at 35 days compared to 
exacerbations where inflammatory levels had returned to baseline (although in the case of 
serum IL-6 this did not meet statistical significance).  
 
Such biomarker data may explain previous symptomatic studies which have shown that  
COPD exacerbations exhibit two distinct patterns-sudden and gradual onset (137). Patients 
who experience sudden onset exacerbations have earlier and higher magnitude peak 
symptoms, along with a shorter median recovery time back to baseline. Conversely, gradual 
onset exacerbations appear more likely to be associated with a longer duration of recovery. 
From the data shown in this chapter it can be inferred that patients with rapid symptom onset 
and resolution have a fast onset and rapid resolution of their neutrophilic inflammatory 
profile. Thus, the persistence of excess neutrophilic inflammation at day 14 despite standard 
therapy (systemic antibiotics and/or corticosteroids) may be driving the increased 
symptomatic burden seen in patients with abnormal, prolonged recovery. Therefore, 
excessive neutrophilic inflammation may provide a novel target to improve exacerbation 
recovery. The use of the anti-neutrophilic agent Roflumilast in a novel acute intervention 
study is further discussed in Chapter 7. 
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In addition to systemic inflammatory markers, this work examined airway inflammation 
during exacerbation recovery. Sputum inflammatory markers also increased at exacerbation: 
IL-18, IL-1β, IL-6, TNFα, IL-8, MMP-1, MMP-8, MMP-9, MPO, TIMP-1. However no 
sputum biomarker showed significant ability to predict exacerbation non-recovery. Sputum 
IL-18 levels however did show important differences between exacerbations which were 
followed by a recurrent event and isolated exacerbations not followed by a separate 
exacerbation within 8 weeks.  
 
Recurrent exacerbations are an important clinical problem for COPD patients. In outpatient 
exacerbations, approximately 27% of first exacerbations are followed by a second discrete 
exacerbation over the subsequent 8 weeks (15). In the UK national COPD audit, despite 
current therapies and attempts to prevent such events, 34% of hospitalised exacerbations were 
readmitted in the subsequent 3 months (138). Previous studies have shown that elevated 
serum CRP during the recovery period of a first exacerbation is related to a shorter time to 
second event (56) and it has been theorised that failure to suppress inflammation during 
recovery may predispose to exacerbation recurrence (15). This is supported by clinical trial 
data showing an increased risk of exacerbation following steroid withdrawal (139). 
Corticosteroids are predominantly effective against eosinophilic inflammation and form the 
mainstay of treatment for asthma. However, up to 30% of COPD exacerbations are 
characterised by an eosinophilic phenotype (52) and COPD patients with high baseline blood 
eosinophil levels appear to experience greater reduction in exacerbation frequency with 
steroid-containing inhaler therapy than individuals with lower eosinophil levels (54). 
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In this study, a recurrent exacerbation was defined as an exacerbation that had an onset within 
8 weeks of a preceding exacerbation as per prior research (15). Exacerbations with an 
eosinophilic profile at exacerbation onset were more likely to be followed by a recurrent 
event than non-eosinophilic exacerbations. Blood eosinophils were higher at exacerbation 
onset in index exacerbations which were followed by recurrent events, than in isolated 
exacerbations, although the numbers of patients included in this sub-analysis were small. 
Furthermore, index exacerbations displayed significantly higher sputum IL-18 and sputum 
MMP-1 levels than isolated exacerbations, cytokines which have been implicated in the 
aetiology and severity of bronchial asthma (140-143).  
 
These findings have potentially important implications for the treatment of exacerbations. In 
this study the majority of exacerbations received 7 days of corticosteroid therapy in the form 
oral prednisolone but it may be that exacerbations with an eosinophilic/asthmatic phenotype 
require a longer course of corticosteroid therapy. Trial data has shown that peripheral blood 
eosinophil counts can be used as a biomarker to direct corticosteroid therapy during COPD 
exacerbations (55), and although a recent Cochrane review has shown no difference in rates 
of treatment failure, relapse or time to next exacerbation between short and prolonged courses 
of corticosteroids (144), this review was largely dominated by a recent trial (145) which did 
not stratify patients based upon eosinophilia at exacerbation. Therefore future studies should 
prospectively evaluate the efficacy of corticosteroids to reduce rates of recurrence following 
eosinophilic COPD exacerbations. 
 
Whilst this study showed important relationships between inflammation, recovery length and 
recurrence, it also investigated the relationship between exacerbation aetiology and symptom 
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recovery. No significant difference in exacerbation length was seen between exacerbations 
depending on infection status at exacerbation presentation. This is inconsistent with previous 
work which has shown that exacerbations with both cold symptoms (a marker of viral 
infection) and a bacterial pathogen, have higher symptom burden than those with a bacterial 
pathogen alone (48). Furthermore, in studies of hospitalised exacerbations, patients 
coinfected with virus and bacteria had a significantly longer length of hospital stay (97, 146). 
Although none of the above studies specifically examined the relationship between 
exacerbation aetiology and total exacerbation length as in this chapter. 
 
A significant limitation of this work, in particular the study of recurrent exacerbations, is the 
relatively small number of exacerbations that have been studied. However, this work was 
conducted in a well characterised cohort where patients are specifically trained to recognise 
and report the symptoms of an exacerbation. Patients subsequently presented early after the 
onset of symptoms and prior to starting additional systemic therapy for an exacerbation thus 
this study is likely to provide an accurate insight into the early inflammatory patterns at 
exacerbation and during recovery. Patients do present at variable time from symptom onset, 
however this is unlikely to have significantly influenced results since the median time from 
diary card exacerbation onset to presentation was just 4 days and patients were only included 
if they attended and were sampled within 7 days of symptom onset. A further potential 
limitation is that the statistical analysis did not include a correction for the multiple 
biomarkers that were assessed at each timepoint. However, using a full Bonferroni correction 
would be highly conservative for a proof of mechanism analysis of changes in biomarker 
concentrations at exacerbation, potentially missing real differences. To overcome these 
concerns regarding adequate power and potential type 1 errors, the findings of this chapter 
should be replicated in larger studies as a priority.  
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Additionally, the results of this work should also be examined in more severe hospitalised 
exacerbations. The population in this research includes patients seen commonly in both 
primary care and hospital clinics with moderate and severe COPD who have a history of 
exacerbations and so the results are also likely to be applicable to exacerbations that warrant 
inpatient therapy, since frequent exacerbators are at higher risk of hospitalisation for 
exacerbations (7). 
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6.6 Conclusion 
In conclusion, this work provides further evidence that neutrophilic inflammation is a key 
therapeutic target for exacerbations of COPD. Reducing neutrophilic inflammation may 
improve recovery time. The use of the anti-neutrophilic agent Roflumilast in a novel acute 
intervention study is further discussed in the next section of this thesis (Chapter 7). 
Furthermore, eosinophilic exacerbations appeared more likely to be followed by a recurrent 
event than non-eosinophilic exacerbations. Future studies should prospectively evaluate the 
efficacy of corticosteroids to reduce rates of recurrence following eosinophilic events. 
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7 
TREATMENT WITH 
ROFLUMILAST AT 
EXACERBATION (TREAT) 
 
Chapter 6 showed that persistently elevated neutrophilic inflammation was associated with 
longer clinical recovery and that exacerbations with an eosinophilic profile at exacerbation 
onset appeared more likely to be followed by a recurrent event. Roflumilast reduces 
neutrophilic and eosinophilic inflammation and the following chapter describes the TREAT 
(Treatment with Roflumilast at ExAcerbaTion) study: a novel, proof-of-mechanism trial to 
investigate if roflumilast can reduce exacerbation severity and improve recovery when 
administered as an acute exacerbation therapy. 
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7.1 Introduction 
COPD exacerbations are critical events that lead to acute hospital admission (14), poor health 
status (11),  increased risk of cardiovascular events (10), and mortality (12). However, 
treatment options for acute exacerbations remain limited and current standard therapy of 
moderate to severe exacerbations (not requiring ventilatory support) consists of increased 
bronchodilators, oral corticosteroids and antibiotics (49). 
 
However, evidence for the efficacy of antibiotics is inconsistent and limited (64), and 
antibiotic resistance is become increasingly prevalent in both hospitals and the community. 
The merits of corticosteroids in the treatment of COPD exacerbations are also debatable. 
Multiple studies have found significant short-term benefits of corticosteroids including 
improving lung function in the first three to five days of treatment (68-70) and oxygenation in 
the first 72 hours in comparison to placebo (70, 71).  Corticosteroids have also been shown to 
reduce hospitalisation length (68, 69), and the likelihood of treatment failure (72). However, 
recent research suggests that the benefit of corticosteroid therapy at exacerbation may be 
limited to patients with an eosinophilic inflammatory profile, and that in fact use of 
corticosteroids in non-eosinophilic exacerbations may impair recovery (55).  
 
Patients suffer from repeated exacerbations (7, 11) and may receive repeated courses of 
corticosteroids, exposing patients to significant side effects including cataracts, osteoporosis 
and suppression of the immune system (77). To quickly respond to the symptoms of a COPD 
exacerbation, healthcare systems encourage widespread self-management of exacerbations 
which may lead to uncontrolled and unnecessary corticosteroid use with all its associated 
complications. Crucially, 27% of patients fail treatment with combined antibiotic and 
corticosteroid therapy by 30 days, and treatment failure rates rise to 37% by 90 days (69, 79). 
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Thus, new therapies for management of acute exacerbations are urgently needed, in particular 
specifically targeting the increased inflammation seen at exacerbation. 
 
Exacerbations are inflammatory events, and persistently elevated systemic inflammation is 
associated with prolonged recovery and recurrence (56). Reduction of inflammation may 
reduce the intensity and length of exacerbations. Roflumilast is a phosphodiesterase 4 (PDE4) 
inhibitor and a non-steroid, anti-inflammatory agent, designed to target both the systemic and 
pulmonary inflammation associated with COPD. The mechanism of action is the inhibition of 
PDE4, the major cyclic adenosine monophosphate (cAMP)-metabolising enzyme in structural 
and inflammatory cells important in the pathogenesis of COPD. Inhibition of PDE4 increases 
intracellular cAMP and typically leads to an anti-inflammatory effect. Roflumilast and its 
major active metabolite, roflumilast N-oxide, demonstrate potent anti-inflammatory effects 
(91, 92). 
 
COPD exacerbations are associated with an increased neutrophilic inflammation (38) which 
is relatively insensitive to corticosteroids. In contrast to corticosteroids, roflumilast 
demonstrates broad anti-inflammatory activities in-vitro and in animal studies, including the 
modulation of mediator release from neutrophils, and has been shown to reduce neutrophilic 
airway inflammation in COPD patients (92). The efficacy and safety of roflumilast in stable 
COPD has been investigated in numerous clinical trials in patients with moderate to very 
severe COPD. In all trials roflumilast improved lung function and reduced exacerbations 
when taken daily for 6-12 months (93-95). In these long-term maintenance therapy trials, 
roflumilast was generally safe and well tolerated. In particular, there is no indication that 
roflumilast use is associated with an increase of pneumonia as observed for inhaled 
corticosteroids (94). Diarrhoea is a common side effect and some patients experience 
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significant weight loss, although this is reversible upon withdrawal. Additionally, roflumilast 
significantly reduces endotoxin-induced influx of neutrophils, eosinophils, and total cells into 
the bronchoalveolar compartment in healthy volunteers (96). Thus, we hypothesised that 
roflumilast will be beneficial in the treatment for COPD exacerbations. 
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7.2 Aim  
Therefore we conducted a randomised, placebo controlled trial to test the hypothesis that 
Roflumilast reduces neutrophilic inflammation during exacerbations of COPD when added to 
the usual care of these patients. Chapter 6 has demonstrated that faster resolution of 
neutrophilic inflammation is associated with shorter clinical recovery. Thus this study serves 
as a proof-of-mechanism trial to examine whether roflumilast can improve clinical recovery 
following COPD exacerbations. In addition, the potential benefit of roflumilast to reduce the 
length and severity of exacerbations has been assessed using patient diaries and 
questionnaires (CAT and EXACT). 
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7.3 Methods 
Full methodology for this chapter is described in methods section 3.5. The TREAT 
(Treatment with Roflumilast at ExAcerbaTion) study was a randomised, double-blind, 
parallel-group, single centre, phase II trial. COPD patients were recruited from the London 
COPD patient cohort at exacerbation between 14
th
 February 2012 and 21
st
 February 2014. 
Patients were consented, recruited and randomised at exacerbation presentation prior to 
commencement of systemic therapy, within 7 days of exacerbation onset as judged by diary 
cards. Patients received Roflumilast or placebo for 28 days on top of standard exacerbation 
therapy with 7 days oral amoxicillin (or clarithromycin in event of penicillin allergy) and 10 
days oral prednisolone. Patients were followed up for 8 weeks following recruitment (Figure 
3.10). 
 
 
 
Figure 3.10. Clinical trial overview. 
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To measure the efficacy of Roflumilast in separate exacerbations within the same patient, 
repeated exacerbations from the same patient were included if the second event occurred at 
least 3 months after end of the initial 8 week exacerbation follow-up period. Therefore 2 
groups were available for analysis: 
1. Initial Approach-included just one exacerbation per patient.  
In the initial approach 38 patients were randomised to the Roflumilast group and 43 
patients into the placebo group. 
2. Extended Approach- included repeated exacerbations from the same patient.  
In the extended approach 48 exacerbations were randomised to the Roflumilast group 
and 47 exacerbations into the placebo group. 
 
The primary endpoint was change in sputum neutrophil counts from Visit V0 to V2, 14 days 
after randomisation. Secondary endpoints included assessment of change from visit V0 to 
each post randomisation visit for sputum markers, blood biomarkers, spirometric 
assessments, PROs and diary card outcomes. 
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Statistical Analysis 
All reported efficacy analyses were predefined. Quantitative endpoints are expressed using 
descriptive statistics (mean ± SD). Categorical data are expressed descriptively by absolute 
and relative frequencies (n and %). 
 
The primary endpoint was analysed with an analysis of covariance model. The model 
contained the primary endpoint as an independent variable and neutrophil count at enrolment 
and treatment as independent variables. The comparison was performed at a 2-sided 
significance level α=0.05 and was based on the full analysis set. Descriptive and inferential 
statistics were used to analyse secondary endpoints. All analyses of secondary endpoints were 
exploratory.  
 
Sample size calculation was based on the primary endpoint, change in sputum neutrophil 
counts from enrolment to Day 14 post exacerbation. With the assumption of an effect size of 
40%, with the neutrophil count at Day 14 post exacerbation with placebo being 20% higher 
than baseline (previously reported as 1.48x10
6
 (147)) and the neutrophil count on roflumilast 
20% lower than baseline, the change in neutrophil count between enrolment and Day 14 was 
expected to be 0.414x10
6
 cells/g with placebo and 1.006x10
6
 cells/g with roflumilast. It was 
also assumed that the standard deviation of the change with these paired samples would be 
the same as the IQR of the neutrophil count at baseline (1.18x10
6
 cells/g (147)). Based on 
these assumptions, 63 patients in each group (total 126) were required to detect such a 
difference with 80% power at the 5% significance level. To allow for a 10% drop-out, we 
aimed to recruit 140 patients. 
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The scientific oversight of the study was provided by a steering committee responsible for 
providing scientific advice about the study design, execution, interpretation, and publication 
of results. As sponsor of this study, Takeda (Takeda Development Centre Europe Ltd, 
London, UK) was responsible for study oversight and overall project management. Accovion 
GmbH (Frankfurt, Germany) managed the administration, coordination, and monitoring of 
the study, including data management and statistical analysis. Statistical analysis was 
performed by Accovion with statistical support from Takeda in accordance with statistical 
analysis plan agreed with myself, Professor Wedzicha and Dr Gavin Donaldson. 
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7.4 Results 
Patient Characteristics 
Full baseline clinical characteristics of the patients included in this paper are reported in 
Table 7.1. The initial approach included 38 patients who were randomised to the Roflumilast 
group and 43 patients into the placebo group, with one exacerbation included per patient. The 
extended approach included repeated exacerbations from the same patient.   
  
 Initial Approach Extended Approach 
 Roflumilast 
n=38 
Placebo 
n=43 
Roflumilast 
n=48 
Placebo 
n=47 
 Mean±SD Mean±SD Mean±SD Mean±SD 
Age (years) 72.9±8.6 70.5±9.3 72.0±8.9 70.3±9.1 
FEV1 (L) 1.3±0.5 1.4±0.6 1.3±0.5 1.4±0.6 
FEV1 (% predicted) 48.6±14.1 50.1±18.0 49.8±14.1 49.2±17.8 
FVC (L) 2.7±0.8 2.9±1.0 2.7±0.9 2.9±1.0 
FEV1 / FVC ratio (%) 46.7±11.7 48.2±13.3 48.5±11.9 47.4±13.0 
Smoking pack years 53.1±40.7 56.0±27.1 53.5±38.0 55.0±26.4 
BMI (kg/m
2
) 26.8±6.4 27.1±5.8 27.6±6.8 26.8±5.8 
HCU exacerbations  in 
year prior to enrolment 
1.4±1.2 1.3±1.3 1.4±1.2 1.3±1.3 
     
 N (%) N (%) N (%) N (%) 
Male gender 22 (57.9) 28 (65.1) 26 (54.2) 31 (66.0) 
Current Smokers 8 (21.1) 11 (25.6) 10 (79.2) 13 (27.7) 
Chronic Bronchitics 24 (63.2) 26 (60.5) 31 (64.6) 29 (61.7) 
Frequent Exacerbators 
(≥2 HCU exacerbations 
in year prior to 
enrolment) 
10 (26.3)  15 (34.9) 14 (29.2) 16 (34.0) 
Table 7.1. Stable state clinical characteristics of patients included in the initial approach with one 
patient per exacerbation, and the extended approach with repeated exacerbations included. 
 
Table 7.1. Baseline clinical characteristics. 
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Roflumilast 
Initial N=38, Extended N=48 
Completed 
Initial N=27, Extended N=32 
Withdrawal 
Initial N=11, Extended N=16 
Withdrawals due to adverse event 
initial N=10, extended N=15 
Completed 
Initial N=40, Extended N=44 
Withdrawal 
Initial N=3, Extended N=3 
Withdrawals due to adverse event 
initial N=1, extended N=1 
 
Placebo 
Initial N=43, Extended N=47 
 
Randomised 
Initial N=81, Extended N=95 
 
Eligible Patients for initial 
study N=131  
Eligible Exacerbations for 
Extended study N=174 Reasons for Non-enrolment 
(N patients, N exacerbations) 
Declined any treatment (N=18, N=24) 
Declined to use steroids (N=3, N=6) 
Unable to attend follow-up (N=7, N=7) 
Declined to participate (N=22, N=42) 
 
Figure 7.1: CONSORT diagram for flow of patients through the study. 
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Primary Outcome: Change in sputum neutrophil count from Exacerbation Presentation (V0) 
to 14 days post exacerbation (V2)  
No significant difference in sputum neutrophil count from V0 to V2 (cells/g sputum) was 
seen between the Roflumilast group and the placebo group, in either the initial or the 
extended approach (Figure 7.2). By the initial approach, LS mean changes from Day 1 to 
Day 14 were -18.705 (95% CI -23.228, -14.183) cells/g sputum and -20.109 (95% CI -
24.095, -16.123) cells/g sputum for roflumilast and placebo, respectively. The between-
treatment difference did not reach statistical significance (1.404 [95% CI -4.731, 7.538] 
cells/g sputum; p=0.6491). By the extended approach, these values were -19.569 (95% CI -
23.367, -15.771) and -19.157 (95% CI -22.854, -15.459) for roflumilast and placebo 
respectively. The between-treatment difference was -0.412 (-95% CI 5.766, 4.943; 
p=0.8786). 
 
 
  
Figure 7.2. Primary Outcome: 
Change in sputum neutrophil 
count from V0 to V2 (cells/g 
sputum), initial and extended 
approach. Roflumilast treated 
events shown as white filled 
bars with black border, placebo 
treated events shown as solid 
black bars. Lines represent 
standard errors. 
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Secondary Outcomes: Airway Inflammation 
Roflumilast use led to significant reductions in airway inflammation as shown by change 
from V0 to V3 (exacerbation presentation, Day 1 to day 28 post exacerbation onset) in % 
sputum neutrophils (p=0.0486 initial approach; p=0.0208 extended approach), and 
myeloperoxidase concentration (p=0.018 initial approach; p=0.0149 extended approach). 
Roflumilast use also led to enhanced reductions in airway inflammation from V0 to V1 that 
approached statistical significance for IL-6 and MPO (IL-6 p=0.0546 initial approach, 
p=0.1312 extended approach; MPO p=0.0884 initial approach, p=0.0881 extended approach). 
Full results for all sputum biomarkers are shown in Table 7.2A and 7.2B). 
 
 
Secondary Outcomes: Systemic Inflammation 
No significant differences were seen in serum inflammatory markers between patients treated 
with Roflumilast or placebo in the initial approach. However, in the extended approach, 
patients treated with Roflumilast displayed a small rise in serum IL-6 and serum CRP from 
V0-V2 (Day 1-14), leading to a statistically significant change compared to placebo (change 
from V0-V2, Roflumilast vs placebo, p=0.0337 for IL-6, and p=0.0318 for CRP). Whilst 
statistically significant, the absolute rise in serum IL-6 and serum CRP from V0-V2 were 
numerically small at 1.607pg/mL and 5.720mg/L respectively, and thus are unlikely to be 
clinically significant. Full results for all blood biomarkers are shown in Table 7.3A and 
7.3B). 
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Data are LS mean (95% CI) in the intention-to-treat population. LS means are from Mixed Model Repeated Measurement (MMRM) for all secondary 
endpoints. *LS means are from ANCOVA for the primary endpoint. ROF=roflumilast. PBO=placebo.  
 Change from V0 to V1 (Day 1–7) Change from V0 to V2 (Day 1–14) Change from V0 to V3 (Day 1–28) Change from V0 to VFU (Day 1–56) 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
Sputum markers 
Sputum neutrophil 
count (106 cells/g 
sputum) 
-20.445 
 (-26.104,  
-14.786) 
-24.024 
(-29.156,  
-18.893) 
3.579 
 (-4.072, 
11.231),  
p=0.3544 
-18.705 
 (-23.228,  
-14.183)* 
-20.109 
 (-24.095,  
-16.123)* 
1.404  
(-4.731, 
7.538) 
p=0.6491* 
-25.704  
(-32.602, 
 -18.807) 
-19.188 
(-25.013, 
 -13.364) 
-6.516 
(-15.563, 
2.532) 
p=0.1555 
-18.400 
(-24.901,  
-11.899) 
-22.817 
(-28.293,  
-17.341) 
4.417  
(-4.093, 
12.927) 
p=0.3045 
Total cells (10
6
 /g) -25.559 
 (-32.585,  
-18.532) 
-27.563  
(-34.200,  
-20.927) 
2.005  
(-7.677, 
11.686) 
p=0.6813 
-21.813  
(-27.201,  
-16.425) 
-25.111  
(-30.098,  
-20.125) 
3.299  
(-4.085, 
10.682) 
p=0.3765 
-29.200  
(-37.207,  
-21.193) 
-22.218  
(-28.910,  
-15.525) 
-6.982 
(-17.449, 
3.484) 
p=0.1880 
-24.477  
(-29.867,  
-19.087) 
-26.474  
(-31.135, 
-21.814) 
1.997  
(-5.164, 
9.159) 
p=0.5803 
Neutrophils (%) -11.325  
(-18.969,  
-3.680) 
-14.484  
(-21.575,  
-7.394) 
3.160  
(-7.277, 
13.597) 
p=0.5483 
-16.770 
 (-24.705,  
-8.836) 
-20.346  
(-27.418, 
 -13.274) 
3.576  
(-7.089, 
14.240) 
p=0.5062 
-27.760  
(-38.267,  
-17.252) 
-13.837  
(-22.797,  
-4.876) 
-13.923 
 (-27.760,  
-0.086) 
p=0.0486 
-19.663 
 (-30.742, 
-8.584) 
-17.047  
(-25.472,  
-8.622) 
-2.615  
(-16.563, 
11.332) 
p=0.7098 
Macrophages (%) 11.393  
(3.749, 
19.036) 
15.430  
(8.339, 
22.520) 
-4.037  
(-14.467, 
6.393) 
p=0.4431 
16.062  
(8.234, 
23.890) 
20.774 
(13.789, 
27.758) 
-4.712 
 (-15.225, 
5.802) 
p=0.3748 
27.535 
(17.009, 
38.060) 
13.382  
(4.411, 
22.352) 
14.153  
(0.304, 
28.002) 
p=0.0453 
16.593  
(5.559, 
27.627) 
15.877  
(7.567, 
24.187) 
0.716  
(-13.117, 
14.548) 
p=0.9182 
Eosinophils (%) -0.259  
(-0.747, 
0.228) 
-0.100  
(-0.548, 
0.347) 
-0.159  
(-0.825, 
0.507) 
p=0.6362 
-0.110 
 (-0.759, 
0.539) 
-0.188  
(-0.762, 
0.386) 
0.078 
 (-0.791, 
0.947) 
p=0.8584 
0.043  
(-2.366, 
2.451) 
1.597  
(-0.434, 
3.628) 
-1.555  
(-4.706, 
1.597) 
p=0.3289 
2.187  
(-2.351, 
6.725) 
1.086  
(-2.432, 
4.605) 
1.101  
(-4.642, 
6.843) 
p=0.7036 
Lymphocytes (%) 0.229  
(-0.474, 
0.932) 
0.182  
(-0.468, 
0.831) 
0.047  
(-0.911, 
1.005) 
p=0.9224 
0.430  
(-0.077, 
0.936) 
0.295  
(-0.154, 
0.743) 
0.135  
(-0.542, 
0.813) 
p=0.6923 
0.039  
(-0.326, 
0.404) 
-0.325  
(-0.633, -
0.016) 
0.363 
 (-0.116, 
0.843) 
p=0.1355 
-0.095  
(-0.467, 
0.278) 
-0.051  
(-0.324, 
0.222) 
-0.043  
(-0.505, 
0.419) 
p=0.8529 
IL-6 (pg/mL) -1317.400  
(-1603.823,  
-1030.976) 
-934.624  
(-1200.065, 
 -669.182) 
-382.776  
(-773.373, 
7.821) 
p=0.0546 
-822.715  
(-1263.721,  
-381.708) 
-695.955  
(-1106.819,  
-288.091)  
-126.760  
(-729.574, 
476.055) 
p=0.6764 
-1232.929 
 (-1656.668,  
-809.109) 
-955.365  
(-1303.530,  
-607.200) 
-277.564  
(-826.228, 
271.101) 
p=0.3167 
-1042.097 
 (-1491.651, -
592.542) 
-996.485 
 (-1388.476,  
-604.494) 
-45.612 
 (-642.166, 
550.943) 
p=0.8793 
IL-8 (pg/mL) -174718.396 
(-265342.682, 
-84094.111) 
-227274.816 
(-310605.023, 
-143944.610) 
52556.420 
 (-70496.843, 
175609.682) 
p=0.3975 
-149198.139 
(-243622.453, 
-54773.826) 
-199515.687 
(-287119.434, 
-111911.940) 
50317.548 
 (-78505.910, 
179141.005) 
p=0.4389 
-255317.294 
(-396618.822, 
-114015.765) 
-160587.365 
(-276044.886, 
-45129.844) 
-94729.929  
(-277217.297, 
87757.440) 
p=0.3043 
-204731.356 
(-305164.180, 
-104298.533) 
-223918.341 
(-309676.552, 
-138160.130) 
19186.984  
(-112898.540, 
151272.508) 
p=0.7731 
Neutrophil elastase 
(μg/mL) 
-222995.020 
(-252658.522, 
-193331.517) 
-224606.396 
(-251844.437, 
-197368.355) 
1611.376 
 (-38762.691, 
41985.444) 
p=0.9368 
-149211.318 
(-227963.551, 
-70459.086) 
-125385.276 
(-198372.069, 
-52398.483) 
-23826.042  
(-131241.297, 
83589.212) 
p=0.6598 
-200905.068 
(-251581.394, 
-150228.742) 
-149865.936 
(-190811.843, 
-108920.029) 
-51039.132  
(-116304.330, 
14226.066) 
p=0.1234 
-141985.838 
(-198332.110, 
-85639.566) 
-169389.587 
(-216748.120, 
-122031.054) 
27403.749  
(-46270.048, 
101077.546) 
p=0.4609 
Myeloperoxidase 
(ng/mL) 
-9253.786  
(-13233.048, 
 -5274.525) 
-4521.397 
 (-8235.233,  
-807.561) 
-4732.389 
 (-10193.012, 
728.233) 
p=0.0884 
-8072.784  
(-12346.581, 
 -3798.987) 
-6318.878  
(-10309.822,  
-2327.935) 
-1753.906  
(-7623.747, 
4115.936) 
p=0.5534 
-13744.824  
(-18678.606,  
-8811.041) 
-5944.184 
 (-10012.135, 
-1876.233) 
-7800.640  
(-14241.610,  
-1359.670) 
p=0.0183 
-10248.612 
 (-15385.680, 
-5111.544) 
-9478.460  
(-13930.276, 
 -5026.644) 
  
-770.151  
(-7607.330, 
6067.027) 
p=0.8230 
Table 7.2A: LS mean change in sputum inflammatory markers (initial approach) 
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Data are LS mean (95% CI) in the intention-to-treat population. LS means are from MMRM for all secondary endpoints. *LS means are from ANCOVA for the 
primary endpoint. ROF=roflumilast. PBO=placebo.  
 Change from V0 to V1 (Day 1–7) Change from V0 to V2 (Day 1–14) Change from V0 to V3 (Day 1–28) Change from V0 to VFU (Day 1–56) 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
Sputum markers 
Sputum neutrophil 
count (106 cells/g 
sputum) 
-21.265 
(-26.389, 
 -16.140) 
-22.326  
(-27.380, 
 -17.271) 
1.061  
(-6.141, 
8.263) 
p=0.7704 
-19.569 
(-23.367,  
-15.771)* 
-19.157 
(-22.854, 
-15.459)* 
-0.412  
(-5.766, 
4.943)  
p= 0.8786* 
-24.112 
 (-30.203, 
-18.020) 
-17.969  
(-23.559, 
-12.378) 
-6.143  
(-14.421, 
2.135) 
p=0.1438 
-12.788 
(-21.283, 
-4.292) 
-21.892  
(-28.821, 
-14.963) 
9.104  
(-1.865, 
20.073) 
p=0.1026 
Total cells (106 /g) -26.634 
(-32.653 -
20.615)  
-26.335 
(-32.541, 
 -20.129) 
-0.299  
(-8.962, 
8.364)  
p=0.9455 
-23.512 
(-28.376, 
 -18.648) 
-25.332 
(-30.239, 
 -20.424) 
1.820  
(-5.130, 
8.769)  
p=0.6042 
-29.023 
(-35.672, 
 -22.373) 
-22.920 
(-28.774, 
 -17.066) 
-6.102 
(-14.984, 
2.779)  
p=0.1757 
-19.551 
(-27.339, 
 -11.764) 
-26.855 
(-33.879, 
 -19.831) 
7.304  
(-3.198, 
17.806)  
p=0.1705 
Neutrophils (%) -14.637 
(-22.088, 
 -7.185) 
-16.060 
(-23.441, 
 -8.678) 
1.423 
(-9.081, 
11.927)  
p=0.7883 
-20.690 
(-28.160, 
 -13.220) 
-21.052 
(-28.364, 
 -13.740) 
0.362 
(-10.124, 
10.848)  
p=0.9455 
-29.848 
(-39.233, 
 -20.462) 
-14.664 
(-23.353, 
 -5.974) 
-15.184  
(-28.004, 
 -2.363)  
p=0.0208 
-21.327 
(-31.283, 
 -11.370) 
-17.328 
(-25.652, 
 -9.003) 
-3.999 
(-17.009, 
9.012)  
p=0.5428 
Macrophages (%) 14.679 
(7.245, 
22.113) 
17.228 
(9.864, 
24.592) 
-2.549  
(-13.023, 
7.925)  
p=0.6297 
20.331 
(12.885, 
27.777) 
21.599 
(14.309, 
28.889) 
-1.268 
(-11.713, 
9.177)  
p=0.8099 
29.510 
(20.132, 
38.888) 
14.463 
(5.781, 
23.144) 
15.048 
(2.245, 
27.850)  
p=0.0218 
19.075  
(9.129 
29.021) 
16.322 
(8.060, 
24.584) 
2.753 
(-10.201, 
15.706)  
p=0.6737 
Eosinophils (%) -0.341  
(-0.749, 
0.068) 
-0.141 
(-0.542, 
0.260) 
-0.200 
(-0.776, 
0.376)  
p=0.4925 
-0.174 
(-0.713, 
0.364) 
-0.214 
(-0.738, 
0.309) 
0.040 
(-0.713, 
0.792)  
p=0.9167 
0.031 
(-2.045, 
2.107) 
1.518 
(-0.374, 
3.411) 
-1.487 
(-4.297, 
1.323)  
p=0.2957 
1.714 
(-2.200, 
5.627) 
0.913 
(-2.378, 
4.203) 
0.801 
(-4.312, 
5.914)  
p=0.7562 
Lymphocytes (%) 0.109 
(-0.502, 
0.720) 
-0.015 
(-0.618, 
0.588) 
0.124 
(-0.735, 
0.983)  
p=0.7747 
0.309 
(-0.188, 
0.805) 
0.195 
(-0.289, 
0.679) 
0.113 
(-0.580, 
0.807)  
p=0.7463 
-0.118 
(-0.462, 
0.225) 
-0.431 
(-0.744, 
 -0.118) 
0.313 
(-0.153, 
0.778)  
p=0.1849 
-0.203 
(-0.530, 
0.123) 
-0.208 
(-0.470, 
0.055) 
0.004 
(-0.414, 
0.422)  
p=0.9843 
IL-6 (pg/mL) -1207.678 
(-1472.709, 
 -942.646) 
-923.325 
(-1182.859, 
 -663.791) 
-284.353 
(-655.351, 
86.645)  
p=0.1312 
-725.454 
(-1114.998, 
 -335.910) 
-705.849 
(-1089.366, 
 -322.331) 
-19.605 
(-566.291, 
527.082)  
p=0.9433 
-1115.741 
(-1514.125, 
 -717.357) 
-877.871 
(-1221.742, 
 -533.999) 
-237.870 
(-764.005, 
288.265)  
p=0.3712 
-860.191 
(-1270.349, 
 -450.032) 
-962.342  
(-1339.748, 
 -584.935) 
102.151 
(-455.166, 
659.468)  
p=0.7164 
IL-8 (pg/mL) -193222.856  
(-271948.714, 
-114496.997) 
-215296.477  
(-291710.432, 
-138882.522) 
22073.621 
(-87606.768, 
131754.011)  
p=0.6901 
-172069.810 
(-254267.450, 
-89872.170) 
-195751.307 
(-276176.478, 
-115326.135) 
23681.497 
(-91333.372, 
138696.366)  
p=0.6833 
-264788.038 
(-388936.322, 
-140639.754) 
-160441.028 
(-267734.979, 
-53147.077) 
-104347.010 
(-268439.773, 
59745.753)  
p=0.2096 
-168204.970 
(-271118.435, 
-65291.506) 
-205822.814 
(-298231.512, 
-113414.117) 
37617.844 
(-100676.823, 
175912.511)  
p=0.5900 
Neutrophil elastase 
(μg/mL) 
-202235.344 
(-228069.915, 
-176400.772) 
-206912.465 
(-231851.593, 
-181973.337) 
4677.121 
(-31294.505, 
40648.747)  
p=0.7966 
-143831.510 
(-211519.846, 
-76143.175) 
-110144.325 
(-176177.838, 
-44110.811) 
-33687.186 
(-128273.181, 
60898.809)  
p=0.4808 
-183452.324 
(-228308.127, 
-138596.522) 
-130613.019 
(-168898.812, 
-92327.225) 
-52839.306 
(-111867.516, 
6188.905)  
p=0.0787 
-118129.436 
(-168625.560, 
-67633.313) 
-156544.533 
(-201380.082, 
-111708.984) 
38415.096 
(-29147.155, 
105977.348)  
p=0.2614 
Myeloperoxidase 
(ng/mL) 
-8606.357 
(-12080.048, 
 -5132.666) 
-4380.803 
(-7786.800, 
 -974.807) 
-4225.553 
(-9094.548, 
 643.441)  
p=0.0881 
-8380.855 
(-12102.755, 
 -4658.956) 
-5929.775 
(-9595.757, 
 -2263.794) 
-2451.080 
(-7683.078, 
2780.919)  
p=0.3543 
-12692.279 
(-17106.977, 
 -8277.581) 
-5351.001 
(-9196.240, 
 -1505.763) 
-7341.277 
(-13217.127, 
 -1465.428)  
p=0.0149 
-9424.227 
(-13949.488, 
 -4898.966) 
-8527.766 
(-12660.203, 
 -4395.329) 
-896.461 
(-7042.991, 
5250.069)  
p=0.7725 
Table 7.2B: LS mean change in sputum inflammatory markers (extended approach) 
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 Change from V0 to V1 (Day 1–7) Change from V0 to V2 (Day 1–14) Change from V0 to V3 (Day 1–28) Change from V0 to VFU (Day 1–56) 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
Blood biomarkers 
IL-6 (pg/mL) -12.469  
(-14.026, 
 -10.911) 
-11.904  
(-13.382, 
 -10.427) 
-0.564 
 (-2.716, 
1.588) 
p=0.6032 
-1.973 
 (-5.792, 
1.847) 
-5.728  
(-9.171, 
 -2.285) 
3.755  
(-1.390, 
8.900) 
p=0.1502 
-8.108 
 (-12.807,  
-3.409) 
-7.243 
 (-11.219, 
 -3.267) 
-0.865  
(-7.022, 
5.293) 
p=0.7806 
-11.665  
(-13.914,  
-9.417) 
-9.431  
(-11.296,  
-7.565) 
-2.235  
(-5.161, 
0.692) 
p=0.1325 
IL-1β (pg/mL) 1.274 
 (-0.084, 
2.631) 
0.378 
 (-0.910, 
1.665) 
0.896  
(-0.975, 
2.767) 
p=0.3434 
0.217  
(-0.499, 
0.932) 
0.495  
(-0.150, 
1.139) 
-0.278 
 (-1.241, 
0.685) 
p=0.5674 
0.657  
(-0.201, 
1.516) 
0.541  
(-0.188, 
1.270) 
0.116  
(-1.010, 
1.243) 
p=0.8376 
-0.003  
(-0.657, 
0.652) 
0.464  
(-0.109, 
1.037) 
-0.467  
(-1.336, 
0.403) 
p=0.2885 
CRP (mg/L) -15.579 
 (-16.546,  
-14.613) 
-16.518  
(-17.437, 
-15.600) 
0.939  
(-0.398, 
2.275) 
p=0.1660 
4.836  
(-3.623, 
13.296) 
-4.369  
(-11.958, 
3.220) 
9.205  
(-2.160, 
20.571) 
p=0.1109 
-9.179 
 (-17.362,  
-0.996) 
-8.018 
 (-15.051,  
-0.985) 
-1.161  
(-11.952, 
9.629) 
p=0.8309 
-14.889  
(-17.665,  
-12.112) 
-13.057  
(-15.312,  
-10.802) 
-1.832 
 (-5.412, 
1.748) 
p=0.3115 
Fibrinogen (μmol/L) -3.916 
 (-4.487, 
 -3.345) 
-3.976 
 (-4.496,  
-3.457) 
0.060 
 (-0.713, 
0.833) 
p=0.8771 
0.404 
 (-0.841, 
1.648) 
-0.184 
 (-1.321, 
0.953) 
0.588 
 (-1.099, 
2.274) 
p=0.4894 
0.210 
 (-1.137, 
1.557) 
0.014 
 (-1.116, 
1.144) 
0.196 
 (-1.562, 
1.955) 
p=0.8247 
-2.127  
(-3.373, 
 -0.882) 
-1.144  
(-2.171,  
-0.117) 
-0.983  
(-2.597, 
0.631) 
p=0.2287 
 Change from V0 to V1 (Day 1–7) Change from V0 to V2 (Day 1–14) Change from V0 to V3 (Day 1–28) Change from V0 to VFU (Day 1–56) 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
Blood biomarkers 
IL-6 (pg/mL) -12.314 
(-13.609, 
 -11.019) 
-11.802 
(-13.124, 
 -10.480) 
-0.512 
(-2.363, 
1.340)  
p=0.5844 
1.607 
(-3.444, 
6.658) 
-6.069 
(-11.015, 
 -1.124) 
7.676 
(0.607, 
14.746)  
p=0.0337 
-7.587 
(-11.734, 
 -3.441) 
-7.619 
(-11.269, 
 -3.970) 
0.032 
(-5.493, 
5.557)  
p=0.9909 
-10.811 
(-12.925, 
 -8.697) 
-9.604 
(-11.428, 
 -7.780) 
-1.207 
(-4.000, 
1.587)  
p=0.3932 
IL-1β (pg/mL) 0.350 
(-0.823, 
1.522) 
-1.002 
(-2.198, 
0.193) 
1.352 
(-0.322, 
3.027)  
p=0.1122 
-0.394 
(-1.099, 
0.311) 
-0.841  
(-1.533, 
 -0.148) 
0.447 
(-0.542, 
1.435)  
p=0.3721 
-0.139 
(-0.960, 
0.682) 
-0.757 
(-1.489, 
 -0.025) 
0.618 
(-0.483, 
1.718)  
p=0.2676 
-0.799 
(-1.459, 
 -0.138) 
-0.806 
(-1.426, 
 -0.187) 
0.008 
(-0.898, 
0.914)  
p=0.9864 
CRP (mg/L) -16.166 
(-16.980, 
 -15.352) 
-16.901 
(-17.729, 
 -16.072) 
0.734 
(-0.434, 
1.903)  
p=0.2152 
5.720 
(-1.429, 
12.870) 
-5.257 
(-12.245, 
1.731) 
10.977 
(0.979, 
20.975)  
p=0.0318 
-8.250 
(-15.801, 
 -0.700) 
-9.254 
(-15.958, 
 -2.550) 
1.004 
(-9.095, 
11.102)  
p=0.8440 
-15.152 
(-17.573, 
 -12.730) 
-13.793  
(-15.847, 
 -11.738) 
-1.359 
(-4.538, 
1.819)  
p=0.3980 
Fibrinogen (μmol/L) -3.971 
(-4.460, 
 -3.481) 
-3.839 
(-4.324, 
 -3.353) 
-0.132 
(-0.822, 
0.558)  
p=0.7046 
0.051 
(-0.984, 
1.087) 
-0.148 
(-1.180, 
0.885) 
0.199 
(-1.263, 
1.661)  
p=0.7873 
0.147  
(-1.044, 
1.337) 
-0.091 
(-1.133, 
0.952) 
0.237 
(-1.345, 
1.820)  
p=0.7664 
-2.155 
(-3.213, 
 -1.096) 
-1.162 
(-2.079, 
 -0.244) 
-0.993 
(-2.395, 
0.408)  
p=0.1625 
Data are LS mean (95% CI) in the intention-to-treat population. LS means are from Mixed Model Repeated Measurement (MMRM) for all 
secondary endpoints. *LS means are from ANCOVA for the primary endpoint. ROF=roflumilast. PBO=placebo. 
Table 7.3A: LS mean change in blood biomarkers (initial approach) 
Table 7.3B. LS mean change in blood biomarkers (extended approach) 
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Secondary Outcomes: Lung Function 
Roflumilast use led to improvements in lung function and full results are shown in Table 
7.4A and 7.4B. FEV1 was improved in the Roflumilast treated group compared to placebo at 
V1 (1week) and V2 (2 weeks) by approximately 50ml, although these improvements did not 
meet the threshold for statistical significance. However, at V3 (4 weeks post exacerbation) 
FEV1 was greater in the Roflumilast arm by 94ml in the initial approach (p=0.0546) and 
87ml in the extended approach which was statistically significant (p=0.0434, Figure 7.3).  
 
Figure 7.3: Change in FEV1 from Baseline. A) Initial approach. B) Extended 
approach. Data are LSmeans ± SE in the intention-to-treat population. 
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Furthermore, FEV1% predicted was significantly improved from V0 to V3 (Day 1–28) 
compared with placebo (p=0.0372 initial approach; p=0.0192 extended approach). The 
FEV1/FVC ratio improved statistically significantly more from V0 (exacerbation 
presentation) to each post-randomisation visit in the roflumilast group compared with the 
placebo group (p=0.0421, 0.088, 0.0275 and 0.0106 from Day 1 to 7, 14, 28 and 56 
respectively initial approach; p=0.0353, 0.081, 0.0158 and 0.0046 from Day 1 to 7, 14, 28 
and 56 respectively extended approach). No significant difference was seen in FVC between 
patients who received Roflumilast or placebo. 
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 Change from Day 1–7 Change from Day 1–14 Change from Day 1–28 Change from Day 1–56 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
FEV1 (L) 0.063 
(0.008, 0.117) 
0.012  
(-0.042, 
0.067) 
0.050 
(-0.027, 
0.127) 
p=0.2007 
0.062 
(0.004, 0.121) 
0.018 
(-0.039, 
0.075) 
0.044 
(-0.038, 
0.125) 
p=0.2913 
0.084 
(0.021, 0.146) 
-0.003 
(-0.060, 
0.053) 
0.087 
(0.003, 0.171) 
p=0.0434 
0.050 
(-0.018, 
0.118) 
0.005 
(-0.055, 
0.065) 
0.045 
(-0.046, 
0.136) 
p=0.3290 
FEV1 (% predicted) 2.533 
(0.572, 4.495) 
-0.093  
(-2.068, 
1.882) 
2.626 
(-0.157, 
5.410)  
p=0.0641 
2.717 
(0.682, 4.752) 
0.401 
(-1.585, 
2.388) 
2.316 
(-0.528, 
5.159)  
p=0.1092 
2.971 
(0.802, 5.141) 
-0.532 
(-2.486, 
1.423) 
3.503 
(0.583, 6.423)  
p=0.0192 
1.653 
(-0.694, 
4.001) 
-0.487 
(-2.544, 
1.571) 
2.140  
(-0.981, 
5.261)  
p=0.1766 
FVC (L) 0.048 
(-0.056, 
0.152) 
0.062 
(-0.043, 
0.166) 
-0.014 
(-0.161, 
0.134)  
p=0.8558 
0.046 
(-0.061, 
0.153) 
0.146 
(0.041, 0.250) 
-0.100 
(-0.250, 
0.050)  
p=0.1898 
0.053 
(-0.071, 
0.177) 
0.067 
(-0.046, 
0.179) 
-0.014 
(-0.182, 
0.154)  
p=0.8697 
0.034 
(-0.095, 
0.162) 
0.084 
(-0.031, 
0.199) 
-0.050 
(-0.224, 
0.123)  
p=0.5645 
FEV1/FVC (%) 1.282 
(-0.298, 
2.861) 
-1.128 
(-2.714, 
0.459) 
2.409 
(0.170, 4.648)  
p=0.0353 
1.394 
(-0.294 3.083) 
-1.830 
(-3.487 -
0.174) 
3.225 
(0.858, 5.591)  
p=0.0081 
2.045 
(0.110, 3.979) 
-1.198 
(-2.962, 
0.566) 
3.243 
(0.624, 5.862)  
p=0.0158 
1.393 
(-0.250, 
3.036) 
-1.881 
(-3.401, 
 -0.361) 
3.274 
(1.035, 5.513)  
p=0.0046 
Data are LS mean (95% CI) in the intention-to-treat population. LS means are from MMRM. ROF=roflumilast. PBO=placebo. FEV1=forced expiratory volume 
in 1s. FVC=forced vital capacity. 
  
 Change from Day 1–7 Change from Day 1–14 Change from Day 1–28 Change from Day 1–56 
ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO ROF PBO ROF vs PBO 
FEV1 (L) 0.051 (-0.010, 
0.112) 
0.010 (-0.048, 
0.067) 
0.041 (-0.043, 
0.125) 
p=0.3328 
0.083 (0.013, 
0.152) 
0.028 (-0.034, 
0.090) 
0.055 (-0.039, 
0.148) 
p=0.2463 
0.095 (0.022, 
0.168) 
0.001 (-0.062, 
0.063) 
0.094 (-0.002, 
0.191) 
p=0.0546 
0.064 (-0.013, 
0.141) 
0.010 (-0.055, 
0.075) 
0.053 (-0.047, 
0.154) 
p=0.2947 
FEV1 (% predicted) 2.108 (-0.135, 
4.351) 
-0.111 (-
2.205, 1.983) 
2.219 (-0.851, 
5.288) 
p=0.1541 
3.370 (0.978, 
5.761) 
0.759 (-1.404, 
2.922) 
2.610 (-0.614, 
5.835) 
p=0.1111 
3.203 (0.697, 
5.709) 
-0.314 (-
2.461, 1.833) 
3.517 (0.215, 
6.820) 
p=0.0372 
1.988 (-0.605, 
4.581) 
-0.294 (-
2.460, 1.872) 
2.282 (-1.100, 
5.664) 
p=0.1830 
FVC (L) 0.002 (-0.117, 
0.122) 
0.057 (-0.054, 
0.168) 
-0.055 (-
0.218, 0.109) 
p=0.5077 
0.039 (-0.084, 
0.162) 
0.166 (0.054, 
0.278) 
-0.127 (-
0.294, 0.040) 
p=0.1341 
0.039 (-0.104, 
0.181) 
0.075 (-0.048, 
0.198) 
-0.036 (-
0.225, 0.153) 
p=0.7037 
0.044 (-0.100, 
0.188) 
0.086 (-0.037, 
0.209) 
-0.042 (-
0.232, 0.148) 
p=0.6613 
FEV1/FVC (%) 1.575 (-0.283, 
3.433) 
-1.064 (-
2.796, 0.668) 
2.639 (0.097, 
5.181) 
p=0.0421 
1.874 (-0.142, 
3.889) 
-1.796 (-
3.615, 0.023) 
3.670 (0.953, 
6.386) 
p=0.0088 
2.350 (0.085, 
4.615) 
-1.029 (-
2.984, 0.927) 
3.379 (0.385, 
6.373) 
p=0.0275 
1.636 (-0.258, 
3.531) 
-1.669 (-
3.317, -0.022) 
3.306 (0.793, 
5.819) 
p=0.0106 
Table 7.4A. LS mean change in spirometry outcomes (initial approach) 
Table 7.4B. LS mean change in spirometry outcomes (extended approach) 
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Secondary Outcomes: Patient Reported Outcomes (CAT & EXACT scores) 
Reduction in CAT score from exacerbation onset to convalescence (Week 1 to Day 56) was 
greater in patients treated with Roflumilast compared to placebo and narrowly missed 
statistical significance (initial approach p=0.0504, extended approach p=0.0753, (Figures 
7.4A and 7.4B, and Tables 7.5A and 7.5B). However, by both the initial and extended 
approach, changes from Day 56 in weekly average EXACT-PRO scores did not differ 
statistically significantly between the roflumilast and the placebo groups at any time point 
(Figures 7.4A and 7.4B, and Tables 7.5A and 7.5B) and no difference was seen in AUC of 
changes from V0 to V3 or VFU in daily EXACT scores. 
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 (A) CAT score and (B) EXACT-PRO score. Data are LS means ± SE in the intention to treat population. 
LS means are from MMRM. CAT=Chronic Obstructive Pulmonary Disease Assessment Test. EXACT-
PRO=EXAcerbations of Chronic pulmonary disease Test-Patient-Reported Outcome. Blue 
line=roflumilast. Redline=placebo 
 
 
 
 
 
  
 (A) CAT score and (B) EXACT-PRO score. Data are LS means ± SE in the intention to treat population. 
LS means are from MMRM. CAT=Chronic Obstructive Pulmonary Disease Assessment Test. EXACT-
PRO=EXAcerbations of Chronic pulmonary disease Test-Patient-Reported Outcome. Blue 
line=roflumilast. Redline=placebo 
 
  
A B 
A B 
Figure 7.4A: Weekly change in patient reported outcomes (initial approach) 
Figure 7.4B: Weekly change in patient reported outcomes (extended approach) 
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Data are LS means (95% CI) in the intention to treat population. LS means are from MMRM. 
CAT=Chronic Obstructive Pulmonary Disease Assessment Test. EXACT-PRO=EXAcerbations of Chronic 
pulmonary disease Test-Patient-Reported Outcome. ROF=roflumilast. PBO=placebo. 
 
  
 
Weekly average CAT Weekly average EXACT-PRO 
Day 56 to week 1 
ROF 6.448 (3.411, 9.485) 6.182 (-0.429, 12.792) 
PBO 2.695 (0.481, 4.910) 4.753 (-0.067, 9.573) 
ROF vs PBO 3.752 (-0.007, 7.511) p=0.0504 1.429 (-6.753, 9.610) p=0.7260 
Day 56 to week 2 
ROF 3.778 (1.273, 6.283) 4.423 (-0.706, 9.552) 
PBO 0.804 (-1.037, 2.645) 1.558 (-2.208, 5.325) 
ROF vs PBO 2.974 (-0.135, 6.083) p=0.0603 2.865 (-3.499, 9.229) p=0.3683 
Day 56 to week 3 
ROF 2.002 (0.153, 3.851) 2.080 (-2.045, 6.205) 
PBO 0.278 (-1.075, 1.631) 0.317 (-2.702, 3.335) 
ROF vs PBO 1.724 (-0.568, 4.015) p=0.1363 1.763 (-3.350, 6.875) p=0.4899 
Day 56 to week 4 
ROF 0.559 (-0.935, 2.053) 0.002 (-4.046, 4.051) 
PBO 0.277 (-0.806, 1.360) 0.657 (-2.292, 3.606) 
ROF vs PBO 0.282 (-1.563, 2.127) p=0.7589 -0.655 (-5.664, 4.354) p=0.7930 
Day 56 to week 5 
ROF -0.412 (-1.652, 0.828) -1.058 (-4.590, 2.475) 
PBO -0.392 (-1.297, 0.512) -0.307 (-2.887, 2.272) 
ROF vs PBO -0.019 (-1.555, 1.516) p=0.9797 -0.750 (-5.125, 3.625) p=0.7307 
Day 56 to week 6 
ROF -0.924 (-1.754, -0.093) -1.688 (-3.740, 0.365) 
PBO -0.062 (-0.663, 0.539) -0.002 (-1.493, 1.489) 
ROF vs PBO -0.862 (-1.887, 0.164) p=0.0972 -1.686 (-4.224, 0.852) p=0.1871 
Day 56 to week 7 
ROF -0.228 (-0.920, 0.464) -0.773 (-2.183, 0.638) 
PBO 0.048 (-0.463, 0.559) 0.002 (-1.038, 1.041) 
ROF vs PBO -0.276 (-1.136, 0.585) p=0.5206 -0.774 (-2.529, 0.981) p=0.3779 
Day 56 to week 8 
ROF 0.002 (-0.118, 0.122) -0.190 (-0.713, 0.334) 
PBO -0.048 (-0.136, 0.041) -0.154 (-0.539, 0.232) 
ROF vs PBO 0.050 (-0.102, 0.201) p=0.5127 -0.036 (-0.694, 0.622) p=0.9121 
Table 7.5A: Change from stable state (Day 56) in weekly average CAT and EXACT-
PRO scores (initial approach) 
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Data are LS means (95% CI) in the intention to treat population. LS means are from MMRM. 
CAT=Chronic Obstructive Pulmonary Disease Assessment Test. EXACT-PRO=EXAcerbations of Chronic 
pulmonary disease Test-Patient-Reported Outcome. ROF=roflumilast. PBO=placebo. 
 
 
Weekly average CAT Weekly average EXACT-PRO 
Day 56 to week 1 
ROF 6.232 (3.364, 9.099) 7.163 (1.408, 12.919) 
PBO 3.009 (0.890, 5.128) 4.697 (0.517, 8.878) 
ROF vs PBO 3.223 (-0.343, 6.788) p=0.0753 2.466 (-4.648, 9.580) p=0.4888 
Day 56 to week 2 
ROF 3.558 (1.186, 5.930) 4.839 (0.292, 9.386) 
PBO 1.074 (-0.690, 2.837) 1.433 (-1.892, 4.757) 
ROF vs PBO 2.484 (-0.472, 5.440) p=0.0974 3.406 (-2.227, 9.040) p=0.2298 
Day 56 to week 3 
ROF 2.044 (0.338, 3.750) 2.988 (-0.776, 6.753) 
PBO 0.458 (-0.805, 1.722) 0.179 (-2.564, 2.922) 
ROF vs PBO 1.586 (-0.538, 3.709) p=0.1396 2.809 (-1.850, 7.468) p=0.2310 
Day 56 to week 4 
ROF 0.545 (-0.928, 2.019) 0.909 (-2.838, 4.655) 
PBO 0.429 (-0.646, 1.505) 0.743 (-1.962, 3.448) 
ROF vs PBO 0.116 (-1.708, 1.940) p=0.8986 0.165 (-4.456, 4.787) p=0.9429 
Day 56 to week 5 
ROF -0.347 (-1.599, 0.904) -0.657 (-3.786, 2.472) 
PBO -0.170 (-1.095, 0.755) -0.318 (-2.591, 1.954) 
ROF vs PBO -0.177 (-1.734, 1.379) p=0.8195 -0.338 (-4.207, 3.530) p=0.8610 
Day 56 to week 6 
ROF -0.668 (-1.478, 0.142) -0.889 (-2.855, 1.076) 
PBO -0.043 (-0.636, 0.551) -0.140 (-1.562, 1.282) 
ROF vs PBO -0.625 (-1.630, 0.379) p=0.2163 -0.749 (-3.177 1.679) p=0.5376 
Day 56 to week 7 
ROF -0.121 (-0.746, 0.504) -0.311 (-1.628, 1.005) 
PBO 0.014 (-0.453, 0.481) -0.075 (-1.039, 0.889) 
ROF vs PBO -0.135 (-0.915, 0.645) p=0.7294 -0.237 (-1.872, 1.399) p=0.7722 
Day 56 to week 8 
ROF -0.010 (-0.133, 0.112) -0.240 (-0.731, 0.251) 
PBO -0.031 (-0.122, 0.060) -0.115 (-0.474, 0.244) 
ROF vs PBO 0.021 (-0.134, 0.176) p=0.7895 -0.125 (-0.742, 0.492) p=0.6855 
Table 7.5B: Change from stable state (Day 56) in weekly average CAT and EXACT-
PRO scores (extended approach) 
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Secondary Outcomes: Exacerbation Length 
By the initial approach, Kaplan Meier estimates for exacerbation length in the intention to 
treat population, were 12.0 (95% CI 8.0, 18.0) days for roflumilast and 14.0 (95% CI 10.0, 
17.0) days for placebo. The between treatment difference did not reach statistical 
significance, with a log rank 2-sided p value of 0.4733. Median exacerbation length in the 
intention to treat population was 12 days for roflumilast and 10 days for placebo. By the 
extended approach, Kaplan Meier estimates for exacerbation length in the intention to treat 
population, were 13.0 (95% CI 9.0, 19.0) days for roflumilast and 14.0 (95% CI 11.0, 17.0) 
days for placebo. The between treatment difference did not reach statistical significance, with 
a log rank 2-sided p value of 0.4427. Median exacerbation length in the intention to treat 
population was 12 days for roflumilast and 11 days for placebo.  
 
Adverse Events 
By the initial approach, adverse events were reported by 37 (97.4%) of 38 patients who 
received roflumilast and by 30 (69.8%) of 43 patients who received placebo; serious adverse 
events were reported by 4 (10.5%) patients and 1 (2.3%) patient in the roflumilast and 
placebo groups, respectively (Table 7.6). The most frequently reported adverse events were 
diarrhoea, chronic obstructive pulmonary disease exacerbations, and insomnia (Table 7.7). 
Adverse events led to withdrawal from the study in 10 (26.3%) patients in the roflumilast 
group compared with 2 (4.7%) patients in the placebo group (Table 7.8). By the extended 
approach, adverse events were reported by 47 (97.9%) of 48 patients who received 
roflumilast and by 33 (70.2%) of 47 patients who received placebo; serious adverse events 
were reported by 4 (8.3%) patients and 1 (2.1%) patient in the roflumilast and placebo 
groups, respectively. The most frequently reported adverse events were diarrhoea, chronic 
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obstructive pulmonary disease exacerbations, and insomnia. Adverse events led to 
withdrawal from the study in 15 (31.3%) patients in the roflumilast group compared with 2 
(4.3%) patients in the placebo group. No deaths occurred over the entire course of the study. 
 
Table 7.6: Total Adverse Events 
 Initial Approach Extended Approach 
 Roflumilast 
(N=38) 
Placebo 
(N=43) 
Roflumilast 
(N=48) 
Placebo 
(N=47) 
All AEs 37 (97.4%) 30 (69.8%) 47 (97.9%) 33 (70.2%) 
Non-serious AEs 36 (94.7%) 30 (69.8%) 46 (95.8%) 33 (70.2%) 
Serious AEs 
 Deaths 
 Other SAEs 
4 (10.5%) 
0 
4 (10.5%) 
 
1 (2.3%) 
0 
1 (2.3%) 
4 (8.3%) 
0 
4 (8.3%) 
1 (2.1%) 
0 
1 (2.1%) 
AEs with suggested relationship 
to IMP 
33 (86.8%) 16 (37.2%) 42 (87.5%) 17 (36.2%) 
AEs with suggested relationship 
to trial procedures 
0 1 (2.3%) 0 1 (2.1%) 
AEs leading to withdrawal 10 (26.3%) 2 (4.7%) 15 (31.3%) 2 (4.3%) 
AEs not recovered at trial 
termination 
0 0 0 0 
AEs with changes in trial 
treatment or concomitant 
medication 
32 (84.2%) 18 (41.9%) 40 (83.3%) 20 (42.6%) 
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Table 7.7: Frequent Adverse Events (≥5% of patients) 
 Initial Approach Extended Approach 
 Roflumilast 
(N=38) 
Placebo 
(N=43) 
Roflumilast 
(N=48) 
Placebo 
(N=47) 
Diarrhoea 25 (65.8%) 10 (23.3%) 32 (66.7%) 11 (23.4%) 
COPD 17 (44.7%) 14 (32.6%) 19 (39.6%) 16 (34.0%) 
Insomnia 12 (31.6%) 2 (4.7%) 14 (29.2%) 2 (4.3%) 
Nausea 6 (15.8%) 3 (7.0%) 9 (18.8%) 3 (6.4%) 
Dizziness 6 (15.8%) 1 (2.3%) 6 (12.5%) 1 (2.1%) 
Decreased appetite 4 (10.5%) 2 (4.7%) 6 (12.5%) 2 (4.3%) 
Headache 3 (7.9%) 2 (4.7%) 4 (8.3%) 2 (4.3%) 
Abdominal pain 2 (5.3%) 1 (2.3%)   
Constipation 2 (5.3%) 1 (2.3%)   
Gastrooesophageal reflux 2 (5.3%) 1 (2.3%) 3 (6.3%) 1 (2.1%) 
Cellulitis 2 (5.3%) 0   
Flatulence 2 (5.3%) 0   
Muscle spasms 2 (5.3%) 0   
Oral candidiasis 2 (5.3%) 0   
Pneumonia 2 (5.3%) 0   
Vomiting   3 (6.3%) 1 (2.1%) 
 
 
Table 7.8: Trial Discontinuation Rates 
 Initial Approach Extended Approach 
 Roflumilast 
(N=38) 
Placebo 
(N=43) 
Roflumilast 
(N=48) 
Placebo 
(N=47) 
Total number of early 
discontinued patients 
11 (28.9%) 3 (7.0%) 16 (33.3%) 3 (6.4%) 
Death 0 0 0 0 
Adverse event 10 (26.3%) 2 (4.7%) 15 (31.3%) 2 (4.3%) 
Withdrawal by patient 1 (2.6%) 1 (2.3%) 1 (2.1%) 1 (2.1%) 
     
Total number of trial completers 27 (71.1%) 40 (93.0%) 32 (66.7%) 44 (93.6%) 
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Weight Loss 
By the initial approach, patients in the roflumilast group lost 1.96kg (SD 1.631) in body 
weight during the course of double-blind treatment; in the placebo group, patients gained 
0.11kg (SD 0.886) over the same timeframe. By the end of follow up, body weight partially 
recovered to enrolment values in patients assigned to roflumilast (-1.29kg [SD 1.277]). By 
the extended approach, patients in the roflumilast group lost 1.89kg (SD 1.704) in body 
weight during the course of double-blind treatment; in the placebo group, patients gained 
0.14kg (SD 0.865) over the same timeframe. By the end of follow up, body weight partially 
recovered to enrolment values in patients assigned to roflumilast (-1.21kg [SD 1.275]).  
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7.5 Discussion 
This is the first randomised placebo-controlled trial to evaluate the use of the PDE4 inhibitor, 
Roflumilast during COPD exacerbations. Roflumilast did not accelerate reduction of sputum 
neutrophils from exacerbation onset to 2 weeks post exacerbation when given on top of 
standard therapy, but did lead to significantly enhanced recovery of other airway 
inflammatory markers. Patients treated with Roflumilast also experienced significantly 
improved lung function compared to patients receiving steroids and antibiotics alone. 
However, Roflumilast use was associated with higher rates of adverse events, and further 
study is required to determine the optimal timing and duration of Roflumilast therapy at 
exacerbation.      
 
As shown in Chapter 6, inflammation rises acutely at exacerbation onset and falls during 
subsequent recovery. Persistently elevated inflammation during exacerbations is associated 
with clinical non-recovery and recurrence (56). Roflumilast reduces neutrophilic airway 
inflammation in the stable state (92) and reduces endotoxin-induced influx of neutrophils, 
eosinophils, and total cells into the bronchoalveolar compartment in healthy volunteers (96). 
Thus, this study examined whether Roflumilast would enhance inflammation reduction at 
acute exacerbations of COPD. 
 
No significant difference was detected in the primary outcome: change of sputum neutrophils 
from exacerbation onset to 2 weeks thereafter between the groups treated with Roflumilast or 
placebo. However at 4 weeks, patients treated with Roflumilast experienced a statistically 
significant greater reduction in percentage sputum neutrophils and a larger reduction in 
absolute numbers of sputum neutrophils (although the enhanced reduction in absolute 
neutrophil count was not statistically significant). Furthermore, Roflumilast use led to 
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significant improvements in sputum myeloperoxidase after 4 weeks of treatment, and 
numerical superiority in sputum IL-8, sputum IL-6, and sputum neutrophil elastase levels at 
this time-point.  
 
Exacerbations are typically triggered by infective pathogens and it is likely that a significant 
proportion of the rise in neutrophilic inflammation seen at exacerbation onset is a direct 
consequence of increased bacterial and/or viral load (40, 47, 49). Antibiotics improve 
exacerbation recovery (63), potentially by reducing bacterial load and the resultant 
neutrophilic inflammation.  Therefore, it appears that during the early phase of acute 
exacerbations, the ability of Roflumilast to reduce airway inflammation is superseded by the 
efficacy of standard antibiotic treatment and the main benefits from Roflumilast in reducing 
airway inflammation are seen between 2 and 4 weeks post exacerbation onset.  
 
Importantly, Roflumilast use led to significant clinical benefits in exacerbation recovery, in 
particular in lung function. Patients treated with Roflumilast in the initial approach had over 
40ml improvement at 1 week, over 50ml improvement at 2 weeks, and almost 100ml 
additional improvement in FEV1 at 4 weeks compared to patients treated with antibiotics and 
steroids alone which was statistically significant in the extended approach. The benefits of 
Roflumilast also persisted 4 weeks after treatment discontinued, although were not 
statistically significant. Previous trials at acute exacerbation have shown that patients 
receiving systemic corticosteroid therapy experience approximately 50-100ml improvement 
in FEV1 compared to placebo (68, 69). Although there is no clear established minimal 
clinically important difference (MCID) in FEV1 at acute exacerbation, an improvement of 
100ml compared to placebo has been proposed as the MCID for pharmacological trials 
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conducted in the stable state (148), so an additional improvement of the magnitude observed 
in this study on top of 10 days of oral prednisolone is highly beneficial.  
 
Patients treated with Roflumilast also displayed greater reduction in CAT scores from the 
start of the exacerbation to follow-up 8 weeks later, although these benefits narrowly missed 
statistical significance. However, these findings were not replicated in the EXACT analyses, 
and the PRO results may have been compromised by relatively low numbers of patients 
completing these tools throughout recovery so should be interpreted cautiously. 
 
Patients treated with Roflumilast did not have significantly shorter exacerbation length than 
those patients who received antibiotics and corticosteroids alone, perhaps since this study was 
not powered to detect a change in exacerbation duration. Long-term erythromycin use has 
been shown to reduce exacerbation duration (149), however few acute exacerbation studies 
have previously examined exacerbation length as an endpoint, instead focusing on treatment 
failure or clinical cure rate as an outcome measure. Antibiotics have been shown to increase 
clinical cure rate and prolong time to next exacerbation in mild to moderate exacerbations 
(63), in addition to reducing mortality and length of inpatient stay in severe exacerbations 
(65). Oral corticosteroids have also been shown to reduce rates of treatment failure and length 
of inpatient stay by 1-2 days (68, 69) compared to placebo. Observational data has shown that 
patients who were initiated on Roflumilast during hospitalised exacerbations of COPD had 
short lengths of inpatient stay (150). In this study exacerbation length was reduced by 1-2 
days when assessed using Kaplan Meier estimates in patients treated with Roflumilast but 
importantly this was in addition to the beneficial effects of oral corticosteroids and 
antibiotics, so the ability of Roflumilast to reduce exacerbation length when used at acute 
exacerbation should be explored in future, larger studies. 
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A recent trial of the tumour necrosis factor α (TNFα) antagonist Etanercept failed to show 
any benefit at acute exacerbations of COPD compared to prednisolone, although subgroup 
analyses suggested that patients without peripheral blood eosinophilia did equally well with 
etanercept or steroids (83). This study is the first trial of a novel acute exacerbation agent to 
show additional benefits on top of standard therapy with antibiotics and corticosteroids. 
However, adverse events (in particular diarrhoea, insomnia and weight loss) and withdrawal 
rates were higher in the Roflumilast arm of the study.  
 
These adverse events are well recognised in long-term studies using Roflumilast as 
maintenance therapy to prevent COPD exacerbations, although side effects and withdrawal 
rates in this study exceeded those seen in previous industry sponsored trials (94, 95), where 
10-15% of patients withdrew due to adverse events, as opposed to approximately 30% in this 
trial. Diarrhoea and insomnia are common side effects of antibiotics and corticosteroids 
respectively, as well as Roflumilast alone. The high adverse event rates observed in this study 
suggest that these side effects are potentiated when Roflumilast is given concurrently with 
antibiotics and corticosteroids during acute exacerbations. Despite this, withdrawal rates in 
this study remain lower than reported in some recent “real-world” reports (151, 152) where 
over half of patients discontinued therapy due to adverse events.  
 
Therefore further trials are now urgently required to confirm and accurately define the 
optimum use of Roflumilast as an acute exacerbation treatment. The nadir of gastrointestinal 
side effects in trials of Roflumilast as maintenance therapy occurs early after initiation of 
treatment and then adverse events stabilise over time (93, 94). Studies are already underway 
attempting to improve adherence to Roflumilast (NCT02018432, NCT02165826), by 
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reducing the initial dosage from 500μg to 250μg per day, or administering full dose treatment 
on alternate days (NCT01849341) although this may reduce efficacy in the acute setting. 
Standard exacerbation therapy with oral corticosteroids is associated with serious adverse 
health effects when patients who take frequent courses of therapy (77), therefore future 
studies might also seek to establish whether Roflumilast can effectively replace oral 
corticosteroids at exacerbation. Since corticosteroids appear to be most beneficial in 
eosinophilic exacerbations (55), future studies may also examine whether exacerbation 
therapy should vary according to patient phenotype, with corticosteroids being reserved for 
eosinophilic events and Roflumilast used in non-eosinophilic exacerbations. In this way, 
Roflumilast may be used as part of a personalised exacerbation treatment strategy. 
 
This study was designed as a proof-of-mechanism trial and meant to support a potential 
second larger study to investigate the ability of Roflumilast to improve acute exacerbation 
recovery and reduce recurrence rates. As such, our sample size was not large, and in fact our 
study did not reach the original power calculation because recruitment was curtailed early by 
the scientific oversight committee. This early stoppage was due to the sputum cell counts 
exceeding those used in the power calculation and were consistent with previously seen 
levels of severe COPD exacerbations (97). The high neutrophil counts may result from the 
inclusion criteria of this study which enrolled only bronchitic exacerbations which are known 
to have higher airway inflammation than non-bronchitic exacerbations (50). Thus the 
oversight committee decided that fewer events would be required to show a significant 
difference in the primary outcome. This could potentially have impacted the ability of the 
study to meet the primary endpoint.  
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However, analysis of sputum data from the ECLIPSE study suggested that to detect a 
difference of 10 percentage points in mean sputum neutrophil % between two groups with 
80% power would require 34 subjects per treatment arm based on a two-sample t-test and 
alpha level 0.05, which was exceeded by recruitment of this study (153). Furthermore, no 
improvement was seen in reduction of airway inflammation between the 2 treatment groups 
at 14 days on any of the airway inflammatory markers measured in this study. This suggests a 
type 2 error is unlikely and as discussed previously, in this first very early phase of acute 
exacerbations, the ability of Roflumilast to reduce airway inflammation appears to be 
superseded by the efficacy of standard therapy treatment. Nevertheless, a priority is now a 
larger clinical trial to confirm the important clinical benefits that have been indicated in this 
work and to greater phenotype which patients and exacerbations might benefit from the 
addition of Roflumilast. Future studies should also include patients undergoing severe 
exacerbations that require hospitalisation to determine whether Roflumilast reduces length of 
inpatient stay and readmission rates. 
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7.6 Conclusion 
In conclusion, Roflumilast is a promising novel addition to current exacerbation therapy. 
Although the primary outcome of this trial was negative, patients treated with Roflumilast on 
top of standard therapy had improved lung function and reduced airway inflammation 
compared to patients treated with corticosteroids alone. However, patients treated with 
Roflumilast also experienced more adverse events. Further studies are required to confirm 
and accurately define the use of Roflumilast as an acute exacerbation treatment. In particular, 
Roflumilast may be useful as part of a personalised strategy that treats patients according to 
exacerbation phenotype. 
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8 
CONCLUSIONS AND 
SUGGESTIONS FOR FUTURE 
STUDIES 
 
This chapter summarises the main findings of this thesis, with reference to the stated 
Hypothesis and Aims of Chapter 2, and concludes with suggestions for future studies based 
on the present results. 
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8.1 Conclusions 
The key findings of this thesis may be summarised thus: 
 Baseline CAT scores are significantly elevated in stable COPD patients with a history 
of frequent exacerbations. 
 At exacerbation, CAT scores were significantly elevated from paired baseline values. 
 CAT scores reflect exacerbation severity as measured by exacerbation length, 
increased systemic inflammation and reduction in lung function.  
 EXACT is as an effective tool to assess exacerbation severity. EXACT scores 
increase at COPD exacerbation, the magnitude of which reflects the severity of the 
event in terms of treatment, systemic inflammation, airflow limitation and symptom 
recovery time.  
 However, the EXACT is not a reliable tool to detect exacerbations. Approximately 
50% of both diary card-defined and HCU exacerbations crossed the EXACT event 
threshold but only approximately one third fulfilled the criteria for an EXACT event. 
Baseline disease severity appears to play an important role in symptom reporting and 
physician prescribing thresholds at exacerbation. 
 In the stable state, increasing cough frequency was associated with worsening health 
related quality of life.  
 Cough frequency increases acutely from baseline levels at exacerbation and falls 
during subsequent recovery. However, the rise in cough frequency at exacerbation 
onset did not predict exacerbation severity, and cough frequency at exacerbation onset 
did not predict recovery time or the likelihood of recurrence. 
 Increased systemic inflammation, as measured by absolute levels and change in IL-6, 
at exacerbation onset predicts clinical non-recovery at 35 days.  
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 Airway inflammation also increased at exacerbation, although no sputum biomarker 
showed significant ability to predict exacerbation non-recovery.  
 Slower resolution of systemic markers of neutrophilic inflammation was associated 
with longer clinical recovery.  
 Exacerbations with an eosinophilic profile at exacerbation onset appeared more likely 
to be followed by a recurrent event than non-eosinophilic exacerbations.  
 Roflumilast did not accelerate reduction of sputum neutrophils from exacerbation 
onset to 2 weeks post exacerbation when given on top of standard therapy. Although 
Roflumilast use led to enhanced reduction of other airway inflammatory markers and 
improved lung function recovery. 
 Roflumilast use was associated with high rates of adverse events and study 
withdrawal. 
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Therefore, with regard to the specific Aims of the thesis, described in Chapter 2: 
1. Can patient reported outcomes, specifically the CAT and EXACT questionnaires, be 
used to monitor COPD exacerbation severity and recovery?  
Yes, both the CAT and EXACT questionnaires are effective instruments to monitor 
COPD exacerbation severity and recovery. Due to its simplicity, ease of use and 
availability the CAT is more suitable for clinical practice, where as the more detailed 
EXACT may be more suitable for pharmaceutical studies of novel acute exacerbation 
therapies.  
 
2. What is the relationship between exacerbations diagnosed using validated London 
COPD cohort diary cards and physician review, and symptom-defined events 
captured by the EXACT patient reported outcome?  
There was only a modest relationship found between exacerbations identified using 
the London Cohort diary card, physician review and the EXACT. Approximately 50% 
of both diary card-defined and HCU exacerbations crossed the EXACT event 
threshold but only approximately one third fulfilled the criteria for an EXACT event. 
At exacerbation, patients exhibited smaller rises in EXACT score as baseline disease 
severity increased, suggesting that patients with more severe stable disease are more 
likely to report and receive additional systemic therapy at exacerbations associated 
with smaller increases in symptom intensity than patients with milder baseline 
disease. This result confirms that people seek care and are treated for exacerbations 
for a variety of reasons, including varied tolerance to symptomatic change, and means 
that the EXACT cannot reliably be used to detect HCU exacerbations. 
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3. Is objective cough monitoring an accurate means of determining the severity of an 
exacerbation and can this method identify patients at risk of prolonged recovery 
and recurrence?  
No, the rise in cough frequency at exacerbation onset did not predict exacerbation 
severity, and cough frequency at exacerbation onset was not capable of predicting 
recovery time or the likelihood of recurrence. 
 
4. Can airway and systemic inflammatory biomarkers measured at onset or during the 
recovery phase of a COPD exacerbation predict prolonged recovery and 
recurrence? 
Increased systemic inflammation, as measured by absolute levels and change in IL-6, 
at exacerbation onset predicts clinical non-recovery at 35 days. Exacerbations with an 
eosinophilic (blood) profile at exacerbation onset appeared more likely to be followed 
by a recurrent event than non-eosinophilic exacerbations. No airway inflammatory 
biomarker showed the ability to predict exacerbation non-recovery.  
 
5. Does Roflumilast reduce neutrophilic inflammation during exacerbations of COPD 
when added to the usual care of these patients? 
Roflumilast did not accelerate reduction of sputum neutrophils from exacerbation 
onset to 2 weeks post exacerbation when given on top of standard therapy, although it 
did enhance reduction of other inflammatory markers. 
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6. Can Roflumilast reduce exacerbation severity and improve clinical recovery 
following COPD exacerbations? 
Yes. Roflumilast led to statistically and clinically meaningful improvements in lung 
function on top of standard exacerbation therapy. However, patients treated with 
Roflumilast experienced significant adverse events that raise concerns regarding the 
use of this therapy in the acute setting.  
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8.2 Suggestions for Future Work 
8.2.1 Patient Reported Outcomes 
A number of other groups have replicated the findings published in the CAT paper in both 
other outpatient groups and hospitalised patients and confirmed that this instrument can be a 
useful tool to evaluate exacerbation severity and recovery (154, 155). Furthermore, results of 
a study of hospitalised patients suggested that patients with higher CAT score increases 
during the initial days of hospitalisation and with higher area under the curve (AUC) CAT 
scores for the first 5 days of exacerbation may be more likely to require hospitalisation for a 
recurrent exacerbation (155). However, the total number of patients in this study was small at 
45 with only 6 patients undergoing recurrent exacerbations within 6 months of their initial 
hospitalisation for an exacerbation. 
 
Future studies should focus on using the CAT in clinical capacities in both the outpatient and 
inpatient settings. Outpatient studies which use CAT directed treatment algorithms may be 
useful to stratify patients whose persistently elevated scores indicate the need for close 
follow-up and perhaps increased treatment post-exacerbation to prevent deterioration or 
prolonged abnormal recovery. Inpatient studies have shown that exacerbation CAT scores 
relate to length of stay (156) and so future work should examine using the CAT to direct 
discharge planning with falling CAT scores indicative of patients suitable for discharge. 
 
Since the EXACT paper was published in the European Respiratory Journal, the results of the 
ATTAIN study have been released (157). This study examined the ability of aclidinium to 
reduce exacerbation frequency and included EXACT events as an outcome measure. In 
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agreement with the work in this thesis, the authors reported low concordance between HCU 
exacerbations and EXACT events. Future studies should also utilise the EXACT in clinical 
trials involving novel acute intervention therapies. The data in Chapter 4 supports the use of 
the EXACT as an effective tool to measure exacerbation severity and assess recovery, and 
could provide valuable alternative outcome measures for such studies. Historically many 
trials of acute exacerbation treatment have used clinical (or treatment) failure, defined as 
exacerbation symptoms that have not improved or have worsened such that additional or 
alternate systemic antimicrobial and/or systemic corticosteroid therapy is required, as a key 
outcome to determine efficacy of acute exacerbation therapies (158). However, this outcome 
is limited by difficulties discriminating between relapsed exacerbations, where the index 
event has failed to resolve, and recurrent exacerbations which are separate events that occur 
shortly after resolution of the initial insult (15). Furthermore, the decision to retreat a patient 
is subjective and affected by a patient‟s baseline functioning. As shown in this chapter, it 
appears that patients with more severe stable disease are more likely to report and receive 
additional systemic therapy at exacerbations associated with smaller increases in symptom 
intensity than patients with milder baseline disease. It is likely that more severe patients are 
more sensitive to change in symptoms and therefore more likely to report earlier and 
clinicians will naturally be cautious and have a lower threshold to administer repeated 
treatment courses in such individuals. 
  
EXACT scores are less affected by such biases and can provide an objective measurement of 
symptomatic change at exacerbation. EXACT scores also accurately track both symptomatic 
and lung function recovery and thus may discriminate between persistent exacerbation 
symptoms which may require additional treatment and separate recurrent events. 
Furthermore, since the EXACT provides a numerical score on a scale from 0-100 it has the 
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potential to discriminate subtle relative efficacies of new therapies in absolute numerical 
values, by comparing the EXACT scores of patients taking a novel treatment versus those on 
placebo one week after administration of treatment, as well as in proportionate means. For 
example, the relative proportion of patients whose EXACT scores have returned to baseline 
(or fallen by a predetermined magnitude) by 7 days (the median recovery time in a study 
evaluating recovery in over 500 exacerbations (13)) could be a valuable novel outcome 
measure for acute intervention studies. The potential benefit of Roflumilast to reduce the 
length and severity of exacerbations has been assessed using the CAT and EXACT PROs in 
Chapter 7.  
 
8.2.2 Cough Monitoring  
The work presented in Chapter 5 reinforced the importance of cough in COPD patients, and 
reaffirmed that further specific treatments are also needed to target COPD patients with 
increased cough frequency to improve health related quality of life. It also confirmed that 
objective cough monitoring can be successfully used in both the acute setting and at baseline, 
and thus may be a useful tool in trials of new therapies to reduce cough frequency in COPD 
patients both in the stable state and at exacerbation, to measure the efficacy of such novel 
interventions. 
 
Recent trial data has shown that the oral P2X3 antagonist, AF-219, significantly reduces 
cough frequency in patients with refractory chronic cough (159). Future studies could 
consider the use of such agents to reduce cough frequency in COPD patients troubled by 
persistent cough. An important aspect of future studies will be patient selection. The work 
presented in Chapter 5 suggests that those patients who experienced the largest rise in cough 
frequency at exacerbation had lower baseline cough frequency, and patients with higher 
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baseline cough frequency did not always experience a significant rise in cough frequency at 
exacerbation (Figure 5.4, Figure 5.5). This has important implications for the selection of 
patients to be considered for anti-tussive therapies; patients with high baseline cough 
frequency may benefit most from long-term therapy to reduce cough frequency but may not 
gain from such treatments at exacerbation, which might be preferentially offered to patients 
with low baseline cough frequency. 
 
8.2.3 Biomarker Measurement and Personalised Exacerbation Treatment 
Chapter 6 demonstrated that elevated serum IL-6 at exacerbation onset predicts clinical non-
recovery at 35 days. This finding has potentially important clinical implications and should 
be prospectively repeated in a large separate study. If confirmed in this manner then future 
follow-up of clinical patients could be stratified according to this biomarker level, with those 
patients with higher IL-6 levels at exacerbation receiving a routine follow-up during recovery 
(potentially at day 14) so that they could be clinically reviewed and considered for additional 
treatment to accelerate recovery.  
 
Chapter 6 also found that patients with persistently elevated total white blood cell counts and 
neutrophil levels (in addition to those with elevated IL-6) during recovery were more likely to 
have failed to symptomatically recover at 35 days post exacerbation onset. These levels can 
be easily measured in clinical practice. Studies are currently underway to determine if 
retreatment at day 14 with antibiotics enhances exacerbation recovery (NCT02300220), and 
future work should consider targeting patients with elevated levels of these clinically 
available biomarkers for additional treatment. 
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Conventional exacerbation treatment also includes systemic corticosteroids. Corticosteroids 
are particularly effective in combating eosinophilic inflammation. Chapter 6 for the first time 
showed that blood eosinophils were higher at exacerbation onset in index exacerbations 
which were followed by recurrent events, than in isolated exacerbations. This result was 
shown in relatively small numbers and also needs confirmation in future prospective large 
scale studies, but if confirmed could be used to guide therapy. Patients with eosinophilic 
inflammation at exacerbation could be considered for prolonged courses of oral 
corticosteroids in an attempt to reduce the likelihood of recurrence. 
 
The TREAT study showed that Roflumilast could have clinical benefits when added to 
conventional therapy at exacerbation, particularly in enhancing lung function recovery. 
However, use of this drug was also associated with significant adverse effects and high 
withdrawal rates. Future studies could attempt to identify those patients who might receive 
the maximum benefit from this drug so that it can be used as part of a personalised 
exacerbation treatment strategy. Future studies might also attempt to mitigate the adverse 
effects seen with Rofumilast use. Further analysis of large trials of Roflumilast as 
maintenance therapy could attempt to identify patient characteristics associated with 
experience of side effects. Future studies could also attempt to identify biomarkers that might 
reveal patients at increased risk of adverse events. Studies are already underway attempting to 
improve adherence to Roflumilast (NCT02018432, NCT02165826), by reducing the initial 
dosage from 500μg to 250μg per day, or administering full dose treatment on alternate days 
(NCT01849341) although this may reduce efficacy in the acute setting. Additional 
approaches could also include the addition of anti-emetics and/or anti-diarrhoeal treatment to 
be taken concurrently with short term exacerbation Roflumilast therapy to improve tolerance.  
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If it were possible to identify prospectively which patients are more susceptible to the adverse 
effects that would enable further targeting of patient selection and so enhance personalisation 
of acute exacerbation therapy with Roflumilast. 
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9 
APPENDICES 
 
APPENDIX 1: Pre-existing Recovery Biomarker data. 
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9.1 Appendix 1 
The following biomarkers were selected for analysis in Chapter 6 based upon their 
biological/mechanistic plausibility to inform on exacerbation recovery and recurrence:  
 
 Exacerbation Aetiology: Viral markers (IP-10, IFN-γ); Bacterial (IL-1β); Eosinophilic 
(Blood eosinophils-absolute/%, IL-5) 
 Neutrophilic Markers: IL-8, MPO, TNFα, Blood Neutrophils 
 Response to clinical status/therapy: IL-6, SAA, PARC, CRP, Fibrinogen, Total white 
cell count 
 Oxidative Stress: sRAGE, CC-16 
 Pathogenesis/Activity: PLGF, MMP-1, MMP-8, MMP-9, TIMP-1, α2-macroglobulin, 
IL-18 
 
Past studies examining these biomarkers are summarised in Table 9.1. 
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BIOMARKER MEDIUM EVIDENCE 
α2-macroglobulin Serum + 
Sputum 
 α2-macroglobulin forms part of the acute phase response in the coagulation cascade with anti-
inflammatory activity through inhibition of oxidative stress. It plays a key role in humoral defence 
and levels are increased in the sputum in COPD patients.  
 Serum levels have also been shown to distinguish between asthma and COPD (160). 
Clara cell secretory 
protein (CC16) 
Serum  CC-16 is secreted by the non-ciliated Clara cells 8 which are found predominantly in the respiratory 
bronchioles, and by non-ciliated columnar cells of the large and small airways.  
 Serum levels of CC-16 largely reflect protein produced by the lower respiratory tract.  
 CC-16 acts as an immunosuppressant and provides protection against oxidative stress and 
carcinogenesis.  
 Serum levels rise following acute exposure to smoke, chlorine and lipopolysaccharide and can be 
suppressed by inhaled salmeterol/fluticasone (161).  
 Serum CC-16 levels are reduced in individuals with COPD and there is a weak correlation with 
disease severity in former smokers (162). 
 When stratifying COPD patients into GOLD groups and by current smoking, lower serum CC-16 
levels are seen in current smoking COPD patients relative to former smokers in GOLD2 and 
GOLD3 but not in GOLD4.  
 In former-smoking COPD patients, a significant inverse correlation is observed between CC-16 and 
COPD severity.  
 CC-16 can distinguish between patients with or without reversibility in former smoking COPD 
patients (162). 
 Reduced levels of CC-16 are associated with accelerated decline in FEV1 (163) 
 
 
Table 9.1. Past studies examining biomarkers measured in Chapter 6. 
235 
 
C-reactive protein 
(CRP) 
Serum  CRP is an acute phase protein, mainly induced by interleukin 6 (IL-6) and is a component of the 
innate immune response 
 Individuals with a CRP level >3 mg/L compared with those with a value of ≤3 mg/L in the stable 
state have increased risk of COPD hospitalization and COPD death (164). 
 CRP increases at exacerbation (111, 132) and higher CRP levels at exacerbation are associated with 
bacterial aetiology (40). 
 Patients who do not symptomatically recovery within 5 weeks of exacerbation onset have 
persistently higher levels of serum CRP during the recovery period than those who recover (56). 
 Patients who did not recover fully from the symptoms of an exacerbation had a failure to normalize 
CRP at 1 and 2 weeks post-exacerbation and even had a CRP rise from baseline if they hadn‟t 
clinically recovered (56).  
 A high CRP at day 14 following an index exacerbation predicts exacerbation recurrence (56) and an 
elevated CRP at discharge from hospitalised exacerbations predicts readmission (165). 
Fibrinogen Plasma  Fibrinogen is primarily synthesized in the liver, is involved in clotting formation and systemic levels 
are elevated in an IL-6-stimulated acute phase response.  
 Plasma fibrinogen is elevated in patients with stable COPD (112).  
 Bacterial colonisation of the sputum of COPD patients is associated with higher fibrinogen levels 
(166) and chronic respiratory syncytial virus (RSV) infection is also associated with increased 
plasma fibrinogen in the stable state (42).  
 Stable-state plasma fibrinogen levels also increase more quickly over time in frequent exacerbators 
compared with infrequent exacerbators and elevated plasma fibrinogen is also associated with a 
faster decline in lung function (167).  
 High fibrinogen is associated with an increased risk of hospitalised COPD exacerbations and an 
increased risk of death (168). 
 Plasma fibrinogen levels increase at exacerbation (112) and reduce significantly during recovery 
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(59, 169).  
 The rise in fibrinogen seen at exacerbation responds to corticosteroids, since treatment of 
exacerbations with intravenous steroid treatment leads to significantly larger reductions in 
fibrinogen than in patients treated with non-steroid drugs alone (170).  
 Elevated fibrinogen levels seen at exacerbation may relate to infective aetiology, since exacerbations 
characterised by purulent sputum, increased cough and colds have greater rises in fibrinogen (112). 
 Viral exacerbations in particular are associated with higher plasma fibrinogen concentrations than 
non-viral exacerbations (42).  
Full blood count 
(total white cell 
count, neutrophils, 
eosinophils) 
Blood  Total white cell count and neutrophils are increased at exacerbation compared to stable COPD 
patients (97, 171), although eosinophils are not always elevated (52).  
 The presence of high total white cell count (172) and blood neutrophilia is associated with increased 
risk of hospitalization following attendance at the emergency department with COPD exacerbation 
(172, 173).  
 Eosinopaenia may be associated with increased mortality and length of stay during hospitalized 
exacerbations (174). 
 Eosinophils are potentially useful to guide corticosteroid therapy at exacerbation (55). 
Interferon-γ 
(IFN-γ) 
Sputum  IFN-γ is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and 
protozoal infections. IFN-γ is an important activator of macrophages and inducer of Class I major 
histocompatibility complex (MHC) molecule expression. In particular IFN- γ directly inhibits viral 
replication.  
 IFN-γ is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of 
the innate immune response, and by Th1 CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T 
cells once antigen-specific immunity develops (175).  
 IFN-γ levels are elevated in patients with COPD exacerbation of viral aetiology (176).  
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Interferon-γ-
inducible protein 10 
(IP-10) 
Serum  IP-10 is a chemokine secreted by bronchial epithelial cells, monocytes, lymphocytes, and 
neutrophils in response to interferon-γ and TNF-α (177, 178) 
 IP-10 is elevated by Human Rhinovirus (HRV) infection (179) 
 HRV infects and replicates in bronchial epithelial cells. This active replication of HRV triggers 
production of IP-10 (179) 
 Serum IP-10  is higher in patients with COPD than controls 
 HRV-16 induces expression of IP-10 and levels of IP-10 correlate with symptom severity, viral titre, 
and numbers of lymphocytes in airway secretions of healthy volunteers (179). 
 In COPD patients, serum IP-10 levels increase significantly from baseline to exacerbation in human 
rhinovirus (HRV)-positive exacerbations (180), although no change in IP-10 was observed between 
baseline and exacerbation in HRV-negative exacerbations.  
 At exacerbation, IP-10 correlates with sputum viral load and In receiver operating characteristics 
analysis, the combination of IP-10 and coryzal symptoms gave an area under the curve of 0.82 for 
predicting the presence of HRV at exacerbation (180). 
Interleukin-1β  
(IL-1β) 
Sputum  Interleukin-1 (IL-1) is a superfamily of cytokines. IL-1β is produced by activated macrophages as a 
proprotein, which is proteolytically processed to its active form by caspase 1. This cytokine is an 
important mediator of the inflammatory response.  
 IL-1β induces the transcription of pro-inflammatory cytokines, and is involved in a variety of 
cellular activities, including cell proliferation, differentiation, and apoptosis (181).  
 In a murine cigarette-smoking model, IL-1β mRNA has been shown to dramatically increase in lung 
tissue after lipopolysaccharide challenge (182). 
 In COPD patients, in the stable state, airway IL-1β relates to exacerbation frequency, is higher in 
frequent exacerbators (183) and is elevated in patients with bacterial colonisation (184).  
 At exacerbation, airway IL-1β predicts bacterial aetiology (52) and levels relate to bacterial load 
(185). 
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Interleukin-5  
(IL-5) 
Sputum  Interleukin-5 is a Th2 cytokine involved in the differentiation, maturation, migration, development, 
survival, trafficking and effector function of blood and local tissue eosinophils (186) and release of 
IL-5 from CD4+ cells is increased in stable COPD (187). 
 28% of exacerbations are associated with sputum eosinophilia (52) and IL-5 correlates with sputum 
eosinophil counts (188).  
 IL-5 levels increase during exacerbations of COPD associated with sputum/peripheral blood 
eosinophilia (52, 189) and are attenuated following treatment with prednisolone (188). Sputum IL-5 
levels have also been shown to predict exacerbations after cessation of inhaled corticosteroids in 
COPD (190).Benralizumab, anti-interleukin-5 receptor α monoclonal antibody, has been proposed 
as an agent to reduce exacerbation frequency in COPD patients with an eosinophilic phenotype 
(191), although evidence of benefit is still lacking.  
Interleukin-6  
(IL-6) 
Serum + 
Sputum 
 IL-6 is produced by mononuclear cells, lymphocytes, fibroblasts and airway epithelium.  IL-6 is 
associated with induction of the serum acute-phase response and augmentation of antibody 
production.   
 IL-6 is the primary cytokine regulator of both CRP and fibrinogen.  
 Frequent exacerbators (>3/year) have higher stable sputum IL-6 levels (38). 
 When stable, patients with high IL-6 have faster lung function decline and frequent exacerbators (> 
2.52/yr) have a faster rise over time in sputum IL-6 compared to patients with infrequent 
exacerbations (< 2.52/yr) (167). 
 Serum, plasma and sputum IL-6 levels increase from stable values at exacerbation (37, 38, 56, 111) 
and serum IL-6 levels fall during recovery (56, 112). 
 The rise in serum IL-6 at exacerbation is greater in viral in comparison to non-viral exacerbations 
(42). 
 Exacerbations associated with rhinovirus and H.influenzae infection have higher serum IL-6 than 
exacerbations without both pathogens (48). 
 During recovery, frequent exacerbators have a smaller reduction in serum IL-6 between 
exacerbation and day 35, despite treatment, compared with infrequent exacerbators (56). 
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Interleukin-8  
(IL-8) 
Serum + 
Sputum 
 IL-8 is produced by neutrophils, macrophages, airway epithelium, T-lymphocytes, endothelium, 
smooth-muscle cells and fibroblasts. 
 IL-8 is a neutrophil chemoattractant and activator of neutrophils.  
 Stable state sputum IL-8 is increased in frequent exacerbators (>3/year) compared to infrequent 
exacerbators (38). 
 Sputum IL-8 is increased stable COPD patients colonised with potentially pathogenic 
microorganisms (105), with sputum IL-8 increasing with increasing bacterial load (129, 192). 
 At exacerbation, the rise in bacterial load correlates with the rise in sputum interleukin (IL)-8 and 
fall in FEV1 (48). 
 Sputum IL-8 levels fall rapidly following exacerbation treatment during the initial recovery phase 
(193). 
Interleukin-18  
(IL-18) 
Sputum  IL-18 is a member of the IL-1 super family and a pro-inflammatory cytokine, synthesized as an 
inactive precursor requiring processing by caspase-1. The IL-18 precursor is in nearly all cells in 
healthy humans. 
 Following cleavage by active caspase-1, mature IL-18 is secreted from monocyte/macrophages. IL-
18 induces IFN-γ production from NK cells.  
 IL-18 increases cell adhesion molecules, promotes nitric oxide synthesis and chemokine production, 
regulates macrophage/neutrophil accumulation and function, and cellular apoptosis (134).  
 IL-18/IL-18binding protein levels are increased in plasma, BAL and lung tissue in COPD patients 
and in mouse models (194-198) 
 In murine models, IL-18 causes pulmonary inflammation and emphysema, and IL-18 receptor (IL-
18R) expression is increased on alveolar macrophages in COPD patients (198). 
 In COPD patients sputum IL-18 increases at exacerbation compared to paired baseline data, 
although no significant increase in serum levels are observed at exacerbation (199). 
 The time course of IL-1β and IL-18 in BAL following LPS exposure in mouse model also suggests 
promise for these biomarkers in modelling exacerbation recovery (182). 
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Matrix 
metalloproteinases 
(MMPs) and tissue 
inhibitors of 
metalloproteinases 
(TIMPs)  
MMP-1, MMP-8, 
MMP-9, TIMP-1 
Serum + 
Sputum 
 MMPs and TIMPs can degrade the extracellular membrane (ECM). Dysregulation of proteolytic 
MMP activity leads to exaggerated ECM turnover, impaired repair and scar formation, or to ECM 
accumulation with subsequent tissue fibrosis.  
 In cystic fibrosis (CF) exacerbations, serum MMP-1/8/9 levels are elevated and decrease in response 
to treatment (200).  
 In COPD, sputum MMP-8/9 levels increase and serum TIMP-1 levels decrease at exacerbation (105, 
201, 202).  Furthermore, in the ECLIPSE biomarker cohort, MMP8/9 levels correlate with GOLD 
stage and the degree of emphysema (203). 
Myeloperoxidase  
(MPO) 
Sputum  MPO is a strong oxidant stored in primary granules of neutrophils with potent antibacterial and 
proatherogenic properties (135). Although generation of oxidants by MPO is beneficial in terms of 
the immune response to invading pathogens, inappropriate stimulation of oxidant formation can 
result in host tissue damage.  
 In stable patients with COPD, increased serum MPO levels are associated with rapid lung function 
decline and poor cardiovascular outcomes (135). 
 At exacerbation, sputum MPO increases at exacerbation (37) but no increase has previously been 
seen in plasma levels (111). 
Placenta growth 
factor (PLGF) 
Serum  PLGF is a member of vascular endothelial growth factor family that promotes angiogenesis (204).  
 PLGF is released from bronchial epithelial cells and may contribute to COPD pathogenesis (205, 
206).  
 PLGF induces apoptosis of type II alveolar epithelial cells and so can cause emphysema when over-
expressed in murine lungs and PLGF knock-out mice are protected from elastase-induced 
emphysema (205, 206).  
 Higher levels of PLGF have been shown in serum and broncho-alveolar lavage (BAL) fluid of 
COPD patients and the PLGF levels is inversely proportional to lung function deterioration (207). 
 In COPD patients, elevated serum PLGF is associated with increased risk of pneumonia (208). 
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Pulmonary and 
Activation-
Regulated 
Chemokine  
(PARC) 
Serum  PARC is constitutively expressed by monocytes/macrophages and dendritic cells and is secreted 
predominantly in the lungs.  
 Serum levels are increased in COPD patients compared to controls (209) and plasma levels increase 
at exacerbation compared to the stable state (111). 
 PARC levels are decreased by prednisolone (209). 
 Elevated serum PARC levels were associated with increased risk of cardiovascular hospitalisation or 
mortality in the Lung Health Study cohort and with total mortality in the ECLIPSE cohort (209). 
Serum Amyloid A 
(SAA) 
Serum  SAA is an acute-phase protein, induced by inflammatory mediators, including IL-6, IL-1b, and 
TNF-α, that rise acutely in at exacerbations of COPD and is associated with neutrophil accumulation 
and activation (210). 
 Bozinovski and colleagues found that SAA increases at acute exacerbation and may have the 
potential to differentiate exacerbations based on severity of the event: SAA was able to differentiate 
AECOPD requiring hospitalisation from stable COPD. Higher SAA levels were seen in bacterial 
compared to non-bacterial exacerbations (132). 
 When used in a small number of patients during exacerbation recovery, results indicated that SAA 
may have the potential to study the time course of recovery and recurrence (132). 
 Recent work also suggests that proinflammatory SAA is disproportionately expressed relative to 
pro-resolving lipoxins in AECOPD. This imbalance during severe events may represent a 
fundamental mechanism for prolonging and intensifying inflammation that is associated with 
AECOPD-related hospitalisation, respiratory failure, and death (210). 
Soluble receptor for 
advanced glycation 
end-products 
(sRAGE) 
 
Serum  sRAGE mediates responses to cell injury mediated by stimuli including oxidative stress.  
 Serum Amyloid A is a ligand for sRAGE and is expressed in normal lung tissue and treatment with 
sRAGE can reverse inflammation in animal models.  
 Plasma sRAGE is elevated in hospitalised exacerbations and falls on discharge (133). 
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Tumour Necrosis 
Factor-α (TNFα) 
 
Serum + 
Sputum 
 TNF-α is a potent pro-inflammatory cytokine produced by macrophages, T-lymphocytes and airway 
epithelium  
 TNFα is a neutrophil chemoattractant that is elevated in stable COPD patients relative to normal 
control subjects, when measured in sputum.  
 Sputum TNFα levels also rise from baseline at exacerbation and resolve during convalescence (36). 
 Rise in TNFα seen at exacerbation correlates to increase in bacterial load (185) 
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